Author: "Maspero, Jf" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Maspero, Jf"' showing total 80 results

Start Over Author "Maspero, Jf"

80 results on '"Maspero, Jf"'

1. Adult Severe Asthma Registries: A Global and Growing Inventory

Author: Cushen B, Koh MS, Tran TN, Martin N, Murray R, Uthaman T, Goh CYY, Vella R, Eleangovan N, Bulathsinhala L, Maspero JF, Peters MJ, Schleich F, Pitrez P, Christoff G, Sadatsafavi M, Torres-Duque CA, Porsbjerg C, Altraja A, Lehtimäki L, Bourdin A, Taube C, Papadopoulos NG, Zsuzsanna C, Björnsdóttir U, Salvi S, Heffler E, Iwanaga T, al-Ahmad M, Larenas-Linnemann D, van Boven JF, Aarli BB, Kuna P, Loureiro CC, Al-lehebi R, Lee JH, Marina N, Bjermer L, Sheu CC, Mahboub B, Busby J, Menzies-Gow A, Wang E, and Price DB
Subjects: asia-pacific, biologics, covid-19, europe, isar, international severe asthma registry, oral corticosteroids, registry, middle east, severe asthma, latin america, usa, Medicine
Abstract: Breda Cushen,1,&ast; Mariko Siyue Koh,2,&ast; Trung N Tran,3 Neil Martin,3,4 Ruth Murray,5 Thendral Uthaman,6 Celine Yun Yi Goh,5,6 Rebecca Vella,7 Neva Eleangovan,5,6 Lakmini Bulathsinhala,5,6 Jorge F Maspero,8,9 Matthew J Peters,10 Florence Schleich,11 Paulo Pitrez,12 George Christoff,13 Mohsen Sadatsafavi,14 Carlos A Torres-Duque,15,16 Celeste Porsbjerg,17 Alan Altraja,18 Lauri Lehtimäki,19 Arnaud Bourdin,20 Christian Taube,21 Nikolaos G Papadopoulos,22,23 Csoma Zsuzsanna,24 Unnur Björnsdóttir,25 Sundeep Salvi,26 Enrico Heffler,27 Takashi Iwanaga,28 Mona al-Ahmad,29 Désirée Larenas-Linnemann,30 Job FM van Boven,31 Bernt Bøgvald Aarli,32,33 Piotr Kuna,34 Cláudia Chaves Loureiro,35,36 Riyad Al-lehebi,37 Jae Ha Lee,38 Nuria Marina,39 Leif Bjermer,40 Chau-Chyun Sheu,41,42 Bassam Mahboub,43 John Busby,44 Andrew Menzies-Gow,45 Eileen Wang,46 David B Price5,6,47 On behalf of ISAR Inventory Study Group1Department of Respiratory Medicine, Beaumont Hospital, Dublin, Ireland; 2Department of Respiratory and Critical Care Medicine, Singapore General Hospital, Singapore, Singapore; 3AstraZeneca, Gaithersburg, MD, USA; 4Department of Respiratory Medicine, University of Leicester, Leicester, UK; 5Optimum Patient Care Global, Cambridge, UK; 6Observational Pragmatic Research Institute, Singapore, Singapore; 7Optimum Patient Care, Brisbane, Queensland, Australia; 8Clinical Research for Allergy and Respiratory Medicine, CIDEA Foundation, Buenos Aires, Argentina; 9University Career of Specialists in Allergy and Clinical Immunology at the Buenos Aires University School of Medicine, Buenos Aires, Argentina; 10Department of Thoracic Medicine, Concord Hospital, Sydney, Australia; 11CHU Sart-Tilman, GIGA I3, University of Liege, Liège, Wallonia, Belgium; 12Pulmonology Division, Hospital Santa Casa de Porto Alegre, Porto Alegre, Brazil; 13Faculty of Public Health, Medical University, Sofia, Bulgaria; 14Respiratory Evaluation Sciences Program, Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, Canada; 15CINEUMO, Respiratory Research Center, Fundación Neumológica Colombiana, Bogotá, Colombia; 16Universidad de La Sabana, Chia, Colombia; 17Department of Respiratory Medicine and Infectious Diseases, Research Unit, Bispebjerg Hospital, Copenhagen, Denmark; 18Department of Pulmonology, University of Tartu and Lung Clinic, Tartu University Hospital, Tartu, Estonia; 19Allergy Centre, Tampere University Hospital, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland; 20PhyMedExp, Univ Montpellier, CNRS, INSERM, CHU Montpellier, Montpellier, France; 21Department of Pulmonary Medicine, University Medical Center Essen-Ruhrlandklinik, Essen, Germany; 22Division of Infection, Immunity & Respiratory Medicine, University of Manchester, Manchester, UK; 23Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece; 24Asthma Outpatient Clinic, National Koranyi Institute for Pulmonology, Budapest, Hungary; 25Department of Allergy and Respiratory Medicine, University Hospital, Reykjavik, Iceland; 26Pulmocare Research and Education Foundation, Pune, India; 27Personalized Medicine, Asthma and Allergy, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy; 28Kindai University Hospital, Osakasayama, Japan; 29Microbiology Department, College of Medicine, Kuwait University, Kuwait, Al-Rashed Allergy Center, Ministry of Health, Kuwait City, Kuwait; 30Centro de Excelencia en Asma y Alergia, Hospital Médica Sur, Ciudad de México, Mexico; 31University of Groningen, University Medical Center Groningen, Groningen Research Institute for Asthma and COPD (GRIAC), Department of Clinical Pharmacy & Pharmacology, Groningen, the Netherlands; 32Department of Thoracic Medicine, Haukeland University Hospital, Bergen, Norway; 33Department of Clinical Science, University of Bergen, Bergen, Norway; 34Division of Internal Medicine Asthma and Allergy, Medical University of Lodz, Lodz, Poland; 35Pneumology Unit, Hospitais da Universidade de Coimbra, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; 36Centre of Pneumology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal; 37Department of Pulmonology, King Fahad Medical City, Riyadh, Saudi Arabia, Alfaisal University, Riyadh, Saudi Arabia; 38Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Republic of Korea; 39Pneumology Service, Biocruces, Cruces University Hospital, Barakaldo, Spain; 40Respiratory Medicine and Allergology, Department of Clinical Sciences, Skåne University Hospital, Lund University, Lund, Sweden; 41Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; 42Department of Internal Medicine, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; 43Rashid Hospital, Dubai Health Authority (DHA), Dubai, United Arab Emirates; 44Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen’s University Belfast, Belfast, Northern Ireland, UK; 45Lung Division, Royal Brompton & Harefield Hospital, London, UK; 46Division of Allergy and Clinical Immunology, Department of Medicine, National Jewish Health and University of Colorado School of Medicine, Denver and Aurora, CO, USA; 47Centre of Academic Primary Care, Division of Applied Health Sciences, University of Aberdeen, Aberdeen, Scotland, UK&ast;These authors contributed equally to this workCorrespondence: David B Price, Observational and Pragmatic Research Institute (OPRI) Pte Ltd, 22 Sin Ming Lane, &num;06-76, Midview City, 573969, Singapore, Tel +65 3105 1489, Email dprice@opri.sgAim: The International Severe Asthma Registry (ISAR; http://isaregistries.org/) uses standardised variables to enable multi-country and adequately powered research in severe asthma. This study aims to look at the data countries within ISAR and non-ISAR countries reported collecting that enable global research that support individual country interests.Methods: Registries were identified by online searches and approaching severe asthma experts. Participating registries provided data collection specifications or confirmed variables collected. Core variables (results from ISAR’s Delphi study), steroid-related comorbidity variables, biologic safety variables (serious infection, anaphylaxis, and cancer), COVID-19 variables and additional variables (not belonging to the aforementioned categories) that registries reported collecting were summarised.Results: Of the 37 registries identified, 26 were ISAR affiliates and 11 non-ISAR affiliates. Twenty-five ISAR-registries and 4 non-ISAR registries reported collecting > 90% of the 65 core variables. Twenty-three registries reported collecting all optional steroid-related comorbidity variables. Twenty-nine registries reported collecting all optional safety variables. Ten registries reported collecting COVID-19 variables. Twenty-four registries reported collecting additional variables including data from asthma questionnaires (10 Asthma Control Questionnaire, 20 Asthma Control Test, 11 Asthma Quality of Life Questionnaire, and 4 EuroQol 5-dimension 5-level Questionnaire). Eight registries are linked to databases such as electronic medical records and national claims or disease databases.Conclusion: Standardised data collection has enabled individual severe asthma registries to collect unified data and increase statistical power for severe asthma research irrespective of ISAR affiliations.Keywords: Asia-Pacific, biologics, COVID-19, Europe, ISAR, International Severe Asthma Registry, oral corticosteroids, Registry, Middle East, Severe Asthma, Latin America, USA
Published: 2023

2. Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization

Author: Corren J, Jackson DJ, Casale TB, Borish L, Rabe KF, Busse WW, Maspero JF, Daizadeh N, Altincatal A, Radwan A, Khodzhayev A, Djandji M, Jacob-Nara JA, Rowe PJ, and Deniz Y
Subjects: dupilumab, allergic asthma, type 2 asthma, perennial aeroallergen, Immunologic diseases. Allergy, RC581-607
Abstract: Jonathan Corren,1 David J Jackson,2,3 Thomas B Casale,4 Larry Borish,5,6 Klaus F Rabe,7,8 William W Busse,9 Jorge F Maspero,10 Daniel J Jackson,11 Nadia Daizadeh,12 Arman Altincatal,12 Amr Radwan,13 Angela Khodzhayev,13 Michel Djandji,12 Juby A Jacob-Nara,12,14 Paul J Rowe,14 Yamo Deniz13 1David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; 2King’s College London, London, UK; 3Guy’s and St Thomas’ NHS Foundation Trust, London, UK; 4Division of Allergy and Immunology, University of South Florida, Tampa, FL, USA; 5Asthma and Allergic Disease Center, University of Virginia Health System, Charlottesville, VA, USA; 6Carter Immunology Center, University of Virginia Health System, Charlottesville, VA, USA; 7LungenClinic Grosshansdorf (Member of the German Center for Lung Research [DZL]), Airway Research Center North (ARCN), Grosshansdorf, Germany; 8Christian-Albrechts University (Member of the German Center for Lung Research [DZL]), Airway Research Center North (ARCN), Kiel, Germany; 9UW Allergy, Pulmonary and Critical Care Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; 10Fundación CIDEA, Buenos Aires, Argentina; 11University of Wisconsin School of Medicine and Public Health, Madison, WI, USA; 12Sanofi, Cambridge, MA, USA; 13Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; 14Sanofi, Bridgewater, NJ, USACorrespondence: Jonathan Corren, David Geffen School of Medicine at UCLA, 10780 Santa Monica Blvd., Suite 280, Los Angeles, CA, 90025, USA, Email jcorren@ucla.eduPurpose: Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukins-4/-13, key and central drivers of type 2 (T2) inflammation in multiple diseases. In phase 3 QUEST (NCT02414854), dupilumab vs placebo significantly reduced asthma exacerbation rates (AER) and improved pre-bronchodilator forced expiratory volume in 1 second (FEV1) in patients with uncontrolled, moderate-to-severe asthma, with greater effects in patients with elevated T2 biomarkers (≥ 150 eosinophils/μL or fractional exhaled nitric oxide [FeNO] ≥ 25 parts per billion). Overall safety was consistent with the known dupilumab safety profile. This post hoc analysis assessed dupilumab efficacy in QUEST patients with T2 asthma with evidence of an allergic phenotype (baseline serum IgE ≥ 30 IU/mL and aeroallergen-specific IgE ≥ 0.35 IU/mL) by number of aeroallergen sensitizations: 1, 2, 3, or ≥ 4. Non-sensitized patients (serum total IgE < 30 IU/mL without evidence of allergic phenotype) were also assessed.Patients and Methods: Endpoints were annualized AER, change from baseline in pre-bronchodilator FEV1 and asthma control (5-item Asthma Control Questionnaire [ACQ-5]), and FeNO and serum total IgE levels over the 52-week treatment period.Results: In all subgroups by number of allergens sensitized, dupilumab vs placebo reduced AER by 35– 67% and improved both pre-bronchodilator FEV1 at Week 12 (least squares mean differences: 0.10– 0.26 L across subgroups) and ACQ-5 score at Week 52 (– 0.26 to – 0.43). Dupilumab significantly reduced FeNO and total IgE levels at Week 52 compared with placebo. Similar results were observed in non-sensitized patients.Conclusion: Dupilumab improved clinical outcomes and reduced biomarker levels in patients with uncontrolled, moderate-to-severe T2 asthma irrespective of allergen sensitization status or number.Clinical Trial Registration: ClinicalTrials.gov Identifier: NCT02414854.Keywords: dupilumab, allergic asthma, type 2 asthma, perennial aeroallergen
Published: 2023

3. Health-Related Quality of Life Impairment Among Patients with Severe Chronic Rhinosinusitis with Nasal Polyps in the SINUS-24 Trial

Author: Maspero JF, Khan AH, Philpott C, Hellings PW, Hopkins C, Wagenmann M, Siddiqui S, Msihid J, Nash S, Chuang CC, Kamat S, Rowe PJ, Deniz Y, and Jacob-Nara JA
Subjects: chronic rhinosinusitis with nasal polyps, health-related quality of life, symptom burden, Immunologic diseases. Allergy, RC581-607
Abstract: Jorge F Maspero,1 Asif H Khan,2 Carl Philpott,3 Peter W Hellings,4 Claire Hopkins,5 Martin Wagenmann,6 Shahid Siddiqui,7 Jérôme Msihid,8 Scott Nash,7 Chien-Chia Chuang,9 Siddhesh Kamat,7 Paul J Rowe,10 Yamo Deniz,7 Juby A Jacob-Nara10 1Allergy & Respiratory Research Unit, Fundación CIDEA, Buenos Aires, Argentina; 2Global Medical Affairs, Sanofi, Chilly-Mazarin, France; 3Rhinology and ENT Research Group, Norwich Medical School, University of East Anglia, Norwich, UK; 4Department of Otorhinolaryngology – Head and Neck Surgery, University Hospitals Leuven, Leuven, Belgium; 5Department of Otorhinolaryngology, King’s College London, London, UK; 6Department of Otorhinolaryngology, Düsseldorf University Hospital (UKD), Düsseldorf, Germany; 7Medical Affairs, Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA; 8Health Economics and Value Assessment, Sanofi, Chilly-Mazarin, France; 9Health Economics and Value Assessment, Sanofi, Cambridge, MA, USA; 10Global Medical Affairs, Sanofi, Bridgewater, NJ, USACorrespondence: Jorge F Maspero, Allergy & Respiratory Research Unit, Fundación CIDEA, Paraguay 2035, 2SS, Buenos Aires, Argentina, Tel +54 9 11 4183-7294, Email jorge.maspero@fundacioncidea.org.arPurpose: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a predominantly type 2 inflammatory disease with a high symptom burden. Data are lacking on the comparative health status of patients with CRSwNP. This analysis compared baseline physical and mental health-related quality of life (HRQoL) and overall health status of patients with severe CRSwNP enrolled in a Phase 3 clinical trial with general population norms and with other chronic diseases.Methods: In this post hoc cross-sectional analysis of baseline data from the SINUS-24 study (NCT02912468), HRQoL was measured using the 36-item Short Form (SF-36) questionnaire and general health status was measured using the EuroQol-5 Dimension visual analog scale (EQ-VAS). Analyses included the intention-to-treat (ITT) population and subgroups defined by prior sinonasal surgery, systemic corticosteroid use, and coexisting asthma or non-steroidal anti-inflammatory drug-exacerbated respiratory disease (NSAID-ERD). Scores were compared with published values for population norms (50 for SF-36 physical component summary (PCS) and mental component summary (MCS), 70.4− 83.3 for EQ-VAS) and for rheumatoid arthritis, type 2 diabetes, and asthma.Results: In the ITT population (n=276), mean SF-36 physical component summary (PCS), SF-36 mental component summary (MCS), and EQ-VAS scores were below general population norms (46.4, 48.6, and 66.0, respectively). Mean SF-36 PCS and EQ-VAS scores were below population norms across all subgroups; mean SF-36 MCS scores were below the population norm in all subgroups except no prior surgery. SF-36 PCS and MCS scores from SINUS-24 were generally similar to other chronic diseases, except SF-36 PCS which was lower in rheumatoid arthritis. EQ-VAS scores in SINUS-24 were lower than in other chronic diseases. HRQoL scores weakly correlated with objective measures of disease severity.Conclusion: In patients with severe CRSwNP, including those with coexisting asthma/NSAID-ERD, HRQoL was worse than population norms and as burdensome as diseases such as type 2 diabetes, asthma, and rheumatoid arthritis.Graphical Abstract: Keywords: chronic rhinosinusitis with nasal polyps, health-related quality of life, symptom burden
Published: 2023

4. Clinical Efficacy among Patients with Chronic Rhinosinusitis with Nasal Polyps and Clinical Features of Obstructive Lung Disease: Post Hoc Analysis of the Phase III SINUS-24 and SINUS-52 Studies

Author: Maspero JF, Bachert C, Martinez FJ, Hanania NA, Ortiz B, Patel N, Mannent LP, Praestgaard A, Pandit-Abid N, Siddiqui S, and Hardin M
Subjects: obstructive lung disease, chronic obstructive pulmonary disease, dupilumab, type 2 inflammation, interleukin-4, interleukin-13, Immunologic diseases. Allergy, RC581-607
Abstract: Jorge F Maspero,1 Claus Bachert,2,3 Fernando J Martinez,4 Nicola A Hanania,5 Benjamin Ortiz,6 Naimish Patel,7 Leda P Mannent,8 Amy Praestgaard,7 Nami Pandit-Abid,9 Shahid Siddiqui,6 Megan Hardin7 1Allergy and Respiratory Research Unit, Fundación CIDEA, Buenos Aires, Argentina; 2Upper Airway Research Laboratory, Department of Otorhinolaryngology, Ghent University Hospital, Ghent, Belgium; 3Division of ENT Diseases, CLINTEC, Karolinska Institutet, Stockholm, Sweden; 4Division of Pulmonary and Critical Care, Weill Cornell Medical College, New York, NY, USA; 5Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX, USA; 6Immunology and Allergy Medical Affairs, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; 7Immunology and Inflammation, Sanofi, Cambridge, MA, USA; 8Global Clinical Development, Sanofi, Chilly-Mazarin, France; 9Immunology and Inflammation, Sanofi, Bridgewater, NJ, USACorrespondence: Jorge F Maspero, Allergy and Respiratory Research Unit, Fundación CIDEA, Paraguay 2035, Buenos Aires, C1121ABE, Argentina, Tel +54 91141837294, Email jorge.maspero@fundacioncidea.org.arPurpose: To provide a descriptive summary of clinical efficacy and health-related quality of life (HRQoL) measures in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and clinical features of obstructive lung disease in the Phase III dupilumab studies SINUS-24 and SINUS-52 (NCT02912468, NCT02898454).Patients and Methods: Patients met a “broad” definition of having clinical features of obstructive lung disease with any of 3 criteria: (i) pre-bronchodilator forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) < 0.70 and smoking history; (ii) patient-reported medical history of chronic obstructive pulmonary disease (COPD); or (iii) asthma with > 10 pack-years’ smoking history. A “narrow” definition including criteria (i) or (ii) was also analyzed. CRSwNP and HRQoL measures were evaluated in all patients and lung function (FEV1; FEV1/FVC ratio) was captured and analyzed only in those patients who had a self-reported history of asthma.Results: Across both studies, 131 patients met the “broad” definition, of whom 90 also had asthma, and 115 patients met the “narrow” definition, of whom 74 had asthma. CRSwNP outcomes and HRQoL were improved with dupilumab vs placebo in both the broad and narrow subgroups. Among the 90 patients who met the broad definition and had asthma, dupilumab improved pre-bronchodilator FEV1 and FEV1/FVC ratio at Week 16 (least squares mean differences vs placebo: 0.38 L [95% confidence interval: 0.17, 0.59; p = 0.0004] and 4.8% [1.7%, 7.9%; p = 0.0024], respectively) sustained through Week 24. Similar results were seen in the “narrow” subgroup with asthma.Conclusion: In a population of patients with CRSwNP and clinical features of obstructive lung disease, dupilumab improved CRSwNP and HRQoL outcomes, and, among those with a history of asthma, also improved lung function. These results support further analyses of dupilumab in patients with evidence of type 2 inflammation and obstructive lung disease such as COPD.Keywords: obstructive lung disease, chronic obstructive pulmonary disease, dupilumab, type 2 inflammation, interleukin-4, interleukin-13
Published: 2023

5. Improvement in Lung Function with Dupilumab Does Not Predict Its Effects on Reducing Asthma Exacerbation

Author: Hanania NA, Maspero JF, Halpin DM, Jackson DJ, Panettieri RA, Castro M, Domingo C, Daizadeh N, Gall R, Jacob-Nara JA, Ortiz B, Djandji M, Rowe PJ, and Deniz Y
Subjects: [keywords not included as per research letter guidelines], Immunologic diseases. Allergy, RC581-607
Abstract: Nicola A Hanania,1 Jorge F Maspero,2 David MG Halpin,3 David J Jackson,4,5 Reynold A Panettieri,6 Mario Castro,7 Christian Domingo,8 Nadia Daizadeh,9 Rebecca Gall,10 Juby A Jacob-Nara,11 Benjamin Ortiz,10 Michel Djandji,9 Paul J Rowe,11 Yamo Deniz10 1Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX, USA; 2Fundación CIDEA, Buenos Aires, Argentina; 3University of Exeter Medical School, College of Medicine and Health, University of Exeter, Exeter, UK; 4School of Immunology and Microbial Sciences, King’s College London, London, UK; 5Guy’s Severe Asthma Centre, Guy’s and St Thomas’ NHS Foundation Trust, London, UK; 6Child Health Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, NJ, USA; 7University of Kansas School of Medicine, Kansas City, KS, USA; 8Pulmonary Service, Corporació Sanitària Parc Taulí, Sabadell, Autonomous University of Barcelona, Barcelona, Spain; 9Sanofi, Cambridge, MA, USA; 10Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; 11Sanofi, Bridgewater, NJ, USACorrespondence: Nicola A Hanania, Section of Pulmonary and Critical Care Medicine, Baylor College of Medicine, Houston, TX, USA, Tel +1 713 798-2400, Email hanania@bcm.edu
Published: 2022

6. S126 Dupilumab efficacy in children with uncontrolled type 2 asthma analyzed by baseline high or medium ICS dose: LIBERTY ASTHMA VOYAGE study

Author: Maspero, JF, primary, Antila, MA, additional, Jean, N, additional, Deschildre, A, additional, Bacharier, LB, additional, Altincatal, A, additional, Rimington, T, additional, Laws, E, additional, Akinlade, B, additional, Radwan, A, additional, Jacob-Nara, JA, additional, Deniz, Y, additional, Rowe, PJ, additional, Lederer, DJ, additional, and Hardin, M, additional
Published: 2022
Full Text: View/download PDF

7. Validation of the MASK‐rhinitis visual analogue scale on smartphone screens to assess allergic rhinitis control

Author: Caimmi, D., Baiz, N., Tanno, L. K., Demoly, P., Arnavielhe, S., Murray, R., Bedbrook, A., Bergmann, K. C., De Vries, G., Fokkens, W. J., Fonseca, J., Haahtela, T., Keil, T., Kuna, P., Mullol, J., Papadopoulos, N., Passalacqua, G., Samolinski, B., Tomazic, P. V., Valiulis, A., van Eerd, M., Wickman, M., Annesi‐Maesano, I., Bousquet, J., Agache, I, Angles, R, Anto, JM, Asayag, E, Bacci, E, Bachert, C, Baroni, I, Barreto, BA, Bedolla‐Barajas, M, Bertorello, L, Bewick, M, Bieber, T, Birov, S, Bindslev‐Jensen, C, Blua, A, Bochenska Marciniak, M, Bogus‐Buczynska, I, Bosnic‐Ancevich, S, Bosse, I, Bourret, R, Bucca, C, Buonaiuto, R, Caiazza, D, Caillot, D, Caimmi, DP, Camargos, P, Canfora, G, Cardona, V, Carriazo, AM, Cartier, C, Castellano, G, Chavannes, NH, Ciaravolo, MM, Cingi, C, Ciceran, A, Colas, L, Colgan, E, Coll, J, Conforti, D, Correira de Sousa, J, Cortés‐Grimaldo, RM, Corti, F, Costa, E, Courbis, AL, Cruz, A, Custovic, A, Dario, C, da Silva, M, Dauvilliers, Y, De Blay, F, Dedeu, T, De Feo, G, De Martino, B, Di Capua, S, Di Carluccio, N, Dray, G, Dubakiene, R, Eller, E, Emuzyte, R, Espinoza‐Contreras, JM, Estrada‐Cardona, A, Farrell, J, Ferrero, J, Fontaine, JF, Forti, S, Gálvez‐Romero, JL, Garcia Cruz, MH, García‐Cobas, CI, Gemicioğlu, B, Gerth van Wijck, R, Guidacci, M, Gómez‐Vera, J, Guldemond, NA, Gutter, Z, Hajjam, J, Hellings, P, Hernández‐Velázquez, L, Illario, M, Ivancevich, JC, Jares, E, Joos, G, Just, J, Kalayci, O, Kalyoncu, AF, Karjalainen, J, Khaltaev, N, Klimek, L, Kull, I, Kuna, TP, Kvedariene, V, Kolek, V, Krzych‐Fałta, E, Kupczyk, M, Lacwik, P, Larenas‐Linnemann, D, Laune, D, Lauri, D, Lavrut, J, Lessa, M, Levato, G, Lewis, L, Lieten, I, Lipiec, A, Louis, R, Luna‐Pech, JA, Magnan, A, Malva, J, Maspero, JF, Mayora, O, Medina‐Ávalos, MA, Melen, E, Menditto, E, Millot‐Keurinck, J, Moda, G, Morais‐Almeida, M, Mösges, R, Mota‐Pinto, A, Muraro, A, Noguès, M, Nalin, M, Napoli, L, Neffen, H, OʼHehir, R, Olivé Elias, M, Onorato, G, Palkonen, S, Pépin, JL, Pereira, AM, Persico, M, Pfaar, O, Pozzi, AC, Prokopakis, EP, Raciborski, F, Rizzo, JA, Robalo‐Cordeiro, C, Rodríguez‐González, M, Rolla, G, Roller‐Wirnsberger, RE, Romano, A, Romano, M, Salimäki, J, Serpa, FS, Shamai, S, Sierra, M, Sova, M, Sorlini, M, Stellato, C, Stelmach, R, Strandberg, T, Stroetman, V, Stukas, R, Szylling, A, Tibaldi, V, Todo‐Bom, A, Toppila‐Salmi, S, Tomazic, P, Trama, U, Triggiani, M, Valero, A, Valovirta, E, van Eerd, M, Vasankari, T, Vatrella, A, Ventura, MT, Verissimo, MT, Viart, F, Williams, S, Wagenmann, M, Wanscher, C, Westman, M, Young, I, Yorgancioglu, A, Zernotti, E, Zurbierber, T, Zurkuhlen, A, De Oliviera, B, and Senn, A
Published: 2017
Full Text: View/download PDF

8. P58: DUPILUMAB EFFICACY AND EFFECT ON ASTHMA CONTROL IN PATIENTS WITH UNCONTROLLED PERSISTENT ASTHMA AND COMORBID CHRONIC RHINOSINUSITIS WITH OR WITHOUT NASAL POLYPS

Author: Katelaris, CH, Maspero, JF, Jayawardena, S, Rowe, P, Maroni, J, Pirozzi, G, Amin, N, NMH, Graham, Mannent, L, and Teper, A
Published: 2017
Full Text: View/download PDF

9. P48 Long-term efficacy of dupilumab in patients with moderate-to-severe asthma in the LIBERTY ASTHMA TRAVERSE open-label extension study: improvements in asthma control and health-related quality of life

Author: Pavord, ID, primary, Wechsler, ME, additional, Ford, LB, additional, Maspero, JF, additional, Langton, D, additional, Domingo, C, additional, Papi, A, additional, Bourdin, A, additional, Watz, H, additional, Mao, X, additional, Amin, N, additional, Hardin, M, additional, Zhang, Y, additional, and Khan, AH, additional
Published: 2021
Full Text: View/download PDF

10. Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air ® App

Author: Bédard, Annabelle, Antó, Josep, Fonseca, Joao, Arnavielhe, Sylvie, Bachert, Claus, Bedbrook, Anna, Bindslev-Jensen, Carsten, Bosnic-Anticevich, Sinthia, Cardona, Victoria, Cruz, Alvaro, Fokkens, Wytske, Garcia-Aymerich, Judith, Hellings, Peter, Ivancevich, Juan, Klimek, Ludger, Kuna, Piotr, Kvedariene, Violeta, Larenas-Linnemann, Désirée, Melen, Erik, Monti, Ricardo, Mösges, Ralf, Mullol, Joaquim, Papadopoulos, Nikos, Pham-Thi, Nhan, Samolinski, Boleslaw, V Tomazic, Peter, Toppila-Salmi, Sanna, Ventura, Maria Teresa, Yorgancioglu, Arzu, Bousquet, Jean, Pfaar, Oliver, Basagana, Xavier, Bosnic‐Anticevich, Sinthia, Pham‐Thi, Nhân, Hellings, PW, Aberer, W., Agache, I., Akdis, Ca, Akdis, M., Aliberti, MR, Almeida, R., Amat, F., Angles, R, Annesi‐Maesano, I, Ansotegui, IJ, Anto, JM, Arnavielle, S, Asayag, E, Asarnoj, A, Arshad, H, Avolio, F, Bacci, E, Baiardini, I, Barbara, C, Barbagallo, M., Baroni, I, Barreto, BA, Basagaña, X., Bateman, ED, Bedolla‐Barajas, M, Bewick, M., Beghé, B., Bel, EH, Bergmann, KC, Bennoor, KS, Benson, M, Bertorello, L, Białoszewski, AZ, Bieber, T., Bialek, S, Bindslev‐Jensen, Carsten, Bjermer, L., Blain, H., Blasi, F., Blua, A, Bochenska Marciniak, M, Bogus‐Buczynska, I, Boner, AL, Bonini, M., Bonini, S., Bosnic‐Anticevich, CS, Bosse, I., Bouchard, J., Boulet, LP, Bourret, R., Bousquet, Pj, Braido, F, Briedis, V, Brightling, CE, Brozek, J, Bucca, C, Buhl, R, Buonaiuto, R, Panaitescu, C, Burguete Cabañas, MT, Burte, E., Bush, A, Caballero‐Fonseca, F, Caillaud, D., Caimmi, D., Calderon, MA, Camargos, PAM, Camuzat, T., Canfora, G, Canonica, Gw, Carlsen, KH, Carreiro‐Martins, P, Carriazo, AM, Carr, W, Cartier, C., Casale, T., Castellano, G, Cecchi, L, Cepeda, AM, Chavannes, NH, Chen, Y., Chiron, R., Chivato, T, Chkhartishvili, E, Chuchalin, AG, Chung, KF, Ciaravolo, MM, Ciceran, A, Cingi, C, Ciprandi, G, Carvalho Coehlo, AC, Colas, L, Colgan, E, Coll, J, Conforti, D, Constantinidis, J, de Sousa, J Correia, Cortés‐Grimaldo, RM, Corti, F, Costa, E, Costa‐Dominguez, MC, Courbis, AL, Cox, L, Crescenzo, M, Cruz, AA, Custovic, A., Czarlewski, W., Dahlen, Se, D’Amato, G, Dario, C, Da Silva, J., Dauvilliers, Y., Darsow, U, De Blay, F., De Carlo, G, Dedeu, T, de Fátima Emerson, M, De Feo, G., De Vries, G, De Martino, B, Motta Rubini, NP, Deleanu, D, Denburg, JA, devillier, P., Di Capua Ercolano, S, Di Carluccio, N, Didier, A., Dokic, D, Dominguez‐Silva, MG, Douagui, H, Dray, G., Dubakiene, R, Durham, Sr, Du Toit, G, Dykewicz, MS, El‐Gamal, Y, Eklund, P, Eller, E, Emuzyte, R., Farrell, J, Farsi, A, de Mello, J Ferreira, Ferrero, J, Fink‐Wagner, A, Fiocchi, A, Fokkens, WJ, Fonseca, JA, Fontaine, Jf, Forti, S, Fuentes‐Perez, JM, Gálvez‐Romero, JL, Gamkrelidze, A, Garcia‐Aymerich, Judith, García‐Cobas, CY, Garcia‐Cruz, MH, Gemicioğlu, B, Genova, S, Christoff, G, Gereda, JE, Van Wijk, R Gerth, Gomez, RM, Gómez‐Vera, J, González Diaz, S, Gotua, M., Grisle, I, Guidacci, M, Guldemond, NA, Gutter, Z, Guzmán, MA, Haahtela, T., Hajjam, J, Hernández, L, Hourihane, JO’B, Huerta‐Villalobos, YR, Humbert, M., Iaccarino, G., Illario, M, Ispayeva, Z, Ivancevich, JC, Jares, EJ, Jassem, E, Johnston, Sl, Joos, G, Jung, KS, Just, J., Jutel, M, Kaidashev, I, Kalayci, O, Kalyoncu, AF, Karjalainen, J, Kardas, P, Keil, T, Keith, PK, Khaitov, M, Khaltaev, N, Kleine‐Tebbe, J, Kowalski, Ml, Kuitunen, M, Kull, I., Kupczyk, M, Krzych‐Fałta, E, Lacwik, P, Larenas‐Linnemann, Désirée, Laune, D., Lauri, D, Lavrut, J, Le, LTT, Lessa, M, Levato, G, Li, J., Lieberman, P, Lipiec, A, Lipworth, B, Lodrup Carlsen, KC, Louis, R, Lourenço, O, Luna‐Pech, JA, Magnan, A., Mahboub, B, Maier, D., Mair, A, Majer, I, Malva, J, Mandajieva, E, Manning, P, De Manuel Keenoy, E, Marshall, GD, Masjedi, MR, Maspero, JF, Mathieu‐Dupas, E, Matta Campos, JJ, Matos, AL, Maurer, M, Mavale‐Manuel, S, Mayora, O, Meco, C, Medina‐Avalos, MA, Melo‐Gomes, E, Meltzer, EO, Menditto, E., Miculinic, N, Mihaltan, F., Milenkovic, B, Moda, G, Mogica‐Martinez, MD, Mohammad, Y, Momas, I., Montefort, S, Mora Bogado, D, Morais‐Almeida, M, Morato‐Castro, FF, Mota‐Pinto, A, Moura Santo, P, Münter, L, Muraro, A, Murray, R, Naclerio, R., Nadif, R., Nalin, M, Napoli, L, Namazova‐Baranova, L, Neffen, H, Niedeberger, V, Nekam, K, Neou, A, Nieto, A, Nogueira‐Silva, L, Nogues, M., Novellino, E, Nyembue, TD, O’Hehir, RE, Odzhakova, C, Ohta, K., Okamoto, Y., Okubo, K, Onorato, GL, Ortega Cisneros, M, Ouédraogo, S., Pali‐Schöll, I, Palkonen, S, Panzner, P, Papadopoulos, NG, Park, HS, Papi, A., Passalacqua, G, Paulino, E, Pawankar, R, Pedersen, S, Pépin, JL, Pereira, AM, Persico, M, PHILLIPS, J, Picard, R., Pigearias, B, Pin, I., Pitsios, C., Plavec, D, Pohl, W, Popov, TA, Portejoie, F., Potter, P, Pozzi, AC, Price, D, Prokopakis, EP, Puy, R, Pugin, B, Pulido Ross, RE, Przemecka, M, Rabe, KF, Raciborski, F, Rajabian‐Soderlund, R, Reitsma, S, Ribeirinho, I, Rimmer, J, Rivero‐Yeverino, D, Rizzo, JA, Rizzo, MC, Robalo‐Cordeiro, C, Rodenas, F, Rodo, X, Rodriguez Gonzalez, M, Rodriguez‐Mañas, L, Rolland, C, Rodrigues Valle, S, Roman Rodriguez, M., Romano, A, Rodriguez‐Zagal, E, Rolla, G, Roller‐Wirnsberger, RE, Romano, M, Rosado‐Pinto, J, Rosario, N., Rottem, M, Ryan, D, Sagara, H, Salimäki, J, Sanchez‐Borges, M, Sastre‐Dominguez, J, Scadding, GK, Schunemann, HJ, Scichilone, N, Schmid‐Grendelmeier, P, Sarquis Serpa, F, Shamai, S., Sheikh, A., Sierra, M, Simons, FER, Siroux, V., Sisul, JC, Skrindo, I, Solé, D, Somekh, D, Sondermann, M, Sooronbaev, T, Sova, M, Sorensen, M, Sorlini, M, Spranger, O, Stellato, C, Stelmach, R, Stukas, R, Sunyer, J., Strozek, J, Szylling, A, Tebyriçá, JN, Thibaudon, M., To, T., Todo‐Bom, A, Tomazic, PV, Toppila‐Salmi, Sanna, Trama, U, Triggiani, M, Suppli Ulrik, C, Urrutia‐Pereira, M, Valenta, R, Valero, A., Valiulis, A., Valovirta, E., van Eerd, M, Van Ganse, E., van Hage, M, Vandenplas, O, Ventura, MT, Vezzani, G, Vasankari, T, Vatrella, A., Verissimo, MT, Viart, F., Viegi, G., Vicheva, D, Vontetsianos, T, Wagenmann, M, Walker, S, Wallace, D, Wang, DY, Waserman, S., Werfel, T, Westman, M, Wickman, M., Williams, DM, Williams, S, Wilson, N, Wright, J, Wroczynski, P, Yakovliev, P, Yawn, BP, Yiallouros, PK, Yusuf, OM, Zar, HJ, Zhang, L., Zhong, N, Zernotti, ME, Zhanat, I, Zidarn, M, Zuberbier, T., Zubrinich, C, Zurkuhlen, A, Mercier, Jacques, Instituto de Salud Global - Institute For Global Health [Barcelona] (ISGlobal), Universitat Pompeu Fabra [Barcelona] (UPF), CIBER de Epidemiología y Salud Pública (CIBERESP), IMIM-Hospital del Mar, Generalitat de Catalunya, Center of Research in Health Technologies and Information Systems (CINTESIS), Universidade do Porto = University of Porto, KYomed INNOV, Ghent University Hospital, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Odense University Hospital [Odense, Denmark], Woolcock Institute of Medical Research [Sydney], The University of Sydney, Vall d'Hebron University Hospital [Barcelona], ProAR - FMB, Federal University of Bahia School of Medicine, European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), University Hospitals Leuven [Leuven], Zentrum für Rhinologie und Allergologie [Wiesbaden, Germany], Division of Internal Medicine, Asthma and Allergy, Medical University of Łódź (MUL)-Barlicki University Hospital, Vilnius University [Vilnius], Clínica de Alergia- Asma y Pediatría, Hospital Medica Sur, Institute of Environmental Medicine, Karolinska Institutet [Stockholm]-Karolinska University Hospital [Stockholm]-Astrid Lindgren Children's Hospital, Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Service de Pneumologie Allergologie [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Pasteur [Paris] (IP), Medical University of Warsaw - Poland, Department of Pulmonology, Manisa Celal Bayar University, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Vieillissement et Maladies chroniques : approches épidémiologique et de santé publique (VIMA), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), Center for Rhinology and Allergology Wiesbaden, University Hospital Mannheim, Center for Research in Environmental Epidemiology (CREAL), Universitat Pompeu Fabra [Barcelona] (UPF)-Catalunya ministerio de salud, Department of Allergy and Clinical Immunology, Faculty of Medicine-Transylvania University, Swiss Institute of Allergy and Asthma Research (SIAF), Universität Zürich [Zürich] = University of Zurich (UZH), Department Engineering Quimica (ICEMS), Aix Marseille Université (AMU), Istituto Nazionale di Fisica Nucleare, sezione di Bari (INFN, sezione di Bari), Istituto Nazionale di Fisica Nucleare (INFN), iQ4U consultants Ltd, Divisions of Human Genetics Infection, Inflammation and Repair, University of Southampton-School of Medicine, Department of Respiratory Medicine and Allergy, Department of Pathophysiology and Transplantation, Università degli Studi di Milano = University of Milan (UNIMI), Istituto di Geoscienze e Georisorse, Pavia, Institute of Neurobiology and Molecular Medicine, CNR, Rome, Italy and Department of Medicine-University of Naples Federico II = Università degli studi di Napoli Federico II, CHU Montpellier, Laboratoire National Henri Becquerel (LNHB), Département Métrologie Instrumentation & Information (DM2I), Laboratoire d'Intégration des Systèmes et des Technologies (LIST (CEA)), Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Laboratoire d'Intégration des Systèmes et des Technologies (LIST (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Département d'instrumentation Numérique (DIN (CEA-LIST)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Unité de Nutrition Humaine (UNH), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Laboratoire de recherche sur les mécanismes moléculaires et pharmacologiques de l’obstruction bronchique (LOBIP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Région Languedoc-Roussillon-Midi-Pyrénées, University of South Florida [Tampa] (USF), Chinese academy of sciences Sanya, Centres de Ressources et de Compétences de la Mucoviscidose [Montpellier] (CRCM [Montpellier]), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve-Service des Maladies Respiratoires, Laboratoire de Génie Informatique et d'Ingénierie de Production (LGI2P), IMT - MINES ALES (IMT - MINES ALES), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT), Department of Paediatrics, UCB Pharma, Colombes, CHU Strasbourg, Università degli Studi di Salerno = University of Salerno (UNISA), Hôpital Foch [Suresnes], Service de pneumologie [Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Informatique, Image, Intelligence Artificielle (I3A), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-IMT - MINES ALES (IMT - MINES ALES), Laboratoire Electronique, Informatique et Image [UMR6306] (Le2i), Université de Bourgogne (UB)-École Nationale Supérieure d'Arts et Métiers (ENSAM), Arts et Métiers Sciences et Technologies, HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Arts et Métiers Sciences et Technologies, HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique (CNRS), Center for Allergy and Immunology Research [Tbilisi], Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Center for Turbulence Research [Stanford] (CTR), Stanford University, CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), The Institute of Environmental Medicine [Stockholm] (IMM), Karolinska Institutet [Stockholm], Sysdiag-Modélisation et Ingénierie des Systèmes Complexes Biologiques pour le Diagnostic (SysDiag ), BIO-RAD-Centre National de la Recherche Scientifique (CNRS), Équipe de Recherche en Textes, Informatique, Multilinguisme (ERTIM), Institut National des Langues et Civilisations Orientales (Inalco), Unité de recherche de l'institut du thorax (ITX-lab), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Biomax Informatics AG, 'Federico II' University of Naples Medical School, Pneumology Department, Marius Nasta Institute of Pneumology, Epidémiologie Environnementale : Impact Sanitaire des Pollutions (EA 4064), Université Paris Descartes - Paris 5 (UPD5), Johns Hopkins University School of Medicine [Baltimore], CARSAT-LR, Montpellier, Dept. of Electronic Engineering, Chubu University, Institute for Solid State Physics, The University of Tokyo (UTokyo), Respiratory Medicine, Laboratoire de physique et chimie des nano-objets (LPCNO), Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Institut de Chimie de Toulouse (ICT), Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut de Recherche sur les Systèmes Atomiques et Moléculaires Complexes (IRSAMC), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), CHU Grenoble, University of Cyprus [Nicosia] (UCY), Son Pisa Primary Care Centre, IB-Salut Balearic Health Service, Department of Computer Science [Haifa], University of Haifa [Haifa], University of Edinburgh, Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) (IAB), Centre Hospitalier Universitaire [Grenoble] (CHU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang - Auvergne-Rhône-Alpes (EFS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), Réseau National de Surveillance Aérobiologique (RNSA), CIRCE, Ctr Res Energy Resources & Consumpt, Zaragoza 50018, Spain, University of Turku, Evaluation et modélisation des effets thérapeutiques, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), ASA (Advanced Solution Accelerator) (Data management : Développement Back-Office, hébergement…), 34830 Jacou, Consiglio nazionale delle ricerche, Instituto di fisiologia clinica, McMaster University [Hamilton, Ontario], Department of Molecular Medicine and Surgery, UMR CNRS 8179, Université de Lille, Sciences et Technologies-Centre National de la Recherche Scientifique (CNRS), University Hospital of Cologne [Cologne], Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), ISGlobal, Barcelona, Spain, Universitat Pompeu Fabra (UPF), Barcelona, Spain, CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain, IMIM (Hospital del Mar Research Institute), Barcelona, Spain, CINTESIS, Center for Research in Health Technology and Information Systems, Faculdade de Medicina da Universidade do Porto, Porto, Portugal, Medida, Lda Porto, Porto, Portugal, KYomed INNOV, Montpellier, France, Upper Airways Research Laboratory, ENT Dept, Ghent University Hospital, Ghent, Belgium, MACVIA-France, Montpellier, France, Department of Dermatology and Allergy Centre, Odense University Hospital, Odense Research Center for Anaphylaxis (ORCA), Odense, Denmark, Woolcock Institute of Medical Research, University of Sydney and Woolcock Emphysema Centre and Sydney Local Health District, Glebe, NSW, Australia, Allergy Section, Department of Internal Medicine, Hospital Vall d'Hebron & ARADyAL Research Network, Barcelona, Spain, ProAR – Nucleo de Excelencia em Asma, Federal University of Bahia, Brasil and WHO GARD Planning Group, Salvador, Brazil, Department of Otorhinolaryngology, Amsterdam University Medical Centres, AMC, Amsterdam, Netherlands, Euforea, Brussels, Belgium, Department of Otorhinolaryngology, University Hospitals Leuven, Leuven, Belgium, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina, Center for Rhinology and Allergology, Wiesbaden, Germany, Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland, Department of Pathology, Faculty of Medicine, Institute of Biomedical Sciences, Vilnius University, Vilnius, Lithuania, Clinic of Chest diseases and Allergology, Faculty of Medicine, Institute of Clinical Medicine, Vilnius, Lithuania, Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico, Sachs' Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, Allergy and Clinical Immunology Unit, Department of Medical Sciences, University of Torino & Mauriziano Hospital, Torino, Italy, Institute of Medical Statistics, and Computational Biology, Medical Faculty, University of Cologne, Cologne, Germany, CRI-Clinical Research International-Ltd, Hamburg, Germany, Rhinology Unit & Smell Clinic, ENT Department, Hospital Clínic, University of Barcelona, Barcelona, Spain, Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain, Division of Infection, Immunity & Respiratory Medicine, Royal Manchester Children's Hospital, University of Manchester, Manchester, United Kingdom, Allergy Department, Pasteur Institute, Paris, France, Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland, Department of General ORL, H&NS, Medical University of Graz, Graz, Austria, Skin and Allergy Hospital, Helsinki University Hospital, and University of Helsinki, Helsinki, Finland, Unit of Geriatric Immunoallergology, University of Bari Medical School, Bari, Italy, Department of Pulmonary Diseases, Faculty of Medicine, Celal Bayar University, Manisa, Turkey, University Hospital, Montpellier, France, INSERM U 1168, VIMA: Ageing and Chronic Diseases Epidemiological and Public Health Approaches, Villejuif, France, UMR-S 1168, Université Versailles St-Quentin-en-Yvelines, Versailles, France, Charité, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin, Germany, Comprehensive Allergy Center, Department of Dermatology and Allergy, Berlin Institute of Health, Berlin, Germany, Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Phillipps-Universität, Marburg, Germany, Universidade do Porto, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Institut Pasteur [Paris], University of Milan, University of Naples Federico II-CNR, Rome, Italy and Department of Medicine, Laboratoire d'Intégration des Systèmes et des Technologies (LIST), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Laboratoire d'Intégration des Systèmes et des Technologies (LIST), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Università degli Studi di Salerno (UNISA), CHU Toulouse [Toulouse]-Hôpital Larrey [Toulouse], CHU Toulouse [Toulouse], Université de Bourgogne (UB)-Centre National de la Recherche Scientifique (CNRS)-École Nationale Supérieure d'Arts et Métiers (ENSAM), HESAM Université (HESAM)-HESAM Université (HESAM)-Arts et Métiers Sciences et Technologies, HESAM Université (HESAM)-HESAM Université (HESAM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, University of Helsinki, Service d'Allergologie pédiatrique [CHU Trousseau], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX), Astrophysique Interprétation Modélisation (AIM (UMR_7158 / UMR_E_9005 / UM_112)), Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris Diderot - Paris 7 (UPD7), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut de Chimie de Toulouse (ICT-FR 2599), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Institut de Recherche sur les Systèmes Atomiques et Moléculaires Complexes (IRSAMC), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), University of Cyprus [Nicosia], Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Bedard, A., Anto, J. M., Fonseca, J. A., Arnavielhe, S., Bachert, C., Bedbrook, A., Bindslev-Jensen, C., Bosnic-Anticevich, S., Cardona, V., Cruz, A. A., Fokkens, W. J., Garcia-Aymerich, J., Hellings, P. W., Ivancevich, J. C., Klimek, L., Kuna, P., Kvedariene, V., Larenas-Linnemann, D., Melen, E., Monti, R., Mosges, R., Mullol, J., Papadopoulos, N. G., Pham-Thi, N., Samolinski, B., Tomazic, P. V., Toppila-Salmi, S., Ventura, M. T., Yorgancioglu, A., Bousquet, J., Pfaar, O., Basagana, X., Aberer, W., Agache, I., Akdis, C. A., Akdis, M., Aliberti, M. R., Almeida, R., Amat, F., Angles, R., Annesi-Maesano, I., Ansotegui, I. J., Arnavielle, S., Asayag, E., Asarnoj, A., Arshad, H., Avolio, F., Bacci, E., Baiardini, I., Barbara, C., Barbagallo, M., Baroni, I., Barreto, B. A., Bateman, E. D., Bedolla-Barajas, M., Bewick, M., Beghe, B., Bel, E. H., Bergmann, K. C., Bennoor, K. S., Benson, M., Bertorello, L., Bialoszewski, A. Z., Bieber, T., Bialek, S., Bjermer, L., Blain, H., Blasi, F., Blua, A., Bochenska Marciniak, M., Bogus-Buczynska, I., Boner, A. L., Bonini, M., Bonini, S., Bosse, I., Bouchard, J., Boulet, L. P., Bourret, R., Bousquet, P. J., Braido, F., Briedis, V., Brightling, C. E., Brozek, J., Bucca, C., Buhl, R., Buonaiuto, R., Panaitescu, C., Burguete Cabanas, M. T., Burte, E., Bush, A., Caballero-Fonseca, F., Caillaud, D., Caimmi, D., Calderon, M. A., Camargos, P. A. M., Camuzat, T., Canfora, G., Canonica, G. W., Carlsen, K. H., Carreiro-Martins, P., Carriazo, A. M., Carr, W., Cartier, C., Casale, T., Castellano, G., Cecchi, L., Cepeda, A. M., Chavannes, N. H., Chen, Y., Chiron, R., Chivato, T., Chkhartishvili, E., Chuchalin, A. G., Chung, K. F., Ciaravolo, M. M., Ciceran, A., Cingi, C., Ciprandi, G., Carvalho Coehlo, A. C., Colas, L., Colgan, E., Coll, J., Conforti, D., Constantinidis, J., Correia de Sousa, J., Cortes-Grimaldo, R. M., Corti, F., Costa, E., Costa-Dominguez, M. C., Courbis, A. L., Cox, L., Crescenzo, M., Custovic, A., Czarlewski, W., Dahlen, S. E., D'Amato, G., Dario, C., da Silva, J., Dauvilliers, Y., Darsow, U., De Blay, F., De Carlo, G., Dedeu, T., de Fatima Emerson, M., De Feo, G., De Vries, G., De Martino, B., Motta Rubini, N. P., Deleanu, D., Denburg, J. A., Devillier, P., Di Capua Ercolano, S., Di Carluccio, N., Didier, A., Dokic, D., Dominguez-Silva, M. G., Douagui, H., Dray, G., Dubakiene, R., Durham, S. R., Du Toit, G., Dykewicz, M. S., El-Gamal, Y., Eklund, P., Eller, E., Emuzyte, R., Farrell, J., Farsi, A., Ferreira de Mello, J., Ferrero, J., Fink-Wagner, A., Fiocchi, A., Fontaine, J. F., Forti, S., Fuentes-Perez, J. M., Galvez-Romero, J. L., Gamkrelidze, A., Garcia-Cobas, C. Y., Garcia-Cruz, M. H., Gemicioglu, B., Genova, S., Christoff, G., Gereda, J. E., Gerth van Wijk, R., Gomez, R. M., Gomez-Vera, J., Gonzalez Diaz, S., Gotua, M., Grisle, I., Guidacci, M., Guldemond, N. A., Gutter, Z., Guzman, M. A., Haahtela, T., Hajjam, J., Hernandez, L., Hourihane, J. O. '. B., Huerta-Villalobos, Y. R., Humbert, M., Iaccarino, G., Illario, M., Ispayeva, Z., Jares, E. J., Jassem, E., Johnston, S. L., Joos, G., Jung, K. S., Just, J., Jutel, M., Kaidashev, I., Kalayci, O., Kalyoncu, A. F., Karjalainen, J., Kardas, P., Keil, T., Keith, P. K., Khaitov, M., Khaltaev, N., Kleine-Tebbe, J., Kowalski, M. L., Kuitunen, M., Kull, I., Kupczyk, M., Krzych-Falta, E., Lacwik, P., Laune, D., Lauri, D., Lavrut, J., Le, L. T. T., Lessa, M., Levato, G., Li, J., Lieberman, P., Lipiec, A., Lipworth, B., Lodrup Carlsen, K. C., Louis, R., Lourenco, O., Luna-Pech, J. A., Magnan, A., Mahboub, B., Maier, D., Mair, A., Majer, I., Malva, J., Mandajieva, E., Manning, P., De Manuel Keenoy, E., Marshall, G. D., Masjedi, M. R., Maspero, J. F., Mathieu-Dupas, E., Matta Campos, J. J., Matos, A. L., Maurer, M., Mavale-Manuel, S., Mayora, O., Meco, C., Medina-Avalos, M. A., Melo-Gomes, E., Meltzer, E. O., Menditto, E., Mercier, J., Miculinic, N., Mihaltan, F., Milenkovic, B., Moda, G., Mogica-Martinez, M. D., Mohammad, Y., Momas, I., Montefort, S., Mora Bogado, D., Morais-Almeida, M., Morato-Castro, F. F., Mota-Pinto, A., Moura Santo, P., Munter, L., Muraro, A., Murray, R., Naclerio, R., Nadif, R., Nalin, M., Napoli, L., Namazova-Baranova, L., Neffen, H., Niedeberger, V., Nekam, K., Neou, A., Nieto, A., Nogueira-Silva, L., Nogues, M., Novellino, E., Nyembue, T. D., O'Hehir, R. E., Odzhakova, C., Ohta, K., Okamoto, Y., Okubo, K., Onorato, G. L., Ortega Cisneros, M., Ouedraogo, S., Pali-Scholl, I., Palkonen, S., Panzner, P., Park, H. S., Papi, A., Passalacqua, G., Paulino, E., Pawankar, R., Pedersen, S., Pepin, J. L., Pereira, A. M., Persico, M., Phillips, J., Picard, R., Pigearias, B., Pin, I., Pitsios, C., Plavec, D., Pohl, W., Popov, T. A., Portejoie, F., Potter, P., Pozzi, A. C., Price, D., Prokopakis, E. P., Puy, R., Pugin, B., Pulido Ross, R. E., Przemecka, M., Rabe, K. F., Raciborski, F., Rajabian-Soderlund, R., Reitsma, S., Ribeirinho, I., Rimmer, J., Rivero-Yeverino, D., Rizzo, J. A., Rizzo, M. C., Robalo-Cordeiro, C., Rodenas, F., Rodo, X., Rodriguez Gonzalez, M., Rodriguez-Manas, L., Rolland, C., Rodrigues Valle, S., Roman Rodriguez, M., Romano, A., Rodriguez-Zagal, E., Rolla, G., Roller-Wirnsberger, R. E., Romano, M., Rosado-Pinto, J., Rosario, N., Rottem, M., Ryan, D., Sagara, H., Salimaki, J., Sanchez-Borges, M., Sastre-Dominguez, J., Scadding, G. K., Schunemann, H. J., Scichilone, N., Schmid-Grendelmeier, P., Sarquis Serpa, F., Shamai, S., Sheikh, A., Sierra, M., Simons, F. E. R., Siroux, V., Sisul, J. C., Skrindo, I., Sole, D., Somekh, D., Sondermann, M., Sooronbaev, T., Sova, M., Sorensen, M., Sorlini, M., Spranger, O., Stellato, C., Stelmach, R., Stukas, R., Sunyer, J., Strozek, J., Szylling, A., Tebyrica, J. N., Thibaudon, M., To, T., Todo-Bom, A., Trama, U., Triggiani, M., Suppli Ulrik, C., Urrutia-Pereira, M., Valenta, R., Valero, A., Valiulis, A., Valovirta, E., van Eerd, M., van Ganse, E., van Hage, M., Vandenplas, O., Vezzani, G., Vasankari, T., Vatrella, A., Verissimo, M. T., Viart, F., Viegi, G., Vicheva, D., Vontetsianos, T., Wagenmann, M., Walker, S., Wallace, D., Wang, D. Y., Waserman, S., Werfel, T., Westman, M., Wickman, M., Williams, D. M., Williams, S., Wilson, N., Wright, J., Wroczynski, P., Yakovliev, P., Yawn, B. P., Yiallouros, P. K., Yusuf, O. M., Zar, H. J., Zhang, L., Zhong, N., Zernotti, M. E., Zhanat, I., Zidarn, M., Zuberbier, T., Zubrinich, C., Zurkuhlen, A., HESAM Université (HESAM)-HESAM Université (HESAM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique (CNRS), Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Universitat Pompeu Fabra [Barcelona]-Catalunya ministerio de salud, Universidade do Porto [Porto], Kyomed, Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Nîmes (CHRU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Universitat Pompeu Fabra [Barcelona], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Necker - Enfants Malades [AP-HP], Service des Maladies Respiratoires, Hôpital Arnaud de Villeneuve-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Dermatology [Graz, Austria], Medical University Graz, University of Zürich [Zürich] (UZH), National Institute for Nuclear Physics (INFN), Institut Jean Lamour (IJL), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Université Paris-Saclay-Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Laboratoire d'Intégration des Systèmes et des Technologies (LIST), Clermont Université-Université d'Auvergne - Clermont-Ferrand I (UdA)-Institut National de la Recherche Agronomique (INRA), University of South Florida (USF), University of Salerno (UNISA), CHU Toulouse [Toulouse]-Hôpital Larrey, Institut Mines-Télécom [Paris] (IMT), Center for Turbulence Research (CTR), Stanford University [Stanford], Service d'allergologie [CHU Trousseau], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Trousseau [APHP], Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), The University of Tokyo, Sondra, CentraleSupélec, Université Paris-Saclay (SONDRA), ONERA-CentraleSupélec-Université Paris-Saclay, Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche sur les Systèmes Atomiques et Moléculaires Complexes (IRSAMC), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), RNSA, Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Ear, Nose and Throat, AII - Inflammatory diseases, Pulmonology, CNR, Rome, Italy and Department of Medicine-University of Naples Federico II, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), HUS Inflammation Center, Department of Dermatology, Allergology and Venereology, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (MGD) Service de pneumologie, Bedard A., Anto J.M., Fonseca J.A., Arnavielhe S., Bachert C., Bedbrook A., Bindslev-Jensen C., Bosnic-Anticevich S., Cardona V., Cruz A.A., Fokkens W.J., Garcia-Aymerich J., Hellings P.W., Ivancevich J.C., Klimek L., Kuna P., Kvedariene V., Larenas-Linnemann D., Melen E., Monti R., Mosges R., Mullol J., Papadopoulos N.G., Pham-Thi N., Samolinski B., Tomazic P.V., Toppila-Salmi S., Ventura M.T., Yorgancioglu A., Bousquet J., Pfaar O., Basagana X., Aberer W., Agache I., Akdis C.A., Akdis M., Aliberti M.R., Almeida R., Amat F., Angles R., Annesi-Maesano I., Ansotegui I.J., Arnavielle S., Asayag E., Asarnoj A., Arshad H., Avolio F., Bacci E., Baiardini I., Barbara C., Barbagallo M., Baroni I., Barreto B.A., Bateman E.D., Bedolla-Barajas M., Bewick M., Beghe B., Bel E.H., Bergmann K.C., Bennoor K.S., Benson M., Bertorello L., Bialoszewski A.Z., Bieber T., Bialek S., Bjermer L., Blain H., Blasi F., Blua A., Bochenska Marciniak M., Bogus-Buczynska I., Boner A.L., Bonini M., Bonini S., Bosse I., Bouchard J., Boulet L.P., Bourret R., Bousquet P.J., Braido F., Briedis V., Brightling C.E., Brozek J., Bucca C., Buhl R., Buonaiuto R., Panaitescu C., Burguete Cabanas M.T., Burte E., Bush A., Caballero-Fonseca F., Caillaud D., Caimmi D., Calderon M.A., Camargos P.A.M., Camuzat T., Canfora G., Canonica G.W., Carlsen K.H., Carreiro-Martins P., Carriazo A.M., Carr W., Cartier C., Casale T., Castellano G., Cecchi L., Cepeda A.M., Chavannes N.H., Chen Y., Chiron R., Chivato T., Chkhartishvili E., Chuchalin A.G., Chung K.F., Ciaravolo M.M., Ciceran A., Cingi C., Ciprandi G., Carvalho Coehlo A.C., Colas L., Colgan E., Coll J., Conforti D., Constantinidis J., Correia de Sousa J., Cortes-Grimaldo R.M., Corti F., Costa E., Costa-Dominguez M.C., Courbis A.L., Cox L., Crescenzo M., Custovic A., Czarlewski W., Dahlen S.E., D'Amato G., Dario C., da Silva J., Dauvilliers Y., Darsow U., De Blay F., De Carlo G., Dedeu T., de Fatima Emerson M., De Feo G., De Vries G., De Martino B., Motta Rubini N.P., Deleanu D., Denburg J.A., Devillier P., Di Capua Ercolano S., Di Carluccio N., Didier A., Dokic D., Dominguez-Silva M.G., Douagui H., Dray G., Dubakiene R., Durham S.R., Du Toit G., Dykewicz M.S., El-Gamal Y., Eklund P., Eller E., Emuzyte R., Farrell J., Farsi A., Ferreira de Mello J., Ferrero J., Fink-Wagner A., Fiocchi A., Fontaine J.F., Forti S., Fuentes-Perez J.M., Galvez-Romero J.L., Gamkrelidze A., Garcia-Cobas C.Y., Garcia-Cruz M.H., Gemicioglu B., Genova S., Christoff G., Gereda J.E., Gerth van Wijk R., Gomez R.M., Gomez-Vera J., Gonzalez Diaz S., Gotua M., Grisle I., Guidacci M., Guldemond N.A., Gutter Z., Guzman M.A., Haahtela T., Hajjam J., Hernandez L., Hourihane J.O.'.B., Huerta-Villalobos Y.R., Humbert M., Iaccarino G., Illario M., Ispayeva Z., Jares E.J., Jassem E., Johnston S.L., Joos G., Jung K.S., Just J., Jutel M., Kaidashev I., Kalayci O., Kalyoncu A.F., Karjalainen J., Kardas P., Keil T., Keith P.K., Khaitov M., Khaltaev N., Kleine-Tebbe J., Kowalski M.L., Kuitunen M., Kull I., Kupczyk M., Krzych-Falta E., Lacwik P., Laune D., Lauri D., Lavrut J., Le L.T.T., Lessa M., Levato G., Li J., Lieberman P., Lipiec A., Lipworth B., Lodrup Carlsen K.C., Louis R., Lourenco O., Luna-Pech J.A., Magnan A., Mahboub B., Maier D., Mair A., Majer I., Malva J., Mandajieva E., Manning P., De Manuel Keenoy E., Marshall G.D., Masjedi M.R., Maspero J.F., Mathieu-Dupas E., Matta Campos J.J., Matos A.L., Maurer M., Mavale-Manuel S., Mayora O., Meco C., Medina-Avalos M.A., Melo-Gomes E., Meltzer E.O., Menditto E., Mercier J., Miculinic N., Mihaltan F., Milenkovic B., Moda G., Mogica-Martinez M.D., Mohammad Y., Momas I., Montefort S., Mora Bogado D., Morais-Almeida M., Morato-Castro F.F., Mota-Pinto A., Moura Santo P., Munter L., Muraro A., Murray R., Naclerio R., Nadif R., Nalin M., Napoli L., Namazova-Baranova L., Neffen H., Niedeberger V., Nekam K., Neou A., Nieto A., Nogueira-Silva L., Nogues M., Novellino E., Nyembue T.D., O'Hehir R.E., Odzhakova C., Ohta K., Okamoto Y., Okubo K., Onorato G.L., Ortega Cisneros M., Ouedraogo S., Pali-Scholl I., Palkonen S., Panzner P., Park H.S., Papi A., Passalacqua G., Paulino E., Pawankar R., Pedersen S., Pepin J.L., Pereira A.M., Persico M., Phillips J., Picard R., Pigearias B., Pin I., Pitsios C., Plavec D., Pohl W., Popov T.A., Portejoie F., Potter P., Pozzi A.C., Price D., Prokopakis E.P., Puy R., Pugin B., Pulido Ross R.E., Przemecka M., Rabe K.F., Raciborski F., Rajabian-Soderlund R., Reitsma S., Ribeirinho I., Rimmer J., Rivero-Yeverino D., Rizzo J.A., Rizzo M.C., Robalo-Cordeiro C., Rodenas F., Rodo X., Rodriguez Gonzalez M., Rodriguez-Manas L., Rolland C., Rodrigues Valle S., Roman Rodriguez M., Romano A., Rodriguez-Zagal E., Rolla G., Roller-Wirnsberger R.E., Romano M., Rosado-Pinto J., Rosario N., Rottem M., Ryan D., Sagara H., Salimaki J., Sanchez-Borges M., Sastre-Dominguez J., Scadding G.K., Schunemann H.J., Scichilone N., Schmid-Grendelmeier P., Sarquis Serpa F., Shamai S., Sheikh A., Sierra M., Simons F.E.R., Siroux V., Sisul J.C., Skrindo I., Sole D., Somekh D., Sondermann M., Sooronbaev T., Sova M., Sorensen M., Sorlini M., Spranger O., Stellato C., Stelmach R., Stukas R., Sunyer J., Strozek J., Szylling A., Tebyrica J.N., Thibaudon M., To T., Todo-Bom A., Trama U., Triggiani M., Suppli Ulrik C., Urrutia-Pereira M., Valenta R., Valero A., Valiulis A., Valovirta E., van Eerd M., van Ganse E., van Hage M., Vandenplas O., Vezzani G., Vasankari T., Vatrella A., Verissimo M.T., Viart F., Viegi G., Vicheva D., Vontetsianos T., Wagenmann M., Walker S., Wallace D., Wang D.Y., Waserman S., Werfel T., Westman M., Wickman M., Williams D.M., Williams S., Wilson N., Wright J., Wroczynski P., Yakovliev P., Yawn B.P., Yiallouros P.K., Yusuf O.M., Zar H.J., Zhang L., Zhong N., Zernotti M.E., Zhanat I., Zidarn M., Zuberbier T., Zubrinich C., and Zurkuhlen A.
Subjects: 0301 basic medicine, SYMPTOMS, Smart phone, Allergy, Escala visual analógica, INNOVATION, [SDV]Life Sciences [q-bio], Medical and Health Sciences, Correlation, visual analogue scale, 0302 clinical medicine, Quality of life, Visual analogue scale, QUALITY-OF-LIFE, Màscares, Immunology and Allergy, score, Nose, Rinitis, Rhinitis, PRODUCTIVITY COSTS, asthma, MASK, rhinitis, Score, Explained variation, Response Variability, Mobile Applications, ALLERGIC RHINITIS, rhiniti, medicine.anatomical_structure, TRIALS, Rinite, 1107 Immunology, [SDV.IMM]Life Sciences [q-bio]/Immunology, Smartphone, medicine.medical_specialty, MASK study group, Immunology, MACVIA-ARIA, 03 medical and health sciences, Allergic, medicine, Humans, TECHNOLOGY, IMMUNOTHERAPY, Asma, Asthma, business.industry, Rhinitis, Allergic, medicine.disease, RHINOCONJUNCTIVITIS, 030104 developmental biology, 030228 respiratory system, 3121 General medicine, internal medicine and other clinical medicine, Physical therapy, Clinical Medicine, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: Background: In allergic rhinitis, a relevant outcome providing information on the effectiveness of interventions is needed. In MASK-air (Mobile Airways Sentinel Network), a visual analogue scale (VAS) for work is used as a relevant outcome. This study aimed to assess the performance of the work VAS work by comparing VAS work with other VAS measurements and symptom-medication scores obtained concurrently. Methods: All consecutive MASK-air users in 23 countries from 1 June 2016 to 31 October 2018 were included (14 189 users; 205 904 days). Geolocalized users self-assessed daily symptom control using the touchscreen functionality on their smart phone to click on VAS scores (ranging from 0 to 100) for overall symptoms (global), nose, eyes, asthma and work. Two symptom-medication scores were used: the modified EAACI CSMS score and the MASK control score for rhinitis. To assess data quality, the intra-individual response variability (IRV) index was calculated. Results: A strong correlation was observed between VAS work and other VAS. The highest levels for correlation with VAS work and variance explained in VAS work were found with VAS global, followed by VAS nose, eye and asthma. In comparison with VAS global, the mCSMS and MASK control score showed a lower correlation with VAS work. Results are unlikely to be explained by a low quality of data arising from repeated VAS measures. Conclusions: VAS work correlates with other outcomes (VAS global, nose, eye and asthma) but less well with a symptom-medication score. VAS work should be considered as a potentially useful AR outcome in intervention studies. © 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
Published: 2020
Full Text: View/download PDF

11. Adherence to treatment in allergic rhinitis using mobile technology. the mask study

Author: Menditto, E, Costa, E, Midao, L, Bosnic-Anticevich, S, Novellino, E, Bialek, S, Briedis, V, Mair, A, Rajabian-Soderlund, R, Arnavielhe, S, Bedbrook, A, Czarlewski, W, Annesi-Maesano, I, Anto, JM, Devillier, P, De Vries, G, Keil, T, Sheikh, A, Orlando, V, Larenas-Linnemann, D, Cecchi, L, De Feo, G, Stellato, C, Fonseca, J, Malva, J, Morais-Almeida, M, Pereira, AM, Todo-Bom, AM, Kvedariene, V, Valiulis, A, Bergmann, KC, Klimek, L, Mosges, R, Pfaar, O, Zuberbier, T, Cardona, V, Mullol, J, Papadopoulos, NG, Prokopakis, EP, Bewick, M, Ryan, D, Roller-Wirnsberger, RE, Tomazic, PV, Cruz, AA, Kuna, P, Samolinski, B, Fokkens, WJ, Reitsma, S, Bosse, I, Fontaine, JF, Laune, D, Haahtela, T, Toppila-Salmi, S, Bachert, C, Hellings, PW, Melen, E, Wickman, M, Bindslev-Jensen, C, Eller, E, O'Hehir, RE, Cingi, C, Gemicioglu, B, Kalayci, O, Ivancevich, JC, Bousquet, J, Aberer, W, Agache, I, Akdis, CA, Akdis, M, Aliberti, MR, Almeida, R, Amat, F, Angles, R, Ansotegui, IJ, Arnavielle, S, Asayag, E, Asarnoj, A, Arshad, H, Avolio, F, Bacci, E, Baiar-Dini, I, Barbara, C, Barbagallo, M, Baroni, I, Barreto, BA, Basagana, X, Bateman, ED, Bedolla-Barajas, M, Beghe, B, Bel, EH, Bennoor, KS, Benson, M, Bertorello, L, Bialoszewski, AZ, Bieber, T, Bjermer, L, Blain, H, Blasi, F, Blua, A, Marciniak, MB, Bogus-Buczynska, I, Boner, AL, Bonini, M, Bonini, S, Bosnic-Anticevich, CS, Bouchard, J, Boulet, LP, Bourret, R, Bousquet, P, Braido, F, Brightling, CE, Brozek, J, Bucca, C, Buhl, R, Buonaiuto, R, Panaitescu, C, Cabanas, MTB, Burte, E, Bush, A, Caballero-Fonseca, F, Caillaud, D, Caimmi, D, Calderon, MA, Camargos, PAM, Camuzat, T, Canfora, G, Canonica, GW, Carlsen, KH, Carreiro-Martins, P, Carriazo, AM, Carr, W, Cartier, C, Casale, T, Castellano, G, Cepeda, AM, Chavannes, NH, Chen, Y, Chiron, R, Chivato, T, Chkhartishvili, E, Chuchalin, AG, Chung, KF, Ciaravolo, MM, Ciceran, A, Ciprandi, G, Coehlo, ACC, Colas, L, Colgan, E, Coll, J, Conforti, D, De Sousa, JC, Cortes-Grimaldo, RM, Corti, F, Mc Costa-Dominguez, Al Courbis, Cox, L, Crescenzo, M, Custovic, A, Dahlen, SE, D'Amato, Dario, C, da Silva, J, Dauvilliers, Y, Darsow, U, De Blay, F, De Carlo, G, Dedeu, T, Emerson, MDF, De Martino, B, Rubina, NPM, Deleanu, D, Demoly, P, Denburg, J, Ercolano, SDC, Di Carluccio, N, Didier, A, Dokic, D, Dominguez-Silva, MG, Douagui, H, Dray, G, Dubakiene, R, Durham, SR, Du Toit, G, Dykewicz, MS, El-Gamal, Y, Eklund, P, Emuzyte, R, Farrell, J, Farsi, A, De Mello, JF, Ferrero, J, Fink-Wagner, A, Fiocchi, A, Fok-Kens, WJ, Forti, S, Fuentes-Perez, JM, Galvez-Romero, JL, Gamkrelidze, A, Garcia-Aymerich, J, Garcia-Cobas, CY, Garcia-Cruz, MH, Genova, S, Christoff, G, Gereda, JE, Van Wijk, RG, Gomez, RM, Gomez-Vera, J, Diaz, SG, Gotua, M, Grisle, I, Guidacci, M, Guldemond, N, Gutter, Z, Guzman, M, Hajjam, J, Hernandez, L, Houri-Hane, J, Huerta-Villalobos, YR, Humbert, M, Iaccarino, G, Illario, M, Ispayeva, Z, Jares, E, Jassem, E, Johnston, SL, Joos, G, Jung, KS, Just, J, Jutel, M, Kaidashev, I, Kalyoncu, AF, Karjalainen, J, Kardas, P, Keith, PK, Khaitov, M, Khaltaev, N, Kleine-Tebbe, J, Kowalski, ML, Kuitunen, M, Kull, I, Kupczyk, M, Krzych-Falta, E, Lacwik, P, Lauri, D, Lavrut, J, L, TT, Lessa, M, Levato, G, Li, J, Lieberman, P, Liplec, A, Lipworth, B, Carlsen, KCL, Louis, R, Lourenco, O, Luna-Pech, JA, Magnan, A, Mahboub, B, Maier, D, Majer, I, Mandajieva, E, Manning, P, Keenoy, EDM, Marshall, GD, Masjedi, MR, Maspero, JF, Mathieu-Dupas, E, Campos, JJM, Al Matos, Maurer, M, Mavale-Manuel, S, Mayora, O, Medina-Avalos, MA, Melo-Gomes, E, Meltzer, E, Mercier, J, Miculinic, N, Mihaltan, F, Milenkovic, B, Moda, G, Mogica-Martinez, MD, Mohammad, Y, Momas, I, Monte-Fort, S, Monti, R, Bogado, DM, Morato-Castro, Mota-Pinto, A, Santo, PM, Munter, L, Muraro, A, Murray, R, Naclerio, R, Nadif, R, Nalin, M, Napoli, L, Namazova-Baranova, L, Neffen, H, Niedeberger, V, Nekam, K, Neou, A, Nieto, A, Nogueira-Silva, L, Nogues, M, Nyembue, T, O'Hehir, R, Odzhakova, C, Ohta, K, Okamoto, Y, Okubo, K, Onorato, GL, Cisneros, MO, Ouedraogo, S, Pali-Scholl, I, Palkonen, S, Panzner, P, Park, HS, Papi, A, Passalacqua, G, Paulino, E, Pawankar, R, Pedersen, S, Pepin, JL, Persico, M, Phillips, J, Picard, R, Pigearias, B, Pin, I, Pitsios, C, Plavec, D, Pohl, W, Popov, TA, Portejoie, F, Potter, P, Pozzi, AC, Price, D, Puy, R, Pugin, B, Ross, REP, Przemecka, M, Rabe, KF, Raciborski, F, Raja-Bian-Soderlund, R, Ribeirinho, I, Rimmer, J, Riv-Ero-Yeverino, D, Rizzo, JA, Rizzo, MC, Robalo-Cordeiro, C, Rodenas, F, Rodo, X, Gonzalez, MR, Rodriguez-Manas, L, Rolland, C, Valle, SR, Rodriguez, MR, Romano, A, Rodriguez-Zagal, E, Rolla, G, Romano, M, Rosado-Pinto, J, Rosario, N, Rottem, M, Sagara, H, Salimaki, J, Sanchez-Borges, M, Sastre-Dominguez, J, Scadding, GK, Schunemann, HJ, Scichilone, N, Schmid-Grendelmeier, P, Serpa, FS, Shamai, S, Sierra, M, Simons, FER, Sir-Oux, V, Sisul, JC, Skrindo, I, Sole, D, Somekh, D, Sonder-Mann, M, Sooronbaev, T, Sova, M, Sorensen, M, Sorlini, M, Spranger, O, Stelmach, R, Stukas, R, Sunyer, J, Strozek, J, Szylling, A, Tebyrica, J, Thibaudon, M, To, T, Todo-Bom, A, Trama, U, Triggiani, M, Ulrik, CS, Urrutia-Pereira, M, Valenta, R, Valero, A, Valovirta, E, Van Eerd, M, Van Ganse, E, Van Hague, M, Vandenplas, O, Ventura, MT, Vezzani, G, Vasankari, T, Vatrella, A, Verissimo, MT, Viart, F, Viegi, G, Vicheva, D, Vontetsianos, T, Wagenmann, M, Walker, S, Wallace, D, Wang, DY, Waserman, S, Werfel, T, Westman, M, Williams, DM, Williams, S, Wilson, N, Wright, J, Wroczynski, P, Yakovliev, P, Yawn, BP, Yiallouros, PK, Yorgancioglu, A, Yusuf, OM, Zar, HJ, Zhang, L, Zhong, N, Zernotti, ME, Zhanat, I, Zidarn, M, Zubrinich, C, Zurkuhlen, A, MASK Grp, İÜC, Cerrahpaşa Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Department of Dermatology, Allergology and Venereology, University of Helsinki, Clinicum, Children's Hospital, HUS Children and Adolescents, HUS Inflammation Center, et. al., Universidade do Minho, Internal Medicine, Health Services Management & Organisation (HSMO), Ear, Nose and Throat, AII - Inflammatory diseases, Kyomed, Center for Research in Environmental Epidemiology (CREAL), Universitat Pompeu Fabra [Barcelona] (UPF)-Catalunya ministerio de salud, Università degli Studi di Salerno (UNISA), Center of Research in Health Technologies and Information Systems (CINTESIS), Universidade do Porto, Institute of Medical Statistics, Informatics and Epidemiology (IMSIE), University of Cologne, Department of Otorhinolaryngology, Head, and Neck Surgery, University Hospital Leuven, Institute of Environmental Medicine, Karolinska Institutet [Stockholm]-Karolinska University Hospital [Stockholm]-Astrid Lindgren Children's Hospital, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital-Monash University Building, AMREP, Cerrahpasa Faculty of Medicine, Istanbul University, Hacettepe University = Hacettepe Üniversitesi, Vieillissement et Maladies chroniques : approches épidémiologique et de santé publique (VIMA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Department for Molecular Biomedical Research, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Università degli Studi di Firenze = University of Florence [Firenze] (UNIFI), Department of Otorhinolaryngology, Head and Neck Surgery, Eskisehir Osmangazi University, Instituto de Biologia Molecular e Celular (IBMC), Laboratoire de Génie Informatique et d'Ingénierie de Production (LGI2P), IMT - MINES ALES (IMT - MINES ALES), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT), UCB Pharma, Colombes, Laboratoire de recherche sur les mécanismes moléculaires et pharmacologiques de l’obstruction bronchique (LOBIP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Department of Dermatology and Allergy Centre, Odense University Hospital, Department of Dermatology, Helsinki University Hospital-Skin and Allergy Hospital, Institute of Social Medicine, Epidemiology and Health Economics-Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], German Society for Otorhinolaryngology HNS, Medical University of Łódź (MUL), Vilnius University [Vilnius], Institut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), University of Coimbra [Portugal] (UC), 'Federico II' University of Naples Medical School, Transverse group for research in primary care [Barcelona], Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Naples Federico II, University Hospital Mannheim, Allergy and Respiratory Research Group, University of Edinburgh, Department of Prevention of Envinronmental Hazards and Allergology, Medical University of Warsaw - Poland, Asthma UK Centre for Applied Research [Edinburgh, U.K.], University of Edinburgh-Usher Institute of Population Health Sciences and Informatics [Edinburgh, U.K.], Vilnius University Clinic of Children's Diseases, Sachs’ Children and Youth Hospital [Stockholm, Sweden], Secretary General of the Global Allergy and Asthma European Network (GA2LEN), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Menditto, E, Costa, E, Midão, L, Bosnic-Anticevich, S, Novellino, E, Bialek, S, Briedis, V, Mair, A, Rajabian-Soderlund, R, Arnavielhe, S, Bedbrook, A, Czarlewski, W, Annesi-Maesano, I, Anto, Jm, Devillier, P, De Vries, G, Keil, T, Sheikh, A, Orlando, V, Larenas-Linnemann, D, Cecchi, L, De Feo, G, Illario, M, Stellato, C, Fonseca, J, Malva, J, Morais-Almeida, M, Pereira, Am, Todo-Bom, A, Kvedariene, V, Valiulis, A, Bergmann, Kc, Klimek, L, Mösges, R, Pfaar, O, Zuberbier, T, Cardona, V, Mullol, J, Papadopoulos, Ng, Prokopakis, Ep, Bewick, M, Ryan, D, Roller-Wirnsberger, Re, Tomazic, Pv, Cruz, Aa, Kuna, P, Samolinski, B, Fokkens, Wj, Reitsma, S, Bosse, I, Fontaine, Jf, Laune, D, Haahtela, T, Toppila-Salmi, S, Bachert, C, Hellings, Pw, Melén, E, Wickman, M, Bindslev-Jensen, C, Eller, E, O'Hehir, Re, Cingi, C, Gemicioğlu, B, Kalayci, O, Ivancevich, Jc, Bousquet, J, and Iaccarino, Guido
Subjects: 0301 basic medicine, Male, Allergy, Medicina Básica [Ciências Médicas], CONTROLLER MEDICATION, adherence, mHealth, mobile technology, observational study, rhinitis, treatment, THERAPY, Medical and Health Sciences, Medical Records, DISEASE, 0302 clinical medicine, Surveys and Questionnaires, Immunology and Allergy, Middle Aged, Mobile Applications, 3. Good health, Medication possession ratio, rhiniti, 1107 Immunology, Ciências Médicas::Medicina Básica, Female, TRIAL, Life Sciences & Biomedicine, Adult, medicine.medical_specialty, Immunology, K-ANONYMITY, VALIDATION, 1117 Public Health and Health Services, Medication Adherence, 03 medical and health sciences, Internal medicine, Health Sciences, medicine, Humans, Clinical significance, Mobile technology, [INFO]Computer Science [cs], Asthma, Aged, [SDV.EE.SANT]Life Sciences [q-bio]/Ecology, environment/Health, Science & Technology, Relative efficacy, business.industry, PERSISTENCE, medicine.disease, Rhinitis, Allergic, Cell Phone Use, Patient Outcome Assessment, 030104 developmental biology, Cross-Sectional Studies, 030228 respiratory system, 3121 General medicine, internal medicine and other clinical medicine, MASK group, ASTHMA, Observational study, business
Abstract: Pereira, Ana Margarida/0000-0002-5468-0932; Briedis, Vitalis/0000-0002-5106-6638; Johnston, Sebastian Lennox/0000-0003-3009-9200; Orlando, Valentina/0000-0002-8209-8878; Sova, Milan/0000-0002-8542-7841; Chung, Kian Fan/0000-0001-7101-1426; Ciprandi, Giorgio/0000-0001-7016-8421; Yusuf, M Osman/0000-0002-8067-1204; stelmach, rafael/0000-0002-5132-1934; Sunyer, Jordi/0000-0002-2602-4110; Martins, Pedro/0000-0002-4129-133X; Demoly, Pascal/0000-0001-7827-7964; Fonseca, Joao Almeida/0000-0002-0887-8796; Anto, J M/0000-0002-4736-8529; IACCARINO, Guido/0000-0002-8997-835X; Custovic, Adnan/0000-0001-5218-7071; Lourenco, Olga/0000-0002-8401-5976; Pugin, Benoit/0000-0001-7132-9477; Chavannes, Niels/0000-0002-8607-9199; Rodo, Xavier/0000-0003-4843-6180; Nadif, Rachel/0000-0003-4938-9339; Plavec, Davor/0000-0003-2020-8119; Vicheva, Dilyana/0000-0002-6805-3825; Iaccarino, Guido/0000-0002-8997-835X; Annesi-Maesano, Isabella/0000-0002-6340-9300; N.G., Papadopoulos/0000-0002-4448-3468; J, Garcia-Aymerich/0000-0002-7097-4586; Humbert, Marc/0000-0003-0703-2892; Barbara, C./0000-0003-0915-4105; Gemicioglu, Bilun/0000-0001-5953-4881; Caimmi, Davide/0000-0003-4481-6194; Namazova-Baranova, Leyla/0000-0002-2209-7531; Basagana, Xavier/0000-0002-8457-1489; Midao, Luis/0000-0003-1981-2554; Sheikh, Aziz/0000-0001-7022-3056; O'Hehir, Robyn/0000-0002-3489-7595; Cardona, Victoria/0000-0003-2197-9767; Mota-Pinto, Anabela/0000-0002-0820-9568; Cecchi, Lorenzo/0000-0002-0658-2449; Bindslev-Jensen, Carsten/0000-0002-8940-038X; Costa, Elisio/0000-0003-1158-1480; Kuna, Piotr/0000-0003-2401-0070; Malva, Joao/0000-0002-5438-4447; Zuberbier, Torsten/0000-0002-1466-8875; Toppila-Salmi, Sanna/0000-0003-0890-6686; Nogueira-Silva, Luis/0000-0002-5519-707X; Ivancevich, Juan Carlos/0000-0001-8713-6258 WOS:000463761700007 PubMed ID: 30597673 Background: Mobile technology may help to better understand the adherence to treatment. MASK-rhinitis (Mobile Airways Sentinel NetworK for allergic rhinitis) is a patient-centred ICT system. A mobile phone app (the Allergy Diary) central to MASK is available in 22 countries. Objectives: To assess the adherence to treatment in allergic rhinitis patients using the Allergy Diary App. Methods: An observational cross-sectional study was carried out on all users who filled in the Allergy Diary from 1 January 2016 to 1 August 2017. Secondary adherence was assessed by using the modified Medication Possession Ratio (MPR) and the Proportion of days covered (PDC) approach. Results: A total of 12143 users were registered. A total of 6949 users reported at least one VAS data recording. Among them, 1887 users reported >= 7 VAS data. About 1195 subjects were included in the analysis of adherence. One hundred and thirty-six (11.28%) users were adherent (MPR >= 70% and PDC = 70% and PDC = 1.50) and 176 (14.60%) were switchers. On the other hand, 832 (69.05%) users were non-adherent to medications (MPR
Published: 2019
Full Text: View/download PDF

12. Geolocation with respect to personal privacy for the Allergy Diary app - a MASK study

Author: Samreth, D, Arnavielhe, S, Ingenrieth, F, Bedbrook, A, Onorato, G L, Murray, R, Almeida, R, Mizani, M A, Fonseca, J, Costa, E, Malva, J, Morais-Almeida, M, Pereira, A M, Todo-Bom, A, Menditto, E, Stellato, C, Ventura, M T, Larenas-Linnemann, D, Fuentes-Pérez, J-M, Huerta-Villalobos, Y R, Cruz, A A, Stelmach, R, da Silva, J, Emuzyte, R, Kvedariene, V, Valiulis, A, Annesi-Maesano, I, Bosse, I, Demoly, P, Devillier, P, Fontaine, J F, Kuna, P, Samolinski, B, Klimek, L, Mösges, R, Pfaar, O, Shamai, S, Bewick, M, Ryan, D, Sheikh, A, Anto, J M, Cardona, V, Mullol, J, Valero, A, Chavannes, N H, Fokkens, W J, Reitsma, S, Roller-Wirnsberger, R E, Tomazic, P V, Haahtela, T, Toppila-Salmi, S, Valovirta, E, Makris, M, Papadopoulos, N G, Prokopakis, E P, Psarros, F, Gemicioğlu, B, Yorgancioglu, A, Bindslev-Jensen, C, Eller, E, Kull, I, Wickman, M, Bachert, C, Hellings, P W, Pugin, B, Bosnic-Anticevich, S, O'Hehir, R E, Kolek, V, Sova, M, Wehner, K, De Vries, G, van Eerd, M, Laune, D, Wittmann, J, Bousquet, J, Poncelet, P, Agache, I, Angles, R, Anto, Jm, Asayag, E, Bacci, E, Baiardini, I, Baroni, I, Barreto, Ba, Basagana, X, Bedolla-Barajas, M, Bergmann, Kc, Bertorello, L, Bialek, S, Bieber, T, Bjermer, L, Blua, A, Bochenska Marciniak, M, Bogus-Buczynska, I, Bouchard, J, Bourret, R, Briedis, V, Bucca, C, Buonaiuto, R, Burguete Cabanas MT, Caiazza, D, Caillot, D, Caimmi, D, Camargos, P, Canfora, G, Carriazo, Am, Cartier, C, Carla Carvalho Coelho, A, Castellano, G, Cecchi, L, Chavannes, Nh, Ciaravolo, Mm, Cingi, C, Ciceran, A, Colas, L, Colgan, E, Coll, J, Conforti, D, Correia da Sousa, J, Cortés-Grimaldo, Rm, Corti, F, Costa, Dj, Costa Dominguez MC, Courbis, Al, Cruz, Aa, Custovic, A, Czarlewski, W, Dario, C, Dauvilliers, Y, De Carlo, G, De Blay, F, Dedeu, T, de Fátima Emerson, M, De Feo, G, Garcia Cruz MH, De Martino, B, de Paula Motta Rubini, N, Di Capua Ercolano, S, Di Carluccio, N, Dray, G, Dubakiene, R, Espinoza-Contreras, Jm, Estrada-Cardona, A, Farrell, J, Farsi, A, Ferreira de Mello, J Jr, Ferrero, J, Fokkens, Wj, Fontaine, Jf, Forti, S, Garcia-Aymerich, J, Gálvez-Romero, Jl, García-Cobas, Ci, Gerth van Wijk, R, Guidacci, M, Gómez-Vera, J, Guldemond, Na, Gutter, Z, Hajjam, J, Hellings, Pw, Hernández, L, Illario, M, Ivancevich, Jc, Jares, E, Joos, G, Just, J, Kalayci, O, Kalyoncu, Af, Karjalainen, J, Keil, T, Khaltaev, N, Kowalski, Ml, Krzych-Fałta, E, Kupczyk, M, Lacwik, P, Lauri, D, Lavrut, J, Lessa, Ma, Levato, G, Lewis, L, Lieten, I, Lipiec, A, Louis, R, Luna-Pech, Ja, Maciej, K, Magnan, A, Maspero, Jf, Mathieu-Dupas, E, Matos, Al, Mayora, O, Medina-Ávalos, Ma, Melen, E, Millot-Keurinck, J, Mizani, Ma, Moda, G, Morato-Castro, Ff, Moura Santo, P, Mota-Pinto, A, Murraro, A, Nalin, M, Noguès, M, Novellino, E, Napoli, L, Neffen, H, O'Hehir, Re, Onorato, Gl, Palkonen, S, Papadopoulos, Ng, Passalacqua, G, Pépin, Jl, Pereira, Am, Persico, M, Picard, R, Portejoie, F, Pozzi, Ac, Price, D, Prokopakis, Ep, Puy, R, Przemecka-Green, M, Raciborski, F, Rajabian-Soderlund, R, Ribeirinho, I, Rimmer, J, Rizzo, Ja, Rizzo, Mc, Robalo-Cordeiro, C, Rodo, X, Rodrigues Valle, S, Rodríguez-González, M, Rolla, G, Roller-Wirnsberger, Re, Romano, A, Romano, M, Rosario, N, Salimäki, J, Sierra, M, Simons, Fer, Solé, D, Sorlini, M, Spranger, O, A C, Stellato, Strozek, J, Stukas, R, Sutherland, M, Szylling, A, Tebyriçá, Jn, Thibaudon, M, Tibaldi, V, Tomazic, P, Trama, U, Triggiani, M, Urrutia-Pereira, M, Vandenplas, O, Vasankari, T, Vatrella, A, Ventura, Mt, Verissimo, Mt, Viart, F, Williams, S, Wagenmann, M, Westman, M, Wroczynski, P, Zernotti, E, Zurbierber, T, Zubrinich, C, Zurkuhlen, A., Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Universidade de Lisboa (ULISBOA), Universitat Politècnica de València (UPV), University of Coimbra [Portugal] (UC), 'Federico II' University of Naples Medical School, Microbiologie cellulaire et moléculaire et pathogénicité (MCMP), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique (CNRS), Universidade Federal de Santa Catarina = Federal University of Santa Catarina [Florianópolis] (UFSC), Vilnius University [Vilnius], CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Département pneumologie et addictologie [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve, Hôpital Foch [Suresnes], Erosion torrentielle neige et avalanches (UR ETGR (ETNA)), Institut national de recherche en sciences et technologies pour l'environnement et l'agriculture (IRSTEA), Heidelberg University, University Hospital of Cologne [Cologne], Department of Computer Science [Haifa], University of Haifa [Haifa], University of Edinburgh, Vall d'Hebron University Hospital [Barcelona], University of Barcelona, Karl-Franzens-Universität [Graz, Autriche], University of Helsinki, University of Turku, Department of Cardiovascular Science [Sheffield], University of Sheffield [Sheffield], The Institute of Environmental Medicine [Stockholm] (IMM), Karolinska Institutet [Stockholm], Ghent University Hospital, University Hospitals Leuven [Leuven], The University of Sydney, Monash University [Melbourne], Institut de Recherche en Infectiologie de Montpellier (IRIM), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), ADVanced Analytics for data SciencE (ADVANSE), Laboratoire d'Informatique de Robotique et de Microélectronique de Montpellier (LIRMM), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Ear, Nose and Throat, AII - Inflammatory diseases, Department of Dermatology, Allergology and Venereology, Clinicum, Sanna Katriina Toppila-Salmi / Principal Investigator, HUS Inflammation Center, Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Nîmes (CHRU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Universidad Politécnica de Valencia, Federal University of Santa Catarina (UFSC), University of Graz, Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), MACVIA-France, Fondation partenariale FMC VIA-LR, Montpellier, France, INSERM U 1168, VIMA: Ageing and chronic diseases Epidemiological and public health approaches, Villejuif, Université Versailles St-Quentin-en-Yvelines, UMR-S 1168, Montigny le Bretonneux, France and Euforea, Brussels, Belgium, Faculty of Medicine, Transylvania University, Brasov, Romania, Center for Health Technology and Services Research-CINTESIS, Faculdade de Medicina, Universidade do Porto, and Medina, Lda Porto, Portugal, Innovación y nuevas tecnologías, Salud Sector sanitario de Barbastro, Barbastro, Spain, Epidemiology of Allergic and Respiratory Diseases, Department Institute Pierre Louis of Epidemiology and Public Health, INSERM and Sorbonne Université, Medical School Saint Antoine, Paris, France, ISGlobAL, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain, IMIM (Hospital del Mar Research Institute), Barcelona, Spain, CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain, Universitat Pompeu Fabra (UPF), Barcelona, Spain, Kyomed, Montpellier, France, Argentine Society of Allergy and Immunopathology, Buenos Aires, Argentina, Regione Liguria, Genoa, Italy, Upper Airways Research Laboratory, ENT Dept, Ghent University Hospital, Ghent, Belgium, Department of Medicine Solna, Immunology and Allergy Unit, Karolinska Institutet and Department of ENT diseases, Karolinska University Hospital, Stockholm, Sweden, Telbios SRL, Milan, Italy, Universidade do Estado do Pará, Belem, Brazil, Hospital Civil de Guadalajara Dr Juan I Menchaca, Guadalarara, Mexico, Comprehensive Allergy-Centre-Charité, Department of Dermatology and Allergy, Charité-Universitätsmedizin Berlin, Global Allergy and Asthma European Network (GA2LEN), Berlin, Germany, iQ4U Consultants Ltd, London, United Kingdom, Dept of Biochemistry and Clinical Chemistry-Dpt of Postgraduate Education, Faculty of Pharmacy with the Laboratory Medicine Division, Medical University of Warsaw, Poland, Department of Dermatology and Allergy, Rheinische Friedrich-Wilhelms-University Bonn, Bonn, Germany, Department of Dermatology and Allergy Centre, Odense University Hospital, Odense Research Center for Anaphylaxis (ORCA), Odense, Denmark, Department of Respiratory Medicine and Allergology, University Hospital, Lund, Sweden, Argentine Association of Respiratory Medicine, Buenos Aires, Argentina, Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Poland, Woolcock Institute of Medical Research, University of Sydney and Sydney Local Health District, Glebe, NSW, Australia, La Rochelle, France, Associate professor of clinical medecine, Laval's University, Quebec city, Head of medecine department, Hôpital de la Malbaie, Quebec, Canada, Centre Hospitalier Valenciennes, France, Head of Department of Clinical Pharmacy of Lithuanian University of Clinical Sciences, Kaunas, Lithuania, Chief of the University Pneumology Unit-AOU Molinette, Hospital City of Health and Science of Torino, Italy, Municipality PharmacySarno, Italy, Nuove Leon, Monterey, Mexico, Pharmacist, Municipality Pharmacy, Mercato Sam Severino, Italy, Service de pneumologie, CHU et université d'Auvergne, Clermont-Ferrand, France, Department of Respiratory Diseases, Montpellier University Hospital, France, Federal University of Minas Gerais, Medical School, Department of Pediatrics, Belo Horizonte, Brazil, Mayor of Sarno and President of Salerno Province, Director, Anesthesiology Service, Sarno 'Martiri del Villa Malta' Hospital, Italy, S Allergologia, S Medicina Interna, Hospital Vall d'Hebron, Barcelona, Spain, Regional Ministry of Health of Andalusia, Seville, Spain, ASA-Advanced Solutions Accelerator, Clapiers, France, Universidade Federal da Bahia, Salvador, Brazil, Celentano pharmacy, Massa Lubrense, Italy, SOS Allergology and Clinical Immunology, USL Toscana Centro, Prato, Italy, Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands, Specialist social worker, Sorrento, Italy, Eskisehir Osmangazi University, Medical Faculty, ENT Department, Eskisehir, Turkey, Argentine Federation of Otorhinolaryngology Societies, Buenos Aires, Argentina, University of Nantes, Service de Pneumologie, UMR INSERM, UMR 1087 and CNR 6291, l'institut du thorax, Nantes, France, LANUA International Healthcare Consultancy, United Kingdom, Fondazione Bruno Kessler (FBK), Trento, Italy, Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal, Guadalarara, Mexico, FIMMG (Federazione Italiana Medici di Medicina Generale), Milan, Italy, General Practice, Nîmes, France, Dominguez C. Ciutad Mexico, Mexico, IMT Mines-Alès, Univ. Montpellier, Alès, France, ProAR – Nucleo de Excelencia em Asma, Federal University of Bahia, Brasil and WHO GARD Planning Group, Brazil, Department of Pediatric, Imperial College London, United Kingdom, Medical Consulting Czarlewski, Levallois, France, Azienda Provinciale per i Servizi Sanitari di Trento (APSS-Trento), Italy, Department of Internal Medicine and Allergy Clinic of Professor Polydoro Ernani de São, Thiago University Hospital, Federal University of Santa Catarina (UFSC), Florianopolis-SC, Brazil, Sleep Unit, Department of Neurology, Hôpital Gui-de-Chauliac MontpellierInserm U1061, France, EFA European Federation of Allergy and Airways Diseases Patients’ Associations, Brussels, Belgium, Allergy Division, Chest Disease Department, University Hospital of Strasbourg, Strasbourg, France, AQuAS, Barcelna, Spain & EUREGHA, European Regional and Local Health Association, Brussels, Belgium, Policlínica Geral do Rio de Janeiro, Rio de Janeiro, Brazil, Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, Salerno, Italy, Allergy Clinic, National Institute of Respiratory Diseases, Mexico City, Mexico, Social workers oordinator, Sorrento, Italy, Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, UPRES EA220, Pôle des Maladies des Voies Respiratoires, Hôpital Foch, Université Paris-Saclay, Suresnes, France, Peercode BV, Geldermalsen, Netherlands, Farmacie Dei Golfi Group, Massa Lubrense, Italy, Clinic of Children's Diseases, Faculty of Medicine, Vilnius University, Vilnius, Lithuania, University of Aguascalientes, Chihuaha, Mexico, Playa del Carmen, Mexico, JUniversidade de São Paulo, São Paulo, Brazil, Andalusian Agency for Healthcare Quality, Seville, Spain, Department of Otorhinolaryngology, Academic Medical Centre, Amsterdam, Netherlands, Reims, France, Regional hospital of ISSSTE, Puebla, Mexico, Department of Pulmonary Diseases, Istanbul University, Cerrahpasa Faculty of Medicine, Turkey, Department of Internal Medicine, section of Allergology, Erasmus MC, Rotterdam, Netherlands, Hospital de Base de Brasilia, Brazil, Allergy Clinic, Hospital Regional del ISSSTE ‘Lic. López Mateos’, Mexico City, Mexico, Institute of Health Policy and Management iBMG, Erasmus University, Rotterdam, Netherlands, University Hospital Olomouc – National eHealth Centre, Czech Republic, Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland, Centich: centre d’expertise national des technologies de l’information et de la communication pour l’autonomie, Gérontopôle autonomie longévité des Pays de la Loire, Conseil régional des Pays de la Loire, Centre d’expertise Partenariat Européen d’Innovation pour un vieillissement actif et en bonne santé, Nantes, France, Dept of Otorhinolaryngology, Univ Hospitals Leuven, Belgium, and Academic Medical Center, Univ of Amsterdam, The Netherlands and Euforea, Brussels, Belgium, Ensenada, Mexico, Division for Health Innovation, Campania Region and Federico II University Hospital Naples (R&D and DISMET) Naples, Italy, Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina, President, Libra Foundation, Buenos Aires, Argentina, Dept of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium, Allergology department, Centre de l'Asthme et des Allergies Hôpital d'Enfants Armand-Trousseau (APHP), Sorbonne Université, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Equipe EPAR, Paris, France, Pediatric Allergy and Asthma Unit, Hacettepe University School of Medicine, Ankara, Turkey, Hacettepe University, School of Medicine, Department of Chest Diseases, Immunology and Allergy Division, Ankara, Turkey, Allergy Centre, Tampere University Hospital, Tampere, Finland, Institute of Social Medicine, Epidemiology and Health Economics, Charité-Universitätsmedizin Berlin, and Institute for Clinical Epidemiology and Biometry, University of Wuerzburg, Berlin, Germany, GARD Chairman, Geneva, Switzerland, Center for Rhinology and Allergology, Wiesbaden, Germany, Department of Immunology, Rheumatology and Allergy, Medical University of Lodz, and HARC, Poland, Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden, Faculty of Medicine, Vilnius University, Vilnius, Lithuania, Department of Respiratory Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Czech Republic, Department of Prevention of Envinronmental Hazards and Allergology, Medical University of Warsaw, Poland, Center of Excellence in Asthma and Allergy, Hospital Médica Sur, México City, Mexico, Presidente CMMC, Milano, Italy, Head of the Allergy Department of Pedro de Elizalde Children's Hospital, Buenos Aires, Argentina, Faculdade de Medicina da, Universidade Federal da Bahia, Salvador de Bahia, Brazil, Milano, Italy, Promotor B3 Action GRoup EIP on AHA and Senior Fellow, International Foundation for Integreted Care, Aberystwyth, United Kingdom, Tech Life Valley, Diepenbeek, Belgium, Department of Pulmonary Medicine, CHU Sart-Tilman, University of Liege, GIGA I3 research group, Liege, Belgium, University of Guadalajara, Guadalara, Mexico, Institute of Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, University of Coimbra, Portugal, University of Southeast Bahia, Brazil, Veracruz, Mexico, Sachs’ Children and Youth Hospital, Södersjukhuset, Stockholm and Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, CIRFF, Federico II University, Naples, Italy, Caisse d'assurance retraite et de la santé au travail du Languedoc-Roussillon (CARSAT-LR), Montpellier, France, Centre of Medical Informatics, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, United Kingdom, Regione Piemonte, Torino, Italy, Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal, Universidade de São Paulo, São Paulo, Brazil, Federal University of Bahia, Brazil, Institute of Medical Statistics, and Computational Biology, Medical Faculty, University of Cologne, CRI-Clinical Research International-Ltd., Hamburg, Germany, General Pathology Institute, Faculty of Medicine, University of Coimbra, Institute of Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, University of Coimbra, Portugal, Rhinology Unit & Smell Clinic, ENT Department, Hospital Clínic, Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Spain, Food Allergy Referral Centre Veneto Region, Department of Women and Child Health, Padua General University Hospital, Padua, Italy, Director, Medical Communications Consultant, MedScript Ltd, Dundalk, Co Louth, Ireland, Director of Department of Pharmacy of University of Naples Federico II, Naples, Italy, Director, Consortium of Pharmacies and Services COSAFER, Salerno, Italy, Director of Center of Allergy, Immunology and Respiratory Diseases, Argentina, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Central Clinical School, Monash University, Melbourne, VIC, Australia, Center for Pediatrics and Child Health, Institute of Human Development, Royal Manchester Children's Hospital, University of Manchester, Manchester, M13 9WL, United Kingdom, Allergy and Respiratory Diseases, Ospedale Policlino San Martino-University of Genoa, Italy, Université Grenoble Alpes, Laboratoire HP2, Grenoble, INSERM, U1042 and CHU de Grenoble, France, Allergy Unit, CUF-Porto Hospital and Institute, Center for Research in Health Technologies and information systems CINTESIS, Universidade do Porto, Portugal, municipality area n33, Sorrento, Italy, Department of Otorhinolaryngology, Head and Neck Surgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany, Conseil Général de l'Economie Ministère de l'Economie, de l'Industrie et du Numérique, Paris, France, LIRMM, Montpellier, France, Vice-Presidente of IML, Milano, Italy, Observational and Pragmatic Research Institute, Optimum Patient Care, Academic Centre of Primary Care, University of Aberdeen, Cambridge, United Kingdom, Department of Otorhinolaryngology, University of Crete School of Medicine, Heraklion, Greece, European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), Brussels, Belgium, Centre of Pneumology, Coimbra University Hospital, Portugal, Climate and Health Program, ISGlobal and ICREA, Barcelona, Spain, Pediatric Allergy and Clinical Immunology, Hospital Angeles Pedregal, Mexico, Allergy Unit, Presidio Columbus, Catholic University of Sacred Heart, IRCCS Oasi Maria SS, Troina, Italy, Department of Pediatrics & Child Health, Department of Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada, Universidade Federal de São Paulo, São Paulo, Brazil, IML (Lombardy Medical Initiative), Bergamo, Italy, Global Allergy and Asthma Platform GAAPP, Altgasse 8-10, Vienna, 1130, Austria, Pulmonary Division, Heart Institute (InCor), Hospital da Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil, Public Health Institute of Vilnius University, Vilnius, Lithuania, Alfred Hospital, Melbourne, VIC, Australia, RNSA (Réseau National de Surveillance Aérobiologique), Brussieu, France, Imunoalergologia, Centro Hospitalar Universitário de Coimbra and Faculty of Medicine, University of Coimbra, Portugal, Department of ENT, Medical University of Graz, Austria, Campania Region, Division on Pharmacy and devices policy, Naples, Italy, Universidade Federal dos Pampas, Uruguaiana, Brazil, Pneumology and Allergy Department CIBERES and Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, University of Barcelona, Spain, Department of Lung Diseases and Clinical Immunology, University of Turku and Terveystalo allergy clinic, Turku, Finland, Vilnius University Institute of Clinical Medicine, Clinic of Children's Diseases, and Institute of Health Sciences, Department of Public Health, Vilnius, Lithuania, Department of Chest Medicine, Centre Hospitalier Universitaire UCL Namur, Université Catholique de Louvain, Yvoir, Belgium, FILHA, Finnish Lung Association, Helsinki, Finland, University of Bari Medical School, Unit of Geriatric Immunoallergology, Bari, Italy, International Primary Care Respiratory Group IPCRG, Aberdeen, United Kingdom, Dept of Otorhinolaryngology, HNO-Klinik, Universitätsklinikum Düsseldorf, Germany, Department of Physical Pharmacy and Bioanalysis, Faculty of Pharmacy with the Laboratory Medicine Division, Medical University of Warsaw, Warsaw, Poland, Department of Pulmonary Diseases, Celal Bayar University, Faculty of Medicine, Manisa, Turkey, Universidad Católica de Córdoba, Córdoba, Argentina, Gesundheitsregion KölnBonn-HRCB Projekt GmbH, Kohln, Germany, Montpellier, France, Selbstregulierung Informationswirtschaft eV, Berlin, Germany, MedScript Ltd, Dundalk, Co Louth, Ireland, and Medina, Lda, Porto, Portugal, Asthma UK Centre for Applied Research, Centre of Medical Informatics, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, United Kingdom, UCIBIO, REQUINTE, Faculty of Pharmacy and Competence Center on Active and Healthy, Ageing of University of Porto (Porto4Ageing), Porto, Portugal, Institute of Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine, Ageing@Coimbra EIP-AHA Reference Site, University of Coimbra, Coimbra, Portugal, Center for Research in Health Technologies and information systems CINTESIS, Universidade do Porto, Porto, Portugal, Imunoalergologia Centro Hospitalar Universitário de Coimbra and Faculty of Medicine, University of Coimbra, Coimbra, Portugal, Unit of Geriatric Immunoallergology, University of Bari Medical School, Bari, Italy, Mexico City, Mexico, ProAR – Nucleo de Excelencia em Asma, Brasil and WHO GARD Planning Group, Federal University of Bahia, Salvador, Brazil, Department of Internal Medicine and Allergy Clinic of Professor Polydoro Ernani de São, Thiago University Hospital, Federal University of Santa Catarina (UFSC), Florianopolis, SC, Brazil, Clinic of Children’s Diseases, Faculty of Medicine, Vilnius University, Vilnius, Lithuania, Clinic of Children’s Diseases, and Institute of Health Sciences, Department of Public Health, Vilnius University Institute of Clinical Medicine, Vilnius, Lithuania, European Academy of Paediatrics (EAP/UEMS-SP), Brussels, Belgium, Epidemiology of Allergic and Respiratory Diseases, Department Institute Pierre Louis of Epidemiology and Public Health, Medical School Saint Antoine, INSERM and Sorbonne Université, Paris, France, Department of Respiratory Diseases, Montpellier University Hospital, Montpellier, France, Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland, Samolinski. Department of Prevention of Envinronmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland, Institute of Medical Statistics, and Computational Biology, Medical Faculty, University of Cologne, Cologne, Germany, CRI-Clinical Research International Ltd, Hamburg, Germany, Department of Otorhinolaryngology, Head and Neck Surgery, Universitätsmedizin Mannheim, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany, Woodbrook Medical Centre, Loughborough, United Kingdom, Honorary Clinical Research Fellow, Allergy and Respiratory Research Group, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Medical School, Edinburgh, United Kingdom, S Allergologia, S Medicina Interna, Hospital Vall d’Hebron, Barcelona, Spain, Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain, Pneumology and Allergy Department CIBERES and Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, University of Barcelona, Barcelona, Spain, Department of Internal Medicine, Medical University of Graz, Graz, Austria, Department of ENT, Medical University of Graz, Graz, Austria, Division of Infection, Immunity 1 Respiratory Medicine, University of Manchester, Manchester, United Kingdom, Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece, Allergy Department, Athens Naval Hospital, Athens, Greece, Department of Pulmonary Diseases, Istanbul University, Cerrahpasa Faculty of Medicine, Istanbul, Turkey, Department of Pulmonary Diseases, Faculty of Medicine, Turkey and GARD Executive Committee, Celal Bayar University, Manisa, Turkey, Department of Dermatology and Allergy Centre, Odense Research Center for Anaphylaxis (ORCA), Odense University Hospital, Odense, Denmark, Centre for Clinical Research Sörmland, Uppsala University, Eskilstuna, Sweden, Upper Airways Research Laboratory, ENT Department, Ghent University Hospital, Ghent, Belgium, Department of Otorhinolaryngology, Univ Hospitals Leuven, Leuven, Belgium, Academic Medical Center, Univ of Amsterdam, Amsterdam, Netherlands, Euforea, Brussels, Belgium, Department of Immunology, Monash University, Melbourne, VIC, Australia, Department of Respiratory Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Olomouc, Czech Republic, Fachbereich Biologie, Technische Universität, Darmstadt, Germany, INSERM U 1168, VIMA: Ageing and chronic diseases Epidemiological and public health approaches, Villejuif, France, Université Versailles St-Quentin-en-Yvelines, UMR-S 1168, Montigny le Bretonneux, France, Bousquet, J., Agache, I., Almeida, R., Angles, R., Annesi-Maesano, I., Anto, J. M., Arnavielhe, S., Asayag, E., Bacci, E., Bachert, C., Baiardini, I., Baroni, I., Barreto, B. A., Basagana, X., Bedbrook, A., Bedolla-Barajas, M., Bergmann, K. C., Bertorello, L., Bewick, M., Bialek, S., Bieber, T., Bindslev-Jensen, C., Bjermer, L., Blua, A., Marciniak, M. B., Bogus-Buczynska, I., Bosnic-Anticevich, S., Bosse, I., Bouchard, J., Bourret, R., Briedis, V., Bucca, C., Buonaiuto, R., Cabanas, M. T. B., Caiazza, D., Caillot, D., Caimmi, D., Camargos, P., Canfora, G., Cardona, V., Carriazo, A. M., Cartier, C., Coelho, A. C. C., Castellano, G., Cecchi, L., Chavannes, N. H., Ciaravolo, M. M., Cingi, C., Ciceran, A., Colas, L., Colgan, E., Coll, J., Conforti, D., Sousa, J. C. D., Cortes-Grimaldo, R. M., Corti, F., Costa, D. J., Dominguez, M. C. C., Courbis, A. L., Cruz, A. A., Custovic, A., Czarlewski, W., Dario, C., Silva, J. D., Dauvilliers, Y., Carlo, G. D., Blay, F. D., Dedeu, T., Emerson, M. F., Feo, G. D., Cruz, M. H. G., Martino, B. D., Demoly, P., Rubini, N. P. M., Devillier, P., De Vries, G., Ercolano, S. D. C., Di Carluccio, N., Dray, G., Dubakiene, R., Eller, E., Emuzyte, R., Espinoza-Contreras, J. M., Estrada-Cardona, A., Farrell, J., Farsi, A., de Mello, J. F., Ferrero, J., Fokkens, W. J., Fonseca, J., Fontaine, J. F., Forti, S., Garcia-Aymerich, J., Galvez-Romero, J. L., Garcia-Cobas, C. I., Gemicioglu, B., van Wijk, R. G., Guidacci, M., Gomez-Vera, J., Guldemond, N. A., Gutter, Z., Haahtela, T., Hajjam, J., Hellings, P. W., Hernandez, L., Illario, M., Ivancevich, J. C., Jares, E., Joos, G., Just, J., Kalayci, O., Kalyoncu, A. F., Karjalainen, J., Keil, T., Khaltaev, N., Klimek, L., Kowalski, M. L., Kull, I., Kuna, P., Kvedariene, V., Kolek, V., Krzych-Falta, E., Kupczyk, M., Lacwik, P., Larenas-Linnemann, D., Laune, D., Lauri, D., Lavrut, J., Lessa, M. A., Levato, G., Lewis, L., Lieten, I., Lipiec, A., Louis, R., Luna-Pech, J. A., Maciej, K., Magnan, A., Malva, J., Maspero, J. F., Mathieu-Dupas, E., Matos, A. L., Mayora, O., Medina-avalos, M. A., Melen, E., Menditto, E., Millot-Keurinck, J., Mizani, M. A., Moda, G., Morais-Almeida, M., Morato-Castro, F. F., Santo, P. M., Mosges, R., Mota-Pinto, A., Mullol, J., Murraro, A., Murray, R., Nalin, M., Nogues, M., Novellino, E., Napoli, L., Neffen, H., O'Hehir, R. E., Onorato, G. L., Palkonen, S., Papadopoulos, N. G., Passalacqua, G., Pepin, J. L., Pereira, A. M., Persico, M., Pfaar, O., Picard, R., Poncelet, P., Portejoie, F., Pozzi, A. C., Price, D., Prokopakis, E. P., Puy, R., Pugin, B., Przemecka-Green, M., Raciborski, F., Rajabian-Soderlund, R., Reitsma, S., Ribeirinho, I., Rimmer, J., Rizzo, J. A., Rizzo, M. C., Robalo-Cordeiro, C., Rodo, X., Valle, S. R., Rodriguez-Gonzalez, M., Rolla, G., Roller-Wirnsberger, R. E., Romano, A., Romano, M., Rosario, N., Ryan, D., Salimaki, J., Samolinski, B., Samreth, D., Shamai, S., Sheikh, A., Sierra, M., Simons, F. E. R., Sole, D., Sorlini, M., Spranger, O., Stellato, C., Stelmach, A. R., Strozek, J., Stukas, R., Sutherland, M., Szylling, A., Tebyrica, J. N., Thibaudon, M., Tibaldi, V., Todo-Bom, A., Toppila-Salmi, S., Tomazic, P., Trama, U., Triggiani, M., Urrutia-Pereira, M., Valero, A., Valovirta, E., Valiulis, A., Vandenplas, O., van Eerd, M., Vasankari, T., Vatrella, A., Ventura, M. T., Verissimo, M. T., Viart, F., Williams, S., Wagenmann, M., Westman, M., Wickman, M., Wroczynski, P., Yorgancioglu, A., Zernotti, E., Zurbierber, T., Zubrinich, C., Zurkuhlen, A., Ingenrieth, F., Costa, E., Fuentes-Perez, J. -M., Huerta-Villalobos, Y. R., da Silva, J., Tomazic, P. V., Makris, M., Psarros, F., Sova, M., Wehner, K., Wittmann, J., UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (MGD) Service de pneumologie, Internal Medicine, Universidade do Minho, and Göğüs Hastalıkları
Subjects: 0301 basic medicine, Lydia Becker Institute, Respiratory Medicine and Allergy, Anonymization, k-anonymity, Medicina Clínica [Ciências Médicas], Health data, 0302 clinical medicine, 610 Medical sciences Medicine, Medicine and Health Sciences, Medicine, Immunology and Allergy, European commission, HEALTH DATA, Rinitis, Lungmedicin och allergi, Original Research, Rhinitis, App, Asthma, MASK, Immunology, Pulmonary and Respiratory Medicine, Data anonymization, Communication Systems, Kommunikationssystem, lcsh:Immunologic diseases. Allergy, MASK study group, Internet privacy, K-ANONYMITY, Anonymization, App, Asthma, MASK, Rhinitis, 03 medical and health sciences, ResearchInstitutes_Networks_Beacons/lydia_becker_institute_of_immunology_and_inflammation, PROTECTING PRIVACY, TECHNOLOGY, Asma, Ciências Médicas::Medicina Clínica, business.industry, 1103 Clinical Sciences, Geolocation, [MATH.MATH-LO]Mathematics [math]/Logic [math.LO], 030104 developmental biology, 030228 respiratory system, 3121 General medicine, internal medicine and other clinical medicine, Key (cryptography), ComputingMilieux_COMPUTERSANDSOCIETY, Noise (video), business, lcsh:RC581-607
Abstract: Collecting data on the localization of users is a key issue for the MASK (Mobile Airways Sentinel networK: the Allergy Diary) App. Data anonymization is a method of sanitization for privacy. The European Commission's Article 29 Working Party stated that geolocation information is personal data.To assess geolocation using the MASK method and to compare two anonymization methods in the MASK database to find an optimal privacy method., Background Collecting data on the localization of users is a key issue for the MASK (Mobile Airways Sentinel networK: the Allergy Diary) App. Data anonymization is a method of sanitization for privacy. The European Commission’s Article 29 Working Party stated that geolocation information is personal data. To assess geolocation using the MASK method and to compare two anonymization methods in the MASK database to find an optimal privacy method. Methods Geolocation was studied for all people who used the Allergy Diary App from December 2015 to November 2017 and who reported medical outcomes. Two different anonymization methods have been evaluated: Noise addition (randomization) and k-anonymity (generalization). Results Ninety-three thousand one hundred and sixteen days of VAS were collected from 8535 users and 54,500 (58.5%) were geolocalized, corresponding to 5428 users. Noise addition was found to be less accurate than k-anonymity using MASK data to protect the users’ life privacy. Discussion k-anonymity is an acceptable method for the anonymization of MASK data and results can be used for other databases., AMC -Istanbul Üniversitesi(undefined), info:eu-repo/semantics/publishedVersion
Published: 2018
Full Text: View/download PDF

13. Baseline-Charakteristika von Patienten mit chronischer Rhinosinusitis mit nasalen Polypen (mit und ohne Asthma) in SINUS-52, einer randomisierten, doppel-blinden, Phase-3-Studie von Dupilumab

Author: Bachert, C, additional, Desrosiers, M, additional, Mullol, J, additional, Maspero, JF, additional, Wagenmann, M, additional, Niemann, I, additional, Khan, A, additional, Kamat, S, additional, Amin, N, additional, and Mannent, LP, additional
Published: 2019
Full Text: View/download PDF

14. Baseline Characteristics of Patients With Chronic Rhinosinusitis With Nasal Polyps (With and Without Asthma) Enrolled in SINUS-52, a Randomized, Double-Blind, Phase 3 Study of Dupilumab

Author: Bachert, C, additional, Desrosiers, M, additional, Mullol, J, additional, Maspero, JF, additional, Wagenmann, M, additional, Niemann, I, additional, Khan, A, additional, Kamat, S, additional, Amin, N, additional, and Mannent, LP, additional
Published: 2019
Full Text: View/download PDF

15. Transfer of innovation on allergic rhinitis and asthma multimorbidity in the elderly (MACVIA-ARIA) - Reference Site Twinning (EIP on AHA)

Author: Bousquet, J, Agache, I, Aliberti, MR, Angles, R, Annesi-Maesano, I, Anto, JM, Arnavielhe, S, Asayag, E, Bacci, E, Bedbrook, A, Bachert, C, Valero, A, Valovirta, E, Valiulis, A, Van Eerd, M, Vasankari, T, Vatrella, A, Ventura, MT, Verissimo, MT, Viart, F, Bindslev-Jensen, C, Khaltaev, N, Williams, S, Wagenmann, M, Wanscher, C, Westman, M, Wickman, M, Young, I, Yorgancioglu, A, Zernotti, E, Zurbierber, T, Zurkuhlen, A, Klimek, L, Blua, A, De Oliviera, B, Senn, A, Bochenska Marciniak, M, Bogus-Buczynska, I, Bosnic-Anticevich, S, Bosse, I, Bourret, R, Bucca, C, Buonaiuto, R, Kritikos, V, Caiazza, D, Caillot, D, Caimmi, DP, Camargos, P, Canfora, G, Cardona, V, Carriazo, AM, Cartier, C, Castellano, G, Chavannes, NH, Kull, I, Ciaravolo, MM, Cingi, C, Ciceran, A, Colas, L, Colgan, E, Coll, J, Conforti, D, De Sousa, JC, Cortés-Grimaldo, RM, Corti, F, Kuna, P, Costa, E, Courbis, AL, Cousein, E, Cruz, AA, Custovic, A, Cvetkovski, B, Dario, C, Da Silva, M, Dauvilliers, Y, De Blay, F, Kvedariene, V, Dedeu, T, De Feo, G, De Martino, B, Demoly, P, De Vries, G, Di Capua Ercolano, S, Di Carluccio, N, Doulapsi, M, Dray, G, Dubakiene, R, Kolek, V, Eller, E, Emuzyte, R, Espinoza-Contreras, JM, Estrada-Cardona, A, Farrell, J, Ferrero, J, Fokkens, WJ, Fonseca, J, Fontaine, JF, Forti, S, Krzych-Fałta, E, Gálvez-Romero, JL, García-Cobas, CI, Cruz, MHG, Gemicioğlu, B, Van Wijk, RG, Guidacci, M, Gómez-Vera, J, Guldemond, NA, Gutter, Z, Haahtela, T, Kupczyk, M, Hajjam, J, Hellings, PW, Hernández-Velázquez, L, Illario, M, Ivancevich, JC, Jares, E, Joos, G, Just, J, Kalayci, O, Kalyoncu, AF, Lacwik, P, Karjalainen, J, Keil, T, Baroni, I, Larenas-Linnemann, D, Laune, D, Lauri, D, Lavrut, J, Lessa, M, Levato, G, Lewis, L, Lieten, I, Lipiec, A, Louis, R, Barreto, BA, Luna-Pech, JA, Magnan, A, Malva, J, Maspero, JF, Matta-Campos, JJ, Mayora, O, Medina-Ávalos, MA, Melén, E, Menditto, E, Millot-Keurinck, J, Bedolla-Barajas, M, Moda, G, Morais-Almeida, M, Mösges, R, Mota-Pinto, A, Mullol, J, Muraro, A, Murray, R, Noguès, M, Nalin, M, Napoli, L, Bergmann, KC, Neffen, H, O'Hehir, RE, Onorato, G, Palkonen, S, Papadopoulos, NG, Passalacqua, G, Pépin, JL, Pereira, AM, Persico, M, Pfaar, O, Bertorello, L, Pozzi, AC, Prokopakis, E, Raciborski, F, Rimmer, J, Rizzo, JA, Robalo-Cordeiro, C, Rodríguez-González, M, Rolla, G, Roller-Wirnsberger, RE, Romano, A, Bewick, M, Romano, M, Salimäki, J, Samolinski, B, Serpa, FS, Shamai, S, Sierra, M, Sova, M, Sorlini, M, Stellato, C, Stelmach, R, Bieber, T, Strandberg, T, Stroetmann, V, Stukas, R, Szylling, A, Tan, R, Tibaldi, V, Todo-Bom, A, Toppila-Salmi, S, Tomazic, P, Trama, U, Birov, S, and Triggiani, M
Subjects: HEALTH-STATUS, Science & Technology, Allergy Diary, Allergy, CARAT, IMPACT, Immunology, CARE PATHWAYS, QUESTIONNAIRE, asthma, PARTNERSHIP, WORK PRODUCTIVITY, VALIDATION, European Innovation Partnership on Active and Healthy Ageing, rhinitis, QUALITY-OF-LIFE, 1107 Immunology, MASK-RHINITIS, Life Sciences & Biomedicine, EUROPEAN COUNTRIES
Abstract: The overarching goals of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) are to enable European citizens to lead healthy, active and independent lives while ageing. The EIP on AHA includes 74 Reference Sites. The aim of this study is to transfer innovation from an App developed by the MACVIA-France EIP on AHA reference site (Allergy Diary) to other reference sites. The phenotypic characteristics of rhinitis and asthma multimorbidity in adults and the elderly will be compared using validated information and communication technology (ICT) tools (i.e. the Allergy Diary and CARAT: Control of Allergic Rhinitis and Asthma Test) in 22 Reference Sites or regions across Europe. This will improve understanding, assessment of burden, diagnosis and management of rhinitis in the elderly by comparison with an adult population. Specific objectives will: (i) assess the percentage of adults and elderly who are able to use the Allergy Diary, (ii) study phenotypic characteristics and treatment over a period of one year of rhinitis and asthma multimorbidity at baseline (cross-sectional study) and (iii) follow-up using visual analogue scale (VAS). This part of the study may provide some insight into the differences between the elderly and adults in terms of response to treatment and practice. Finally (iv) work productivity will be examined in adults. This article is protected by copyright. All rights reserved.
Published: 2017

16. MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence

Author: Bousquet, J. (Jean), Arnavielhe, S, Bedbrook, A. (Anna), Bewick, M, Laune, D, Mathieu-Dupas, E., Murray, R., Onorato, G.L., Pépin, J.L., Picard, R., Portejoie, F, Costa, E., Fonseca, J., Lourenço, O., Morais-Almeida, M. (Mario), Todo Bom, A., Cruz, A.A. (Alvaro), Silva, J.D., Serpa, F.S., Illario, M., Menditto, E., Cecchi, L., Monti, R., Napoli, L., Ventura, M. T., De Feo, G., Larenas-Linnemann, D. (Désirée), Perez, M, Huerta Villabolos, Y.R., Rivero-yeverino, D., Rodriguez-zagal, E., Amat, F., Annesi-Maesano, I. (Isabella), Bosse, I, Demoly, P., Devillier, P. (Philippe), Fontaine, J.F., Just, P.M., Kuna, T.P., Samolinski, B. (Boleslaw), Valiulis, A. (Arunas), Emuzyte, R., Kvedariene, V. (Violeta), Ryan, D. (Dermot), Sheikh, A. (Aziz), Schmidt-grendelmeier, P., Klimek, L., Pfaar, O, Bergmann, K.-C. (Karl-Christian), Mösges, R., Zuberbier, T. (Torsten), Roller-Wirnsberger, R.E., Tomazic, P., Fokkens, WJ, Chavannes, N.H. (Nicolas), Reitsma, S., Anto, JM, Cardona, V, Dedeu, T, Mullol, J., Haahtela, T. (Tari), Salimäki, J., Toppila-Salmi, S., Valovirta, E. (Erkka), Gemicioğlu, B., Yorgancioglu, A., Papadopoulos, N., Prokopakis, E.P., Bosnic-Anticevich, S, O’hehir, R., Ivancevich, J.C. (Juan), Neffen, H, Zernotti, E., Kull, C.A. (Christian), Melén, E. (Erik), Wickman, M., Bachert, C. (Claus), Hellings, P, Palkonen, S., Bindslev-Jensen, C. (Carsten), Eller, E., Waserman, S., Sova, M., Vries, G. (Gerard) de, Eerd, M. (Maarten) van, Agache, I., Casale, T, Dykewickz, M., Naclerio, RN, Okamoto, Y., Wallace, D.V., Hellings, P.W. (Peter), Aberer, W. (W.), Akdis, C.A., Alberti, M.R., Almeida, R., Angles, R., Ansotegui, I.J. (I.), Arnavielle, S., Asayag, E., Asarnoj, A., Arshad, H, Avolio, F., Bacci, E., Baiardini, I. (Ilaria), Barbara, C, Barbagallo, M., Baroni, I., Barreto, B.A., Basagaña, X. (Xavier), Bateman, E.D. (Eric), Bedolla-Barajas, M., Beghé, B., Bel, E.H., Bennoor, K.S. (K.), Benson, M. (Martin), Bertorello, L., Białoszewski, A.Z., Bieber, T. (Thomas), Bialek, S., Bjermer, L. (Leif), Blain, H, Blasi, F, Blua, A., Bochenska Marciniak, M., Bogus-Buczynska, I., Boner, A.L., Bonini, M. (Matteo), Bonini, S. (Sergio), Bosnic-Anticevich, C.S., Bouchard, J. (Jacques), Boulet, L.P., Bourret, R, Braido, F. (Fulvio), Briedis, V., Brightling, C.E. (C.), Brozek, J., Bucca, C., Buhl, R, Buonaiuto, R., Panaitescu, C., Burguete Cabañas, M.T., Burte, E., Bush, A. (Andrew), Caballero-Fonseca, F, Caillot, D. (Denis), Caimmi, D, Calderon, MA, Camargos, PAM, Camuzat, T, Canfora, G., Canonica, G.W., Carlsen, K.H. (Karin), Carreiro-Martins, P., Carriazo, A.M., Carr, W.W. (Warner), Cartier, C., Castellano, G., Cepeda, F., Chen, Y., Chiron, R, Chivato, T., Chkhartishvili, E. (E.), Chuchalin, A.G., Chung, K.F., Ciaravolo, M.M., Ciceran, A., Cingi, C., Ciprandi, G. (G.), Carvalho Coehlo, A.C., Colas, L., Colgan, E., Coll, J., Conforti, D., Correia de Sousa, J., Cortés-Grimaldo, R.M., Corti, F. (Fabiola), Costa-Dominguez, M.C., Courbis, A.L., Cox, L. (Linda), Crescenzo, M., Custovic, A. (Adnan), Czarlewski, W., Dahlen, S.E., Dario, C., da Silva, J, Dauvilliers, Y. (Yves), Darsow, U. (U.), Blay, F. de, De Carlo, G, de Fátima Emerson, M., De Martino, B., de Paula Motta Rubini, N., Deleanu, D. (D.), Denburg, J., Di Capua Ercolano, S., Di Carluccio, N., Didier, A, Dokic, D. (D.), Dominguez-Silva, M.G., Douagui, H., Dray, G, Dubakiene, R. (R.), Durham, S.R. (Stephen), Du Toit, G, Dykewicz, M.S. (M.), El-Gamal, Y. (Y.), Eklund, P., Farrell, J., Farsi, A., Ferreira de Mello, J., Jr., Ferrero, J., Fink-Wagner, A. (A.), Fiocchi, A. (Alessandro), Fonseca, J.A. (J.), Forti, S., Fuentes-Perez, J.M., Gálvez-Romero, J.L., Gamkrelidze, A. (Amiran), Garcia-Aymerich, J. (Judith), García-Cobas, C.Y., Garcia-Cruz, M.H., Genova, S., George, C., Gereda, JE, Gerth van Wijk, R. (Roy), Gomez, R. M., Gómez-Vera, J., González Diaz, S., Gotua, M. (M.), Grisle, I, Guidacci, M., Guldemond, N. (Nick), Gutter, Z., Guzmán, M.A., Hajjam, J., Hernández, L., Hourihane, JOB, Huerta-Villalobos, Y.R., Humbert, M., Iaccarino, G. (Guido), Jares, EJ, Jassem, E., Johnston, S.L., Joos, G.F. (Guy), Jung, KS, Jutel, M. (M.), Kaidashev, I, Kalayci, O. (Omer), Kalyoncu, A.F. (A.), Karjalainen, J. (Juha), Kardas, P., Keil, M. (Mark), Keith, P.K., Khaitov, M., Khaltaev, N., Kleine-Tebbe, J., Kowalski, M.L., Kuitunen, M., Kuna, P. (Piotr), Kupczyk, M, Krzych-Fałta, E., Lacwik, P., Lauri, D., Lavrut, J., Le, L.T., Lessa, M., Levato, G., Li, J., Lieberman, A.P. (Andrew), Lipiec, A., Lipworth, B., Lodrup Carlsen, K.C., Louis, R, Luna-Pech, J.A., Maciej, K., Magnan, A, Mahboub, B., Maier, D., Mair, A., Majer, I.M. (Istvan), Malva, J., Mandajieva, E., Manning, P, De Manuel Keenoy, E., Marshall, G.D., Masjedi, M.R. (M.), Maspero, JF, Matta Campos, J.J., Matos, A.L., Maurer, M., Mavale-Manuel, S., Mayora, O., Medina-Avalos, M.A., Melén, E., Melo-Gomes, E, Meltzer, E.O., Mercier, J, Miculinic, N, Mihaltan, F. (F.), Milenkovic, B, Moda, G., Mogica-Martinez, M.D., Mohammad, Y., Momas, I. (I.), Montefort, S., Mora Bogado, D., Morato-Castro, F.F., Mota-Pinto, A., Moura Santo, P., Münter, L., Murarol, A. (Antonella), Naclerio, R., Nadif, R. (Rachel), Nalin, M., Namazova-Baranova, L. (L.), Niedeberger, V., Nekam, K., Neou, A. (A.), Nieto, A. (Antonio), Nogueira-Silva, L., Nogues, M., Novellino, E., Nyembue, T.D. (T.), O’hehir, R.E., Odzhakova, C., Ohta, K. (Ken), Okubo, K. (K.), Ortega Cisneros, M., Ouedraogo, S., Pali-Schöll, I., Panzner, P. (P.), Park, H.S. (H.), Papi, A, Passalacqua, G. (Giovanni), Paulino, E., Pawankar, R. (Ruby), Pedersen, S., Pereira, A.M. (A.), Persico, M., Phillips, J., Pigearias, B. (B.), Pin, I. (Isabelle), Pitsios, C, Plavec, D, Pohl, W. (W.), Popov, T.A., Potter, P., Pozzi, A.C., Price, D., Puy, R., Pugin, B., Pulido Ross, R.E., Przemecka, M., Rabe, K.F. (Klaus F.), Raciborski, F, Rajabian-Soderlund, R., Ribeirinho, I., Rimmer, J., Rizzo, J.A., Rizzo, M.C., Robalo-Cordeiro, C, Rodenas, F, Rodo, X., González, M. (Marcos), Rodriguez-Mañas, L., Rolland, C, Rodrigues Valle, S., Rodriguez, M.M. (M. Mirta), Romano, A., Rolla, G., Romano, M. (Matteo), Rosado-Pinto, J., Rosario, K. (Karyna), Rottem, M. (M.), Sagara, H., Sanchez-Borges, M., Sastre-Dominguez, J., Scadding, G.K., Schunemann, HJ, Scichilone, N., Schmid-Grendelmeier, P, Shamai, S., Sierra, M., Simons, F.E.R., Siroux, V. (V.), Sisul, J.C. (J.), Skrindo, I, Solé, D., Somekh, D., Sondermann, M., Sooronbaev, T, Sørensen, M. (Mette), Sorlini, M., Spranger, O., Stellato, C., Stelmach, R, Stukas, R., Sunyer, J. (Jordi), Strozek, J., Szylling, A., Tebyriçá, J.N., Thibaudon, M., To, M.S., Tomazic, P.V., Trama, U., Triggiani, M. (M.), Suppli Ulrik, C., Urrutia-Pereira, M., Valenta, R., Valero, A., Ganse, E. (Éric), Van Hague, M., Vandenplas, O. (Olivier), Vezzani, G, Vasankari, T, Vatrella, A., Verissimo, M.T., Viart, F., Viegi, G., Vicheva, D., Vontetsianos, T., Wagenmann, M, Walker, S., Wallace, D. (D.), Wang, D.Y. (De Yun), Werfel, T., Westman, M. (Mina), Williams, DM, Williams, S. (Stephanie), Wilson, N., Wright, J. (Juliet), Wroczynski, P., Yakovliev, P., Yawn, B.P. (Barbara), Yiallouros, P.K. (P.), Yusuf, O.M. (Osman), Zar, H.J., Zhang, L. (Lingling), Zhong, N., Zernotti, M., Zidarn, M. (M.), Zubrinich, C., Zurkuhlen, A., Bousquet, J. (Jean), Arnavielhe, S, Bedbrook, A. (Anna), Bewick, M, Laune, D, Mathieu-Dupas, E., Murray, R., Onorato, G.L., Pépin, J.L., Picard, R., Portejoie, F, Costa, E., Fonseca, J., Lourenço, O., Morais-Almeida, M. (Mario), Todo Bom, A., Cruz, A.A. (Alvaro), Silva, J.D., Serpa, F.S., Illario, M., Menditto, E., Cecchi, L., Monti, R., Napoli, L., Ventura, M. T., De Feo, G., Larenas-Linnemann, D. (Désirée), Perez, M, Huerta Villabolos, Y.R., Rivero-yeverino, D., Rodriguez-zagal, E., Amat, F., Annesi-Maesano, I. (Isabella), Bosse, I, Demoly, P., Devillier, P. (Philippe), Fontaine, J.F., Just, P.M., Kuna, T.P., Samolinski, B. (Boleslaw), Valiulis, A. (Arunas), Emuzyte, R., Kvedariene, V. (Violeta), Ryan, D. (Dermot), Sheikh, A. (Aziz), Schmidt-grendelmeier, P., Klimek, L., Pfaar, O, Bergmann, K.-C. (Karl-Christian), Mösges, R., Zuberbier, T. (Torsten), Roller-Wirnsberger, R.E., Tomazic, P., Fokkens, WJ, Chavannes, N.H. (Nicolas), Reitsma, S., Anto, JM, Cardona, V, Dedeu, T, Mullol, J., Haahtela, T. (Tari), Salimäki, J., Toppila-Salmi, S., Valovirta, E. (Erkka), Gemicioğlu, B., Yorgancioglu, A., Papadopoulos, N., Prokopakis, E.P., Bosnic-Anticevich, S, O’hehir, R., Ivancevich, J.C. (Juan), Neffen, H, Zernotti, E., Kull, C.A. (Christian), Melén, E. (Erik), Wickman, M., Bachert, C. (Claus), Hellings, P, Palkonen, S., Bindslev-Jensen, C. (Carsten), Eller, E., Waserman, S., Sova, M., Vries, G. (Gerard) de, Eerd, M. (Maarten) van, Agache, I., Casale, T, Dykewickz, M., Naclerio, RN, Okamoto, Y., Wallace, D.V., Hellings, P.W. (Peter), Aberer, W. (W.), Akdis, C.A., Alberti, M.R., Almeida, R., Angles, R., Ansotegui, I.J. (I.), Arnavielle, S., Asayag, E., Asarnoj, A., Arshad, H, Avolio, F., Bacci, E., Baiardini, I. (Ilaria), Barbara, C, Barbagallo, M., Baroni, I., Barreto, B.A., Basagaña, X. (Xavier), Bateman, E.D. (Eric), Bedolla-Barajas, M., Beghé, B., Bel, E.H., Bennoor, K.S. (K.), Benson, M. (Martin), Bertorello, L., Białoszewski, A.Z., Bieber, T. (Thomas), Bialek, S., Bjermer, L. (Leif), Blain, H, Blasi, F, Blua, A., Bochenska Marciniak, M., Bogus-Buczynska, I., Boner, A.L., Bonini, M. (Matteo), Bonini, S. (Sergio), Bosnic-Anticevich, C.S., Bouchard, J. (Jacques), Boulet, L.P., Bourret, R, Braido, F. (Fulvio), Briedis, V., Brightling, C.E. (C.), Brozek, J., Bucca, C., Buhl, R, Buonaiuto, R., Panaitescu, C., Burguete Cabañas, M.T., Burte, E., Bush, A. (Andrew), Caballero-Fonseca, F, Caillot, D. (Denis), Caimmi, D, Calderon, MA, Camargos, PAM, Camuzat, T, Canfora, G., Canonica, G.W., Carlsen, K.H. (Karin), Carreiro-Martins, P., Carriazo, A.M., Carr, W.W. (Warner), Cartier, C., Castellano, G., Cepeda, F., Chen, Y., Chiron, R, Chivato, T., Chkhartishvili, E. (E.), Chuchalin, A.G., Chung, K.F., Ciaravolo, M.M., Ciceran, A., Cingi, C., Ciprandi, G. (G.), Carvalho Coehlo, A.C., Colas, L., Colgan, E., Coll, J., Conforti, D., Correia de Sousa, J., Cortés-Grimaldo, R.M., Corti, F. (Fabiola), Costa-Dominguez, M.C., Courbis, A.L., Cox, L. (Linda), Crescenzo, M., Custovic, A. (Adnan), Czarlewski, W., Dahlen, S.E., Dario, C., da Silva, J, Dauvilliers, Y. (Yves), Darsow, U. (U.), Blay, F. de, De Carlo, G, de Fátima Emerson, M., De Martino, B., de Paula Motta Rubini, N., Deleanu, D. (D.), Denburg, J., Di Capua Ercolano, S., Di Carluccio, N., Didier, A, Dokic, D. (D.), Dominguez-Silva, M.G., Douagui, H., Dray, G, Dubakiene, R. (R.), Durham, S.R. (Stephen), Du Toit, G, Dykewicz, M.S. (M.), El-Gamal, Y. (Y.), Eklund, P., Farrell, J., Farsi, A., Ferreira de Mello, J., Jr., Ferrero, J., Fink-Wagner, A. (A.), Fiocchi, A. (Alessandro), Fonseca, J.A. (J.), Forti, S., Fuentes-Perez, J.M., Gálvez-Romero, J.L., Gamkrelidze, A. (Amiran), Garcia-Aymerich, J. (Judith), García-Cobas, C.Y., Garcia-Cruz, M.H., Genova, S., George, C., Gereda, JE, Gerth van Wijk, R. (Roy), Gomez, R. M., Gómez-Vera, J., González Diaz, S., Gotua, M. (M.), Grisle, I, Guidacci, M., Guldemond, N. (Nick), Gutter, Z., Guzmán, M.A., Hajjam, J., Hernández, L., Hourihane, JOB, Huerta-Villalobos, Y.R., Humbert, M., Iaccarino, G. (Guido), Jares, EJ, Jassem, E., Johnston, S.L., Joos, G.F. (Guy), Jung, KS, Jutel, M. (M.), Kaidashev, I, Kalayci, O. (Omer), Kalyoncu, A.F. (A.), Karjalainen, J. (Juha), Kardas, P., Keil, M. (Mark), Keith, P.K., Khaitov, M., Khaltaev, N., Kleine-Tebbe, J., Kowalski, M.L., Kuitunen, M., Kuna, P. (Piotr), Kupczyk, M, Krzych-Fałta, E., Lacwik, P., Lauri, D., Lavrut, J., Le, L.T., Lessa, M., Levato, G., Li, J., Lieberman, A.P. (Andrew), Lipiec, A., Lipworth, B., Lodrup Carlsen, K.C., Louis, R, Luna-Pech, J.A., Maciej, K., Magnan, A, Mahboub, B., Maier, D., Mair, A., Majer, I.M. (Istvan), Malva, J., Mandajieva, E., Manning, P, De Manuel Keenoy, E., Marshall, G.D., Masjedi, M.R. (M.), Maspero, JF, Matta Campos, J.J., Matos, A.L., Maurer, M., Mavale-Manuel, S., Mayora, O., Medina-Avalos, M.A., Melén, E., Melo-Gomes, E, Meltzer, E.O., Mercier, J, Miculinic, N, Mihaltan, F. (F.), Milenkovic, B, Moda, G., Mogica-Martinez, M.D., Mohammad, Y., Momas, I. (I.), Montefort, S., Mora Bogado, D., Morato-Castro, F.F., Mota-Pinto, A., Moura Santo, P., Münter, L., Murarol, A. (Antonella), Naclerio, R., Nadif, R. (Rachel), Nalin, M., Namazova-Baranova, L. (L.), Niedeberger, V., Nekam, K., Neou, A. (A.), Nieto, A. (Antonio), Nogueira-Silva, L., Nogues, M., Novellino, E., Nyembue, T.D. (T.), O’hehir, R.E., Odzhakova, C., Ohta, K. (Ken), Okubo, K. (K.), Ortega Cisneros, M., Ouedraogo, S., Pali-Schöll, I., Panzner, P. (P.), Park, H.S. (H.), Papi, A, Passalacqua, G. (Giovanni), Paulino, E., Pawankar, R. (Ruby), Pedersen, S., Pereira, A.M. (A.), Persico, M., Phillips, J., Pigearias, B. (B.), Pin, I. (Isabelle), Pitsios, C, Plavec, D, Pohl, W. (W.), Popov, T.A., Potter, P., Pozzi, A.C., Price, D., Puy, R., Pugin, B., Pulido Ross, R.E., Przemecka, M., Rabe, K.F. (Klaus F.), Raciborski, F, Rajabian-Soderlund, R., Ribeirinho, I., Rimmer, J., Rizzo, J.A., Rizzo, M.C., Robalo-Cordeiro, C, Rodenas, F, Rodo, X., González, M. (Marcos), Rodriguez-Mañas, L., Rolland, C, Rodrigues Valle, S., Rodriguez, M.M. (M. Mirta), Romano, A., Rolla, G., Romano, M. (Matteo), Rosado-Pinto, J., Rosario, K. (Karyna), Rottem, M. (M.), Sagara, H., Sanchez-Borges, M., Sastre-Dominguez, J., Scadding, G.K., Schunemann, HJ, Scichilone, N., Schmid-Grendelmeier, P, Shamai, S., Sierra, M., Simons, F.E.R., Siroux, V. (V.), Sisul, J.C. (J.), Skrindo, I, Solé, D., Somekh, D., Sondermann, M., Sooronbaev, T, Sørensen, M. (Mette), Sorlini, M., Spranger, O., Stellato, C., Stelmach, R, Stukas, R., Sunyer, J. (Jordi), Strozek, J., Szylling, A., Tebyriçá, J.N., Thibaudon, M., To, M.S., Tomazic, P.V., Trama, U., Triggiani, M. (M.), Suppli Ulrik, C., Urrutia-Pereira, M., Valenta, R., Valero, A., Ganse, E. (Éric), Van Hague, M., Vandenplas, O. (Olivier), Vezzani, G, Vasankari, T, Vatrella, A., Verissimo, M.T., Viart, F., Viegi, G., Vicheva, D., Vontetsianos, T., Wagenmann, M, Walker, S., Wallace, D. (D.), Wang, D.Y. (De Yun), Werfel, T., Westman, M. (Mina), Williams, DM, Williams, S. (Stephanie), Wilson, N., Wright, J. (Juliet), Wroczynski, P., Yakovliev, P., Yawn, B.P. (Barbara), Yiallouros, P.K. (P.), Yusuf, O.M. (Osman), Zar, H.J., Zhang, L. (Lingling), Zhong, N., Zernotti, M., Zidarn, M. (M.), Zubrinich, C., and Zurkuhlen, A.
Abstract: mHealth, such as apps running on consumer smart devices is becoming increasingly popular and has the potential to profoundly afect healthcare and health outcomes. However, it may be disruptive and results achieved are not always reaching the goals. Allergic Rhinitis and its Impact on Asthma (ARIA) has evolved from a guideline using the best evidence-based approach to care pathways suited to real-life using mobile technology in allergic rhinitis (AR) and asthma multimorbidity. Patients largely use over-the-counter medications dispensed in pharmacies. Shared decision making centered around the patient and based on self-management should be the norm. Mobile Airways Sentinel networK (MASK), the Phase 3 ARIA initiative, is based on the freely available MASK app (the Allergy Diary, Android and iOS platforms). MASK is available in 16 languages and deployed in 23 countries. The present paper provides an over‑ view of the methods used in MASK and the key results obtained to date. These include a novel phenotypic charac‑ terization of the patients, confrmation of the impact of allergic rhinitis on work productivity and treatment patterns in real life. Most patients appear to self-medicate, are often non-adherent and do not follow guidelines. Moreover, the Allergy Diary is able to distinguish between AR medications. The potential usefulness of MASK will be further explored by POLLAR (Impact of Air Pollution on Asthma and Rhinitis), a new Horizon 2020 project using the Allergy Diary.
Published: 2018
Full Text: View/download PDF

17. Geolocation with respect to personal privacy for the Allergy Diary app - A MASK study

Author: Bousquet, J. (Jean), Agache, I., Almeida, R., Angles, R., Annesi-Maesano, I. (Isabella), Anto, JM, Arnavielhe, S, Asayag, E., Bacci, E., Bachert, C. (Claus), Baiardini, I. (Ilaria), Baroni, I., Barreto, B.A., Basagaña, X. (Xavier), Bedbrook, A. (Anna), Bedolla-Barajas, M., Bergmann, K.-C. (Karl-Christian), Bertorello, L., Bewick, M, Bialek, S., Bieber, T. (Thomas), Bindslev-Jensen, C. (Carsten), Bjermer, L. (Leif), Blua, A., Marciniak, M.B., Bogus-Buczynska, I., Bosnic-Anticevich, S, Bosse, I, Bouchard, J. (Jacques), Bourret, R, Briedis, V., Bucca, C., Buonaiuto, R., Cabanas, M.T.B., Caiazza, D., Caillot, D. (Denis), Caimmi, D, Camargos, P., Canfora, G., Cardona, V, Carriazo, A.M., Cartier, C., Coelho, A.C.C., Castellano, G., Cecchi, L., Chavannes, N.H. (Nicolas), Ciaravolo, M.M., Cingi, C., Ciceran, A., Colas, L., Colgan, E., Coll, J., Conforti, D., de Sousa, JC, Cortés-Grimaldo, R.M., Corti, F. (Fabiola), Costa, D.J., Dominguez, M.C.C., Courbis, A.L., Cruz, A.A. (Alvaro), Custovic, A. (Adnan), Czarlewski, W., Dario, C., Silva, J.D., Dauvilliers, Y. (Yves), Carlo, G.D., Blay, F.D., Dedeu, T, Emerson, M.F., Feo, G.D., Cruz, M.H.G., Martino, B.D., Demoly, P., Rubini, N.P.M., Devillier, P. (Philippe), Vries, G. (Gerard) de, Ercolano, S.D., Di Carluccio, N., Dray, G, Dubakiene, R. (R.), Eller, E., Emuzyte, R., Espinoza-Contreras, J.M., Estrada-Cardona, A., Farrell, J., Farsi, A., de Mello, J.F., Jr., Ferrero, J., Fokkens, WJ, Fonseca, J., Fontaine, J.F., Forti, S., Garcia-Aymerich, J. (Judith), Gálvez-Romero, J.L., García-Cobas, C.I., Gemicioğlu, B., Gerth van Wijk, R. (Roy), Guidacci, M., Gómez-Vera, J., Guldemond, N. (Nick), Gutter, Z., Haahtela, T. (Tari), Hajjam, J., Hellings, P.W. (Peter), Hernández, L., Illario, M., Ivancevich, J.C. (Juan), Jares, E., Joos, G.F. (Guy), Just, P.M., Kalayci, O. (Omer), Kalyoncu, A.F. (A.), Karjalainen, J. (Juha), Keil, M. (Mark), Khaltaev, N., Klimek, L., Kowalski, M.L., Kull, C.A. (Christian), Kuna, P. (Piotr), Kvedariene, V. (Violeta), Kolek, V, Krzych-Fałta, E., Kupczyk, M, Lacwik, P., Larenas-Linnemann, D. (Désirée), Laune, D, Lauri, D., Lavrut, J., Lessa, M.A., Levato, G., Lewis, L., Lieten, I., Lipiec, A., Louis, R, Luna-Pech, J.A., Maciej, K., Magnan, A, Malva, J., Maspero, JF, Mathieu-Dupas, E., Matos, A.L., Mayora, O., Medina-ávalos, M.A., Melén, E. (Erik), Menditto, E., Millot-Keurinck, J., Mizani, M.A., Moda, G., Morais-Almeida, M. (Mario), Morato-Castro, F.F., Santo, P.M., Mösges, R., Mota-Pinto, A., Mullol, J., Murraro, A., Murray, R., Nalin, M., Noguès, M., Novellino, E., Napoli, L., Neffen, H, O’hehir, R.E., Onorato, G.L., Palkonen, S., Papadopoulos, N., Passalacqua, G. (Giovanni), Pépin, J.L., Pereira, A.M. (A.), Persico, M., Pfaar, O, Picard, R., Poncelet, P., Portejoie, F, Pozzi, A.C., Price, D., Prokopakis, E.P., Puy, R., Pugin, B., Przemecka-Green, M., Raciborski, F, Rajabian-Soderlund, R., Reitsma, S., Ribeirinho, I., Rimmer, J., Rizzo, J.A., Rizzo, M.C., Robalo-Cordeiro, C, Rodo, X., Valle, S.R., Rodríguez-González, M., Rolla, G., Roller-Wirnsberger, R.E., Romano, A., Romano, M. (Matteo), Rosario, K. (Karyna), Ryan, D. (Dermot), Salimäki, J., Samolinski, B. (Boleslaw), Samreth, D., Shamai, S., Sheikh, A. (Aziz), Sierra, M., Simons, F.E.R., Solé, D., Sorlini, M., Spranger, O., Stellato, C., Stelmach, A.R., Strozek, J., Stukas, R., Sutherland, M, Szylling, A., Tebyriçá, J.N., Thibaudon, M., Tibaldi, V., Todo Bom, A., Toppila-Salmi, S., Tomazic, P., Trama, U., Triggiani, M. (M.), Urrutia-Pereira, M., Valero, A., Valovirta, E. (Erkka), Valiulis, A. (Arunas), Vandenplas, O. (Olivier), Eerd, M. (Maarten) van, Vasankari, T, Vatrella, A., Ventura, M. T., Verissimo, M.T., Viart, F., Williams, S. (Stephanie), Wagenmann, M, Westman, M. (Mina), Wickman, M., Wroczynski, P., Yorgancioglu, A., Zernotti, E., Zurbierber, T., Zubrinich, C., Zurkuhlen, A., Ingenrieth, F., Costa, E., Fuentes-Pérez, J.M., Huerta-Villalobos, Y.R., da Silva, J, Tomazic, P.V., Makris, M. (M.), Psarros, F., Sova, M., Wehner, K., Wittmann, J., Bousquet, J. (Jean), Agache, I., Almeida, R., Angles, R., Annesi-Maesano, I. (Isabella), Anto, JM, Arnavielhe, S, Asayag, E., Bacci, E., Bachert, C. (Claus), Baiardini, I. (Ilaria), Baroni, I., Barreto, B.A., Basagaña, X. (Xavier), Bedbrook, A. (Anna), Bedolla-Barajas, M., Bergmann, K.-C. (Karl-Christian), Bertorello, L., Bewick, M, Bialek, S., Bieber, T. (Thomas), Bindslev-Jensen, C. (Carsten), Bjermer, L. (Leif), Blua, A., Marciniak, M.B., Bogus-Buczynska, I., Bosnic-Anticevich, S, Bosse, I, Bouchard, J. (Jacques), Bourret, R, Briedis, V., Bucca, C., Buonaiuto, R., Cabanas, M.T.B., Caiazza, D., Caillot, D. (Denis), Caimmi, D, Camargos, P., Canfora, G., Cardona, V, Carriazo, A.M., Cartier, C., Coelho, A.C.C., Castellano, G., Cecchi, L., Chavannes, N.H. (Nicolas), Ciaravolo, M.M., Cingi, C., Ciceran, A., Colas, L., Colgan, E., Coll, J., Conforti, D., de Sousa, JC, Cortés-Grimaldo, R.M., Corti, F. (Fabiola), Costa, D.J., Dominguez, M.C.C., Courbis, A.L., Cruz, A.A. (Alvaro), Custovic, A. (Adnan), Czarlewski, W., Dario, C., Silva, J.D., Dauvilliers, Y. (Yves), Carlo, G.D., Blay, F.D., Dedeu, T, Emerson, M.F., Feo, G.D., Cruz, M.H.G., Martino, B.D., Demoly, P., Rubini, N.P.M., Devillier, P. (Philippe), Vries, G. (Gerard) de, Ercolano, S.D., Di Carluccio, N., Dray, G, Dubakiene, R. (R.), Eller, E., Emuzyte, R., Espinoza-Contreras, J.M., Estrada-Cardona, A., Farrell, J., Farsi, A., de Mello, J.F., Jr., Ferrero, J., Fokkens, WJ, Fonseca, J., Fontaine, J.F., Forti, S., Garcia-Aymerich, J. (Judith), Gálvez-Romero, J.L., García-Cobas, C.I., Gemicioğlu, B., Gerth van Wijk, R. (Roy), Guidacci, M., Gómez-Vera, J., Guldemond, N. (Nick), Gutter, Z., Haahtela, T. (Tari), Hajjam, J., Hellings, P.W. (Peter), Hernández, L., Illario, M., Ivancevich, J.C. (Juan), Jares, E., Joos, G.F. (Guy), Just, P.M., Kalayci, O. (Omer), Kalyoncu, A.F. (A.), Karjalainen, J. (Juha), Keil, M. (Mark), Khaltaev, N., Klimek, L., Kowalski, M.L., Kull, C.A. (Christian), Kuna, P. (Piotr), Kvedariene, V. (Violeta), Kolek, V, Krzych-Fałta, E., Kupczyk, M, Lacwik, P., Larenas-Linnemann, D. (Désirée), Laune, D, Lauri, D., Lavrut, J., Lessa, M.A., Levato, G., Lewis, L., Lieten, I., Lipiec, A., Louis, R, Luna-Pech, J.A., Maciej, K., Magnan, A, Malva, J., Maspero, JF, Mathieu-Dupas, E., Matos, A.L., Mayora, O., Medina-ávalos, M.A., Melén, E. (Erik), Menditto, E., Millot-Keurinck, J., Mizani, M.A., Moda, G., Morais-Almeida, M. (Mario), Morato-Castro, F.F., Santo, P.M., Mösges, R., Mota-Pinto, A., Mullol, J., Murraro, A., Murray, R., Nalin, M., Noguès, M., Novellino, E., Napoli, L., Neffen, H, O’hehir, R.E., Onorato, G.L., Palkonen, S., Papadopoulos, N., Passalacqua, G. (Giovanni), Pépin, J.L., Pereira, A.M. (A.), Persico, M., Pfaar, O, Picard, R., Poncelet, P., Portejoie, F, Pozzi, A.C., Price, D., Prokopakis, E.P., Puy, R., Pugin, B., Przemecka-Green, M., Raciborski, F, Rajabian-Soderlund, R., Reitsma, S., Ribeirinho, I., Rimmer, J., Rizzo, J.A., Rizzo, M.C., Robalo-Cordeiro, C, Rodo, X., Valle, S.R., Rodríguez-González, M., Rolla, G., Roller-Wirnsberger, R.E., Romano, A., Romano, M. (Matteo), Rosario, K. (Karyna), Ryan, D. (Dermot), Salimäki, J., Samolinski, B. (Boleslaw), Samreth, D., Shamai, S., Sheikh, A. (Aziz), Sierra, M., Simons, F.E.R., Solé, D., Sorlini, M., Spranger, O., Stellato, C., Stelmach, A.R., Strozek, J., Stukas, R., Sutherland, M, Szylling, A., Tebyriçá, J.N., Thibaudon, M., Tibaldi, V., Todo Bom, A., Toppila-Salmi, S., Tomazic, P., Trama, U., Triggiani, M. (M.), Urrutia-Pereira, M., Valero, A., Valovirta, E. (Erkka), Valiulis, A. (Arunas), Vandenplas, O. (Olivier), Eerd, M. (Maarten) van, Vasankari, T, Vatrella, A., Ventura, M. T., Verissimo, M.T., Viart, F., Williams, S. (Stephanie), Wagenmann, M, Westman, M. (Mina), Wickman, M., Wroczynski, P., Yorgancioglu, A., Zernotti, E., Zurbierber, T., Zubrinich, C., Zurkuhlen, A., Ingenrieth, F., Costa, E., Fuentes-Pérez, J.M., Huerta-Villalobos, Y.R., da Silva, J, Tomazic, P.V., Makris, M. (M.), Psarros, F., Sova, M., Wehner, K., and Wittmann, J.
Abstract: Background: Collecting data on the localization of users is a key issue for the MASK (Mobile Airways Sentinel networK: the Allergy Diary) App. Data anonymization is a method of sanitization for privacy. The European Commission’s Article 29 Working Party stated that geolocation information is personal data. To assess geolocation using the MASK method and to compare two anonymization methods in the MASK database to find an optimal privacy method. Methods: Geolocation was studied for all people who used the Allergy Diary App from December 2015 to November 2017 and who reported medical outcomes. Two different anonymization methods have been evaluated: Noise addition (randomization) and k-anonymity (generalization). Results: Ninety-three thousand one hundred and sixteen days of VAS were collected from 8535 users and 54,500 (58. 5%) were geolocalized, corresponding to 5428 users. Noise addition was found to be less accurate than k-anonymity using MASK data to protect the users’ life privacy. Discussion: k-anonymity is an acceptable method for the anonymization of MASK data and results can be used for other databases.
Published: 2018
Full Text: View/download PDF

18. Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone

Author: Stempel, Da, Raphiou, Ih, Kral, Km, Yeakey, Am, Emmett, Ah, Prazma, Cm, Buaron, Ks, Pascoe, Sj, Austri, Investigators, Altieri, Hh, Antuni, Jd, Bergna, Ma, Cuadrado, Ja, De Gennaro MS, Fazio Lizandrelo CL, Gattolin, G, Gosn, Am, Larrateguy, Ld, Marcipar, Am, Maspero, Jf, Medina, Iv, Perez Chada RD, Silva, D, Victorio, Cf, Bardin, Pg, Carroll, Pa, Clements, Bs, Dore, Nd, Robinson, Pd, Fitzgerald, Da, Robinson, Pj, Russo, Ma, Sajkov, D, Thomas, Ps, Upham, Jw, Forstner, B, Kaik, G, Koeberl, Gh, Studnicka, M, Wallner, G, Balthazar, Y, Bauler, A, Dupont, Lj, Martinot, Jb, Ninane, V, Peché, R, Pilette, C, Dimitrova, R, Dimova, D, Kissyova Ibrishimova, G, Loboshka Becheva, M, Machkovska, M, Madjarov, S, Mandazhieva Pepelanova, M, Naidenova, I, Noleva, K, Takovska, N, Terziev, C, Aggarwal, Nk, Chapman, Kr, Csanadi, Ma, Dhillon, R, Henein, S, Kelly, Aj, Lam, As, Liem, Jj, Lougheed, Md, Lowe, Dw, Rizvi, Q, van den Berg, L, Zidel, B, Barros Monge MJ, Calvo Gil MA, Castillo Hofer CR, Diaz Amor PV, Lezana Soya, V, Quilodran Silva CN, Bolivar Grimaldos, F, Solarte-Rodriguez, I, Butkovic-Tomljanovic, R, Hegedus-Jungvirth, M, Ivkovic-Jurekovic, I, Simunov-Karuza, G, Buresova, M, Bursova, J, Fratrik, J, Guttlerova, E, Hartman, P, Jirmanova, I, Kalina, P, Kolman, P, Kucera, M, Povysilova, L, Pravda, P, Svabkova, A, Zakova, L, Backer, V, Maltbaek, N, Johnsen, Cr, Aries, Sp, Babyesiza, A, Barth, D, Benedix, A, Berg, P, Bergtholdt, B, Bettig, U, Bindig, Hw, Botzen, U, Brehler, R, Breyer, Go, Bruckhaus-Walter, M, Dapper, T, Eckhard, Jg, Engelhard, R, Feldmeyer, F, Fissan, H, Franz, Kh, Frick, Bs, Funck, J, Gessner, Cm, Ginko, T, Grigat, Ce, Grimm-Sachs, V, Groth, G, Hampf, J, Hanf, G, Havasi-Jost, G, Heinz, Gu, Helm, K, Hoeltz, S, Hofmann, S, Jander, R, Jandl, M, Jasch-Hoppe, B, Jung, T, Junggeburth, Jj, Kardos, P, Knueppel, W, Koch, T, Kolorz, C, Korduan, M, Korth-Wiemann, B, Krezdorn, Hg, Kroker, A, Kruell, M, Kuehne, P, Lenk, U, Liefring, E, Merke, J, Micke, L, Mitlehner, W, Mueller, H, Naudts, If, Neumann, G, Oldenburg, W, Overlack, A, Panzer, F, Reinholz, N, Remppis, R, Riegel, P, Rueckert, P, Schaetzl, Rj, Schauer, U, Hamelmann, E, Schenkenberger, I, Schlegel, V, Scholz, G, Schroers, M, Schwittay, A, Sebert, M, Tyler, K, Soemantri, Pa, Stock, P, Stuchlik, G, Unland, M, von Mallinckrodt, C, Wachter, J, Weber, U, Weberling, F, Wehgartner-Winkler, S, Weimer, J, Wiemer, S, Winkelmann, Ej, Zeisler, Kh, Ziegner, A, Zimny, Hh, Andrasofszky, Z, Bartha, A, Farkas, M, Gömöri, K, Kis, S, Major, K, Mészáros, I, Mezei, M, Rakvacs, M, Szalai, Z, Szántó, J, Szentesi, M, Szolnoki, E, Valyon, E, Zibotics, H, Anwar, J, Arimah, C, Djajalaksana, S, Rai, Ib, Setijadi, Ar, Setyanto, Db, Susanti, F, Syafiuddin, T, Syamsi, Ln, Wijanarko, P, Yunus, F, Bonavia, M, Braga, M, Chetta, Aa, Cerveri, I, Luisetti, M, Crimi, N, Cutrera, R, De Rosa, M, Esposito, S, Foresi, A, Gammeri, E, Iemoli, E, Legnani, Dl, Michetti, G, Pastorello, Ea, Pesci, A, Pistolesi, M, Riva, E, Romano, A, Scichilone, N, Terracciano, L, Tripodi, S, Choi, I, Kim, C, Kim, Js, Kim, Wj, Koh, Yy, Kwon, Ss, Lee, Sh, Lee, S, Lee, Sk, Park, Cs, Cirule, I, Eglite, R, Petrova, I, Poga, M, Smiltena, I, Chomiciene, A, Davoliene, I, Griskeviciene, V, Naudziunas, A, Naudziunas, S, Rudzeviciene, O, Sitkauskiene, B, Urbonas, G, Vaicius, D, Valavicius, A, Valiulis, A, Vebriene, J, bin Abdul Aziz FA, Daud, M, Ismail, Ai, Tengku Saifudin TI, Md Kassim RM, Mohd Fadzli FB, Wan Mohamad WH, Aguilar Dominguez PE, Aguilar-Orozco, Ra, Garza-Salinas, S, Ramirez-Diaz, Sp, Sánchez Llamas, F, Soto-Ramos, M, Velarde-Mora, Hj, Aguirre Sosa, I, Cisneros, Am, Estrella Viladegut RA, Matsuno Fuchigami, A, Adiaz-Baui, Tt, Bernan, Ap, Onia, Af, Sandagon, Mj, S-Naval, S, Yu, Cy, Bartuzi, Z, Bielous-Wilk, A, Błażowski, Ł, Bożek, A, Brzostek, J, Chorostowska-Wynimko, J, Ciekalska, K, Ziora, D, Cieslicki, J, Emeryk, A, Folcik, K, Gałuszka-Bilińska, A, Gawlik, R, Giejlo, M, Harat, R, Hofman, T, Jahnz-Różyk, K, Jedrzejczak, M, Kachel, T, Kamiński, D, Kelm Warchol, A, Konieczny, Z, Kwasniewski, A, Leszczyński, W, Mincewicz, G, Niezgoda, K, Olszewska-Ziąber, A, Onasz-Manitius, M, Pawlukiewicz, M, Piotrowicz, P, Piotrowski, W, Pisarczyk-Bogacka, E, Piskorz, P, Prokop-Staszecka, A, Roslan, A, Słomka, A, Smalera, E, Stelmach, I, Swierczynska-Krepa, M, Szmidt, M, Tarnowska-Matusiak, M, Tłuczykont, B, Tyminska, K, Waszkuc-Golonko, J, Wojciechowska, I, Alexandrescu, Ds, Neamtu, Ml, Todea, D, Alekseeva, E, Aleksandrova, E, Asherova, I, Barbarash, Ol, Bugrova, O, Bukreeva, Eb, Chermenskiy, A, Chizhova, O, Demko, I, Evdokimova, A, Giorgadze, Ml, Grigoryev, S, Irkhina, I, Khurkhurova, Nv, Kondyurina, Eg, Kostin, Vi, Kudelya, L, Laleko, Sl, Lenskaya, L, Levashov, S, Logvinenko, N, Martynov, A, Mizernitski, Y, Nemtsov, B, Novozhenov, Vg, Pavlishchuk, S, Popova, Vv, Reshetko, Ov, Sherenkov, A, Shirinsky, Vs, Shpagina, L, Soloviev, Ki, Tkachev, A, Trofimov, Vi, Vertkin, Al, Vorobeva, E, Idrisova, E, Yakushin, S, Zadionchenko, V, Zhiglinskaya, O, Zykov, K, Dopudja Pantic, V, Nadaskic, R, Nestorovic, B, Skodric Trifunovic, V, Stojanovic, A, Vukcevic, M, Vujic, T, Mitic Milikic, M, Banovcin, P, Horvathova, H, Karako, P Sr, Plutinsky, J, Pribulova, E, Szarazova, M, Zlatos, A, Adams, L, Badat, A, Bassa, A, Breedt, J, Bruning, A, Ellis, Gc, Emanuel, S, Fouche, Lf, Fulat, Ma, Gani, M, Ismail, Ms, Jurgens, Jc, Nell, H, Nieuwoudt, G, Noor, F, Bolliger, Ct, Puterman, As, Siddique, N, Trokis, Js, Vahed, Ya, Van Der Berg BJ, Van der Linden, M, Van Zyl, L, Visser, Ss, Antépara Ercoreca, I, Arnedillo Muñoz, A, Barbe Illa, F, Barreiro López, B, Blanco Aparicio, M, Boada Valmaseda, A, Bosque García, M, Bustamante Ruiz, A, Carretero Anibarro, P, Del Campo Matias, F, Echave-Sustaet, Jm, Espinosa de los Monteros Garde MJ, Garcia Hernandez GM, López Viña, A, Lores Obradors, L, Luengo Planas MT, Monsó Molas, E, Navarro Dourdil, A, Nieto García AJ, Perpina Tordera, M, Picado Valles, C, Rodriguez Alvarez Mdel, M, Saura Vinuesa, A, Serra Batlles, J, Soler Sempere MJ, Toran Montserrat, P, Valdés Cuadrado LG, Villasante Fernandez-Montes, C, Cheng, Sl, Chern, Jh, Chiu, Mh, Chung, Cl, Lai, Rs, Lin, Ck, Liu, Yc, Wang, Cc, Wei, Yf, Amer, L, Berenfus, Vi, Besh, L, Duka, Kd, Fushtey, Im, Garmash, N, Dudnyk, O, Godlevska, O, Vlasenko, Ma, Hospodarskyy, I, Iashyna, L, Kaladze, M, Khvelos, Si, Kostromina, Vp, Krakhmalova, O, Kryuchko, T, Kulynych, Ov, Krasko, Mp, Levchenko, O, Litvinova, T, Panina, Ss, Pasiyeshvili, Lm, Prystupa, Ln, Romaniuk, Li, Sirenko, I, Synenko, Vi, Vynnychenko, Lb, Yatsyshyn, Ri, Zaitsev, I, Zhebel, V, Zubarenko, O, Arthur, Cp, Brown, V, Burhan, H, Chaudhuri, R, Collier, D, Barnes, Nc, Davies, Ej, Ellery, A, Kwok, S, Lenney, W, Nordstrom, M, Pandya, Hc, Parker, Iw, Rajakulasingam, K, Seddon, P, Sharma, R, Thomas, Ec, Wakeling, Ja, Abalos-Galito, M, Abboy, C, Abreu, E, Ackerman, If, Acosta, Ia, Adaoag, Aa, Ahmed, M, Ali, Mi, Allen, Dr, Allen GG Jr, Diogo, Jj, Allison, Dc, Alwine, Lk, Apaliski, Sj, Arastu, Rs, Arora, Cm, Auerbach, D, Azzam, Sj, Badar FL 3rd, Baker, Jw, Barasch, Jp, Barber, Ma, Bardinas-Rodriguez, R, Barreiro, Tj, Baumbach, Rr, Baur, Ce, Baxter, Bs, Beach, Jl, Beasley, Rl, Beavins, Je, Beliveau, Wj, Benbow, Mj, Bennett, Nl, Bennett, Rl, Bernal, H, Bernstein, Di, Blaiss, Ms, Blumenthal, Kw, Boas, Sr, Borders, Jl, Boscia, Ja, Boulware, Wn, Bowling, Bt, Brabec, Ba, Bramlet, Dg, Figueroa, Dp, Brautigam, Df, Brownell, Jm, Bruce, Tr, Call, Rs, Campbell, Ca, Canaan, Ya, Cannon, Df, Carpio, Jm, Cathcart, Ws, Cevallos, Jp, Chauhan, Av, Chuang, Rb, Chevalier, D, Christensen, J, Christensen, Ta, Christina, Mo, Chrzanowski, Rr, Civitarese, Fa, Clark, Jp, Clifford, Dp, Lapidus, Rj, Coggi, Ja, Lenz, Jj, Cohen, Kr, Collins, Bg, Collins, H, Comellas, A, Condit, J, Cordasco EM Jr, Corder, Cn, Covar, Ra, Coverston, Kd, Croce, Sa, Cruz, H, Curtis, Ct, Daftary, Pk, Dalan, D, Dalawari, Sp, Daly, Wc, Davis, Kc, Dawes, Kw, Decotiis, Ba, Deluca, Rf, Desantis, Dm, De Valle OL, Diaz, Jl, Diaz, Jd, Dice, Jp, Elizalde, A, Hosler, Mr, Dixon, C, Dobkin, La, Dobrusin, Rs, Dransfield, Mt, Ebbeling, Wl, Edwards, Jd, Elacion, Jm, Elkayam, D, Ellison, Wt, Elsen, Jr, Engel, Lr, Ensz, Dj, Ericksen, Cl, Ervin, Je, Fang, C, Abrahamian, F, Farrah, Vb, Field, Jd, Fishman, Hj, Florea, R, Nayyar, S, Focil, A, Focauld, F, Franco MA Jr, Frandsen, Br, Ganti, K, Garcia, Fl, Lee, Wm, Garscadden, Ag, Gatti, Ea, Gellady, Am, George, Ar, Gibbon, Gw, Gleason, Gp, Goldberg, P, Goldstein, Mf, Gonzalez, Ge, Gower, Rg, Grande, Ja, Gregory, D, Grubb, Sd, Guthrie, Rp, Haas, Ta, Haft, Ks, Hajal, R, Hammond, Gd, Hansel, Nn, Hansen, Vr, Harris, Af, Hartman, An, Harvey, Rr, Hazan-Steinberg, S, Headley, Dm, Heigerick, Gc, Heller, Bn, Hendrix, El, Herrod, Jn, Hewitt, Mj, Hines, Rl, Hirdt, Ap, Hirschfield, Ja, Hoffman, Ks, Hogan, Ad, Howland, Wc, Hsu, Cc, Hsu, Fj, Hubbard, Wm, Hudson, Jd, Huffman, C, Hussain, M, Ioachimescu, Oc, Ismail, Ym, Jaffrani, Na, Jiang, N, Jones, Sw, Jordan, Rs, Joshi, Ke, Kaashmiri, Mw, Kalafer, M, Kamdar, Ba, Kanuga, Jg, Kao, Nl, Karetzky, M, Katsetos, Jc, Kay, Js, Kimmel, Ma, Kimura, Sh, Kingsley, Jk, Mahmood, Sm, Subich, Dc, Kirstein, Jl, Kleerup, Ec, Klein, Rm, Koh, Dw, Kohli, N, Koura, Fa, Kovacs, Sp, Kratzer, J, Kreit, Ci, Kreutter, Fm, Kubicki, Tm, Labuda, Jm, Latorre, Aj, Lara, Mm, Lechin, Ae, Lee, Jj, Lee, Md, Lentnek, Al, Lesh, Kw, Levins, Pf, Anspach, Rb, Levinsky, Dm, Lillestol, Mj, Lim, H, Livezey, Md, Lloyd-Turney, Cw, Lockey, Rf, Long, Ra, Lynch, Mj, Macgillivray, Bk, Mahadevan, Kp, Makam, Sk, Maloney, Mj, Mapel, D, Margolis, Bd, Margulies, J, Martin, Ef, Martin, Ee, Mascolo, M, Mataria, H, Sunbuli, M, Mathur, Rn, Mattar, Pn, Maynard, Km, Maynard, N, Mccormick, B, Mcelya, M, Mcevoy, Ce, Mckenzie, Wc, Medwedeff, Le, Mehta, Kd, Melamed, Ir, Meli, Jv, Merrick, Bh, Meyers, Pj, Miller, Bt, Minton, Sm, Miranda, Fg, Mohar, De, Montenegro, Ch, Morris, Fa, Morrison, Bs, Moss, Mh, Munoz, F, Naini, Gr, Nakamura, Ct, Naseeruddin, S, Nassim, C, Navazo, Lj, Nissim, Je, Norman, D, Oberoi, Ms, O'Connor, Tm, Offenberger, J, Orr, Rr, Osea, Ea, Paine, Wj, Rasmussen, Nl, Palatnik, M, Pangtay, D, Panuto, Ja, Patel, M, Perera, Ms, Perez, A, Peters PH Jr, Pimentel SM Jr, Pluto, Tm, Pollock, Mt, Posner, Ls, Pritchard, Jc, Pudi, Kk, Puig, Cm, Qaqundah, Py, Radbill, Mk, Rahman, St, Raikhel, M, Raissy, Hh, Ramstad, Ds, Ranasinghe, Es, Rangel, Os, Rapo, Se, Raschal, Sp, Reddy, Dg, Rehman, Sm, Reyes, Sr, Rhodes, Rb, Riffer, E, Rihal, Ps, Riley ED 4th, Rodriguez, Dh, Rogers, Cm, Rohlf, Jl, Romeu, H, Roney, Cw, Ronsick, So, Rosen, Jb, Rowe, Ms, Ruoff, Ge, Ryan, Eh, Saff, Rh, Saini, N, Anand, S, Balakrishnan, K, Samuels, Bs, Samuelson, Rj, Saniuk, Rj, Sargeant, Wo, Saunders, Mk, Saway, W, Scarupa, Md, White, Mv, Schear, Mj, Schwarz, Cm, Scott, Rb, Segall, N, Seibert, Af, Seidmeyer, V, Seidner, Mr, Seifer, Fd, Serje, J, Shah, Ms, Shah, Sb, Shapero, Pa, Shearer, Sd, Sheikh, Sq, Shepherd, Ts, Sher, Er, Sher, Ld, Short, Bh, Silas, Pe, Alvey, Jc, Silverfield, Jc, Simon, Sj, Sitar, S, Skoner, Dp, Smallow, Sa, Smart, Ba, Smith, Ca, Smith, Ke, Smith, Sk, Snyders, Gc, Soong, W, Soufer, J, Spangenthal, S, Stahlman, Je, Steele, Lg, Stegemoller, Rk, Stocks, J, Storms, Ww, Suen, J, Surowitz, Rz, Swauger, Jr, Taber, La, Tan, Ae, Pratt, Se, Tanus, T, Tarpay, Mm, Tarshis, Ga, Tenney, Jw, Tilghman, Kg, Trevino, Me, Troyan, Be, Twiddy, Sk, Updegrove, Jd, Urval, Kr, Uusinarkaus, Kt, Vaela, R, Van Cleeff, M, Varano, S, Vo, Qd, Wainz, Rj, Wald, Ja, Wall, Sj, Wasserman, Rl, Weinstein, Dl, Welker, Ja, Wellmon, B 2nd, Wells, T, Wenocur, Hs, Williams, Dl, Williams, Sl, Win, Ph, Wingo, Td, Wisman PP Jr, Wyszomierski, Da, Yamada, Hm, Yarows, S, Yunger TM Jr, Ziering, Rw., the AUSTRI Investigators, Stempel, D., Raphiou, I., Kral, K., Yeakey, A., Emmett, A., Prazma, C., Buaron, K., and Pascoe, S. Scichilone N tra i collaboratori
Subjects: Male, asthma, serious events, fluticasone, salmeterol, AUSTRI, Exacerbation, Intention to Treat Analysi, INHALED CORTICOSTEROIDS, Severity of Illness Index, law.invention, 0302 clinical medicine, Randomized controlled trial, law, immune system diseases, Ús terapèutic, Broncodilatadors, 030212 general & internal medicine, Child, Fluticasone, RISK, ACTING BETA-AGONISTS, EXACERBATIONS, METAANALYSIS, MORTALITY, SAFETY, DEATH, FDA, Medicine (all), Hazard ratio, General Medicine, Bronchodilator agents, Middle Aged, Fluticasone-Salmeterol Drug Combination, Bronchodilator Agents, Intention to Treat Analysis, Anesthesia, Female, Salmeterol, medicine.drug, Human, Adult, medicine.medical_specialty, Adolescent, Settore MED/10 - Malattie Dell'Apparato Respiratorio, Fluticasone propionate, 03 medical and health sciences, Double-Blind Method, Internal medicine, Administration, Inhalation, medicine, Humans, Asma, Bronchodilator Agent, Asthma, Aged, Proportional Hazards Models, business.industry, Therapeutic use, medicine.disease, respiratory tract diseases, 030228 respiratory system, Fluticasone Propionate, Salmeterol Xinafoate Drug Combination, Proportional Hazards Model, business
Abstract: BACKGROUND The safe and appropriate use of long-acting beta-agonists (LABAs) for the treatment of asthma has been widely debated. In two large clinical trials, investigators found a potential risk of serious asthma-related events associated with LABAs. This study was designed to evaluate the risk of administering the LABA salmeterol in combination with an inhaled glucocorticoid, fluticasone propionate. METHODS In this multicenter, randomized, double-blind trial, adolescent and adult patients (age, ≥12 years) with persistent asthma were assigned to receive either fluticasone with salmeterol or fluticasone alone for 26 weeks. All the patients had a history of a severe asthma exacerbation in the year before randomization but not during the previous month. Patients were excluded from the trial if they had a history of lifethreatening or unstable asthma. The primary safety end point was the first serious asthma-related event (death, endotracheal intubation, or hospitalization). Noninferiority of fluticasone–salmeterol to fluticasone alone was defined as an upper boundary of the 95% confidence interval for the risk of the primary safety end point of less than 2.0. The efficacy end point was the first severe asthma exacerbation. RESULTS Of 11,679 patients who were enrolled, 67 had 74 serious asthma-related events, with 36 events in 34 patients in the fluticasone–salmeterol group and 38 events in 33 patients in the fluticasone-only group. The hazard ratio for a serious asthmarelated event in the fluticasone–salmeterol group was 1.03 (95% confidence interval [CI], 0.64 to 1.66), and noninferiority was achieved (P = 0.003). There were no asthma-related deaths; 2 patients in the fluticasone-only group underwent asthmarelated intubation. The risk of a severe asthma exacerbation was 21% lower in the fluticasone–salmeterol group than in the fluticasone-only group (hazard ratio, 0.79; 95% CI, 0.70 to 0.89), with at least one severe asthma exacerbation occurring in 480 of 5834 patients (8%) in the fluticasone–salmeterol group, as compared with 597 of 5845 patients (10%) in the fluticasone-only group (P
Published: 2016

19. Rupatadine oral solution in children with persistent allergic rhinitis: A randomized, double-blind, placebo-controlled study

Author: Potter P, Maspero JF, Vermeulen J, Barkai L, Németh I, Baillieau RA, Garde JM, Giralt J, Doménech A, Izquierdo I, and Nieto A
Abstract: Allergic rhinitis (AR) is one of the most common chronic diseases in childhood. No large, multicentre clinical trials in children with persistent allergic rhinitis (PER) have previously been performed. Rupatadine, a newer second-generation antihistamine, effective and safe in adults, is a promising treatment for children with AR. The aim of the present study was to evaluate the efficacy and safety of a new rupatadine oral solution in children aged 6-11 yr with PER.
Published: 2013

20. Mometasone Furoate and Formoterol (MF/F) Combination Administered Via a Metered-Dose Inhaler (MDI) for the Treatment of Asthma: Results from a 1-Yr Safety Study.

Author: Maspero, JF, primary, Cherrez, I, additional, and Nolte, H, additional
Published: 2009
Full Text: View/download PDF

21. Efficacy and safety of fluticasone propionate hydrofluoroalkane inhalation aerosol in pre-school-age children with asthma: a randomized, double-blind, placebo-controlled study.

Author: Qaqundah PY, Sugerman RW, Ceruti E, Maspero JF, Kleha JF, Scott CA, Wu W, Mehta R, Crim C, Qaqundah, Paul Y, Sugerman, Robert W, Ceruti, Elaina, Maspero, Jorge Fernando, Kleha, Joseph F, Scott, Catherine A, Wu, Wei, Mehta, Rashmi, and Crim, Courtney
Abstract: Objective: To evaluate the efficacy and tolerability of fluticasone propionate (FP) hydrofluoroalkane (HFA) in children age 1 to < 4 years with asthma.Study Design: Children were assigned (2:1) to receive FP HFA 88 mug (n = 239) or placebo HFA (n = 120) twice daily through a metered-dose inhaler with a valved holding chamber and attached facemask for 12 weeks. The primary efficacy measure was mean percent change from baseline to endpoint in 24-hour daily (composite of daytime and nighttime) asthma symptom scores.Results: The FP-treated children had significantly greater (P < or = .05) reductions in 24-hour daily asthma symptom scores (-53.9% vs -44.1%) and nighttime symptom scores over the entire treatment period compared with the placebo group. Daytime asthma symptom scores and albuterol use were slightly more decreased with FP than with placebo; however, the differences were not statistically significant. Increases in the percentage of symptom-free days were comparable. The percentage of patients who experienced at least 1 adverse event was similar in the 2 groups. Baseline median urinary cortisol excretion values were comparable between the groups, and there was little change from baseline at endpoint. FP plasma concentrations demonstrated that systemic exposure was low.Conclusions: FP HFA 88 mug twice daily was effective and well tolerated in pre-school-age children with asthma. [ABSTRACT FROM AUTHOR]
Published: 2006
Full Text: View/download PDF

22. A Randomized, Controlled Phase 3 Study, LIBERTY ASTHMA QUEST, Evaluating the Efficacy and Safety of Dupilumab in Uncontrolled Moderate-to-Severe Asthma

Author: Castro, M, Corren, J, Pavord, ID, Maspero, JF, Wenzel, SE, Rabe, KF, Busse, WW, Ford, LB, Sher, L, Fitzgerald, JM, Katelaris, C, Tohda, Y, Zhang, B, Staudinger, H, Pirozzi, G, Amin, N, Ruddy, M, Akinlade, B, Khan, A, Chao, J, Martincova, R, Graham, NMH, and Teper, A

23. Dupilumab Efficacy in Children With Type 2 Asthma Receiving High- to Medium-Dose Inhaled Corticosteroids (VOYAGE).

Author: Maspero JF, Antila MA, Deschildre A, Bacharier LB, Altincatal A, Laws E, Mortensen E, Radwan A, Jacob-Nara JA, Deniz Y, Rowe PJ, Lederer DJ, and Hardin M
Subjects: Humans, Child, Female, Male, Administration, Inhalation, Treatment Outcome, Double-Blind Method, Drug Therapy, Combination, Adolescent, Asthma drug therapy, Adrenal Cortex Hormones therapeutic use, Adrenal Cortex Hormones administration & dosage, Antibodies, Monoclonal, Humanized therapeutic use, Antibodies, Monoclonal, Humanized administration & dosage, Anti-Asthmatic Agents therapeutic use, Anti-Asthmatic Agents administration & dosage
Abstract: Background: In phase 3 VOYAGE (NCT02948959; Evaluation of Dupilumab in Children With Uncontrolled Asthma), dupilumab showed clinical efficacy with an acceptable safety profile in children aged 6 to 11 years with uncontrolled moderate to severe type 2 asthma (blood eosinophils ≥150 cells/μL or FeNO ≥20 ppb)., Objective: We analyzed dupilumab's efficacy in children with type 2 asthma by high- or medium-dose inhaled corticosteroids (ICS) at baseline., Methods: Children were randomized to receive add-on dupilumab 100/200 mg (by body weight ≤30 kg/>30 kg) every 2 weeks or placebo for 52 weeks and stratified by high- or medium-dose ICS at baseline. End points were annualized severe exacerbation rate, changes from baseline in percent predicted FEV 1 , and seven-item Asthma Control Questionnaire-Interviewer Administered (ACQ-7-IA) score, proportions of ACQ-7-IA responders (improvement ≥0.5), and biomarker changes., Results: In children receiving high-dose (n = 152) or medium-dose (n = 195) ICS at baseline, dupilumab versus placebo reduced severe exacerbation rates by 63% (P < .001) and 59% (P = .003), respectively. At week 52, dupilumab improved percent predicted FEV 1 by least squares mean difference versus placebo of 5.7 percentage points (P = .02) and 9.35 points (P < .001), and reduced ACQ-7-IA scores by 0.53 points (P < .001) and 0.40 points (P < .001), respectively. No significant treatment interactions between ICS subgroups were detected at week 52. Significant improvements were observed in ACQ-7-IA responder rates and most type 2 biomarker levels., Conclusion: Dupilumab reduced severe exacerbation rates and improved lung function and asthma control in children with uncontrolled moderate to severe type 2 asthma regardless of ICS dose at baseline., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
Published: 2024
Full Text: View/download PDF

24. Dupilumab improves pediatric type 2 asthma outcomes independent of patient baseline characteristics.

Author: Maspero JF, Fiocchi AG, Deschildre A, Bacharier LB, Altincatal A, Laws E, Lederer DJ, Akinlade B, and Hardin M
Published: 2024
Full Text: View/download PDF

25. Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthma.

Author: Bacharier LB, Pavord ID, Maspero JF, Jackson DJ, Fiocchi AG, Mao X, Jacob-Nara JA, Deniz Y, Laws E, Mannent LP, Amin N, Akinlade B, Staudinger HW, Lederer DJ, and Hardin M
Subjects: Humans, Child, Male, Female, Prognosis, Fractional Exhaled Nitric Oxide Testing, Leukocyte Count, Anti-Asthmatic Agents therapeutic use, Exhalation, Asthma drug therapy, Asthma diagnosis, Asthma metabolism, Eosinophils immunology, Biomarkers, Nitric Oxide metabolism, Antibodies, Monoclonal, Humanized therapeutic use
Abstract: Background: Blood eosinophils and fractional exhaled nitric oxide (Feno) are prognostic biomarkers for exacerbations and predict lung function responses to dupilumab in adolescents and adults with asthma., Objective: We evaluated the relationship between baseline blood eosinophils and Feno and response to dupilumab in children with asthma., Methods: Children aged 6 to 11 years with uncontrolled moderate-to-severe asthma (n = 408) were randomized to receive dupilumab 100/200 mg by body weight or volume-matched placebo every 2 weeks for 52 weeks. Annualized exacerbation rate (AER) reduction and least squares mean change in prebronchodilator percent predicted forced expiratory volume in 1 second (ppFEV 1 ) at week 12 were assessed according to cutoff baseline levels for Feno (<20 ppb vs ≥20 ppb) and blood eosinophil count (<150, ≥150 to <300, ≥300 to <500, and ≥500 cells/μL). Quadrant analyses in populations defined by biomarker thresholds and spline models across continuous end points assessed the relationship with Feno and eosinophil count. Interaction testing evaluated the independent roles of Feno and blood eosinophils as predictive markers., Results: Exacerbation risk and magnitude of AER reduction increased in subgroups with higher baseline biomarker levels. Quadrant analyses revealed that disease of patients with either elevated Feno or eosinophil counts demonstrated a clinical response to dupilumab. Interaction testing indicated blood eosinophil counts or Feno independently added value as predictive biomarkers., Conclusions: In children with uncontrolled moderate-to-severe asthma, blood eosinophil counts and Feno are clinically relevant biomarkers to identify those at risk for asthma exacerbations, as well as those with disease with clinical response to dupilumab., Trial Registration: Liberty Asthma VOYAGE ClinicalTrials.gov NCT02948959., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
Published: 2024
Full Text: View/download PDF

26. Biomarkers Associated with Lung Function Decline and Dupilumab Response in Patients with Asthma.

Author: Pavord ID, De Prado Gómez L, Brusselle G, Jackson DJ, Brightling CE, Papi A, Maspero JF, Rabe KF, Korn S, Zhang M, Soler X, Jacob-Nara JA, and Hardin M
Subjects: Humans, Antibodies, Monoclonal, Humanized therapeutic use, Biomarkers, Lung diagnostic imaging, Double-Blind Method, Asthma drug therapy, Anti-Asthmatic Agents therapeutic use
Published: 2024
Full Text: View/download PDF

27. Long-Term Safety of Dupilumab in Patients With Moderate-to-Severe Asthma: TRAVERSE Continuation Study.

Author: Maspero JF, Peters AT, Chapman KR, Domingo C, Stewart J, Hardin M, Maroni J, Tawo K, Khokhar FA, Mortensen E, Laws E, Radwan A, Jacob-Nara JA, Deniz Y, and Rowe PJ
Subjects: Adult, Adolescent, Humans, Treatment Outcome, Double-Blind Method, Antibodies, Monoclonal, Humanized adverse effects, Asthma drug therapy, Asthma epidemiology, Asthma chemically induced
Abstract: Background: Previous clinical trials have demonstrated dupilumab efficacy and safety in adults and adolescents with moderate to severe asthma for up to 3 years., Objective: The TRAVERSE continuation study (NCT03620747), a single-arm, open-label study, assessed safety and tolerability of dupilumab 300 mg every 2 weeks up to an additional 144 weeks (∼3 years) in patients with moderate to severe asthma who previously completed TRAVERSE (NCT02134028)., Methods: Primary end points were incidence and event rates per 100 patient-years of treatment-emergent adverse events (TEAEs). Secondary end points included adverse events (AEs) of special interest, serious AEs, and AEs leading to study discontinuation., Results: A total of 393 patients participated in the TRAVERSE continuation study (cumulative dupilumab exposure, 431.7 patient-years; median treatment duration, 309 days). A total of 29 patients (7.4%) received more than 958 days of treatment. A total of 214 (54.5%) patients reported at least 1 TEAE (event rate: 171.4); 37 (9.4%) experienced at least 1 treatment-related TEAE, none of which were considered severe; 2 patients reported 6 TEAEs of moderate intensity. A total of 22 (5.6%) patients reported serious AEs (event rate: 6.9). AEs of special interest were reported in 24 patients (6.1%; event rate: 6.0). Five (1.3%) deaths occurred (event rate: 1.2) following serious AEs of coronavirus disease 2019 (COVID-19)-related pneumonia (3 patients), pancreatitis (1 patient), and pulmonary embolism (1 patient). None of the TEAEs leading to death were considered treatment-related., Conclusions: Dupilumab treatment was well tolerated for up to an additional 3 years. Safety findings were consistent with the known safety profile of dupilumab. These findings further support the long-term use of dupilumab in patients with moderate to severe asthma., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
Published: 2024
Full Text: View/download PDF

28. Management of CRSwNP in Latin America: A multidisciplinary consensus from an expert working group.

Author: Maspero JF, Anselmo-Lima W, Bedoya D, Jimenez Chobillón MA, Ospina J, Roithmann R, Sadek Gonzalez A, and Silva Rueda R
Abstract: Chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory condition of the nasal and paranasal tissues, characterized by the presence of bilateral nasal polyps. While etiology and pathogenetic mechanisms are heterogeneous and complex, in most patients, disease is mediated predominantly through type 2 inflammatory processes. Clinical management is challenging, and a multidisciplinary approach is preferred. Principal treatment approaches are the use of local/systemic corticosteroids and sinonasal surgery, although outcomes can be unsatisfactory. Recent availability of biological therapies targeting underlying inflammatory processes can offer effective treatment options in uncontrolled disease. Specialist guidelines greatly assist clinical decision-making, although as these are chiefly written from a global/international perspective, they may not wholly accommodate disease patterns and clinical practice at a regional level. An expert panel of specialists from Latin America was convened to develop regional guidance on the management of CRSwNP through a consensus approach. The present article presents the chief observations and recommendations which can provide guidance for clinicians in the Latin American region., Competing Interests: JFM has acted as a speaker, advisory board member, and/or investigator for Sanofi, AstraZeneca, Novartis, Inmunito, Uriach, GSK, Menarini and MSD. DB has attended advisory board and received sponsorship from Sanofi. AS has acted as an advisor for Sanofi. WA-L, MAJC, JO, RR and RSR have no direct or indirect conflict of interests to declare., (© 2024 Published by Elsevier Inc. on behalf of World Allergy Organization.)
Published: 2024
Full Text: View/download PDF

29. Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study.

Author: Bacharier LB, Maspero JF, Katelaris CH, Fiocchi AG, Gagnon R, de Mir I, Guilbert TW, Jackson DJ, Staudinger HW, Laws E, Mannent LP, Akinlade B, Maloney J, Tawo K, Khokhar FA, Li N, Hardin M, Abdulai RM, Lederer DJ, and Robinson LB
Subjects: Child, Humans, Double-Blind Method, Severity of Illness Index, Treatment Outcome, Multicenter Studies as Topic, Randomized Controlled Trials as Topic, Clinical Trials, Phase III as Topic, Antibodies, Monoclonal, Humanized adverse effects, Asthma drug therapy
Abstract: Background: Dupilumab efficacy and safety in children aged 6-11 years with uncontrolled, moderate-to-severe asthma were shown in the VOYAGE study-a 52-week, multinational, multicentre, phase 3 randomised, double-blind, placebo-controlled trial. We aimed to evaluate the long-term safety and efficacy of dupilumab in children with moderate-to-severe asthma who previously participated in the VOYAGE study., Methods: 365 of 408 children with moderate-to-severe asthma from VOYAGE enrolled in EXCURSION, a 52 week, open-label extension study conducted at 70 centres across 17 countries. 240 children continued with add-on dupilumab (dosed according to bodyweight: 100 mg for those weighing ≤30 kg and 200 mg for those weighing more than 30 kg at EXCURSION baseline) once every 2 weeks administered by subcutaneous injection (dupilumab/dupilumab group) and 125 children on placebo during VOYAGE initiated dupilumab (100 or 200 mg, according to bodyweight), once every 2 weeks administered by subcutaneous injection (placebo/dupilumab group). Following a protocol amendment, for a subset of children weighing 30 kg or less, the dose was changed to 300 mg once every 4 weeks. The primary endpoint for the open-label extension study was the number and proportion of patients with any treatment-emergent adverse event (TEAE) during the 52-week study period in the overall population (defined as children aged 6-11 years old with moderate-to-severe asthma who previously completed VOYAGE). Statistical analyses were descriptive. This study is registered with ClinicalTrials.gov (NCT03560466; EXCURSION)., Findings: Children who completed VOYAGE were eligible to enrol in EXCURSION between June 21, 2018 and Aug 18, 2020. During EXCURSION, the safety profile and proportion of patients reporting TEAEs were consistent with those observed during the parent study (VOYAGE). In the overall population, 232 (63·6%) of 365 patients experienced at least one TEAE (dupilumab/dupilumab: 147 [61·3%]; placebo/dupilumab: 85 [68·0%]). The most frequently reported TEAEs were nasopharyngitis, pharyngitis, and upper respiratory tract infections., Interpretation: In EXCURSION, long-term treatment with dupilumab was well tolerated with an acceptable safety profile., Funding: Sanofi and Regeneron Pharmaceuticals., Competing Interests: Declaration of interests LBB has received speaker fees from AstraZeneca, GSK, Regeneron Pharmaceuticals, and Sanofi; is a member of the data and safety monitoring board for DBV Technologies and Cystic Fibrosis Foundation; and has received research support from the US National Institutes of Health, Sanofi, and Vectura. JFM is a consultant for AstraZeneca and Sanofi; has received speaker fees from GSK, Menarini, Novartis, and Uriach; and reports research grants from Novartis. CHK reports honoraria for presentations; and was a principal investigator of the dupilumab asthma phase 2b (NCT01854047) and phase 3 (NCT02414854) studies for Regeneron Pharmaceuticals and Sanofi. AGF is a member of the advisory boards for Abbott, Danone, DBV Technologies, HiPP Organic, Novartis, and Stallergenes Greer; and reports currently sponsoring research from Danone, Ferrero, HiPP Organic, and Sanofi. RG reports research grants from ALK, AstraZeneca, BioCryst, DBV Technologies, Genentech, Greencross, Novartis, Regeneron Pharmaceuticals, Sanofi, and Shire; is a consultant for ALK, AstraZeneca, Pfizer, and Sanofi; and has received speaker fees from Novartis. IdM reports personal fees for lectures and boards from GSK and Sanofi; conference registration and travel fees from Novartis; and conference registration fees from Aldo-Unión. TWG reports grants from NIH and GSK; grants and consulting fees from Sanofi, Regeneron Pharmaceuticals, Amgen, and AstraZeneca; consulting fees from Novartis, Genentech, Polarean, OM Pharma, AiCME, and Best Pharmaceuticals for Children Act; and royalties from UpToDate. DJJ is a consultant for AstraZeneca, Avillion, GSK, Novartis, Regeneron Pharmaceuticals, Sanofi, and Vifor Pharma; and is a member of the data and safety monitoring board for Pfizer. HWS, NL, EL, LPM, KT, MH, RMA, and LBR are employees of Sanofi, and might hold stock or stock options in the company. BA, JM, FAK, and DJL are employees and shareholders of Regeneron Pharmaceuticals., (Copyright © 2024 Elsevier Ltd. All rights reserved.)
Published: 2024
Full Text: View/download PDF

30. Dupilumab efficacy in high sleep disturbance management among patients with type 2 asthma.

Author: Maspero JF, Shafazand S, Cole J, Pavord ID, Busse WW, Msihid J, Gall R, Soler X, Radwan A, Khan AH, de Prado Gómez L, and Jacob-Nara JA
Subjects: Humans, Antibodies, Monoclonal therapeutic use, Quality of Life, Double-Blind Method, Treatment Outcome, Anti-Asthmatic Agents, Asthma complications, Asthma drug therapy, Asthma chemically induced
Abstract: Background: Patients with asthma often experience sleep disturbances. We assessed the 5-item Asthma Control Questionnaire (ACQ-5) score ≥2.5 as a useful threshold to identify patients with moderate-to-severe type 2 asthma and high sleep disturbance (HSD) and investigated dupilumab efficacy on clinical and sleep-related outcomes among patients with HSD., Methods: QUEST (NCT02414854) data were used in this post hoc analysis. A composite endpoint from validated patient-reported outcomes was developed to identify patients with HSD using sleep-related items from the ACQ-5, Asthma-Related Quality-of-Life Questionnaire, Rhino-Conjunctivitis Quality-of-Life Questionnaire, and Sino-Nasal Outcome Test-22. Impairment in at least 1 item was considered an indication of HSD. Change from baseline to Week 52 in nighttime symptoms, ACQ-5 score, lung function, annualized severe exacerbation rates (AER), and short-acting β-agonists use during treatment was used to assess dupilumab efficacy., Results: In type 2 asthma patients, 64% had HSD at baseline; of those with ACQ-5 ≥2.5 at baseline, 82% had HSD. In this population, dupilumab reduced nighttime symptoms and ACQ-5 score by 0.31 and 0.56 points, respectively, by Week 52 versus placebo, and led to a 66% reduction in AER during QUEST and 0.34 L improvement in pre-bronchodilator (pre-BD) forced expiratory volume in 1 s (FEV 1 ) at Week 52., Conclusion: A majority of patients with moderate-to-severe type 2 asthma with ACQ-5 ≥2.5 at baseline had HSD. Dupilumab reduced nighttime symptoms and exacerbations, and improved lung function, overall asthma control, and quality of life. Further studies are needed to confirm the association between ACQ-5 score ≥2.5 and higher sleep disturbance rates., (Copyright © 2023 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
Published: 2023
Full Text: View/download PDF

31. Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthma.

Author: Corren J, Katelaris CH, Castro M, Maspero JF, Humbert M, Halpin DMG, Altincatal A, Pandit-Abid N, Soler X, Radwan A, Jacob-Nara JA, Deniz Y, and Rowe PJ
Abstract: Background: The phase 3 QUEST (NCT02414854) and TRAVERSE (NCT02134028) studies demonstrated the efficacy of dupilumab 200/300 mg versus placebo every 2 weeks for 52 weeks (QUEST) and dupilumab 300 mg up to an additional 96 weeks (TRAVERSE) in patients ≥12 years of age with uncontrolled, moderate-to-severe asthma. Overall, safety was consistent with the known dupilumab safety profile. This post hoc analysis assessed long-term dupilumab efficacy for up to 3 years by exacerbation history., Patients and Methods: Unadjusted annualised severe exacerbation rates (AER) and change from parent study baseline (PSBL) in pre-bronchodilator forced expiratory volume in 1 s (FEV 1 ) and 5-item Asthma Control Questionnaire (ACQ-5) score were assessed in patients with PSBL eosinophils ≥150 cells·µL -1 or fractional exhaled nitric oxide ≥20 ppb and 1 (n=624), 2 (n=344), or ≥3 (n=311) exacerbations in the year before enrolment in QUEST., Results: In all three groups, dupilumab treatment progressively reduced AER range to 0.17-0.30 during TRAVERSE (Weeks 48-96), increased pre-bronchodilator FEV 1 range by 0.28-0.49 L by Week 96 and improved asthma control (reduced ACQ-5 score range by 1.51-2.03 by Week 48). For patients who first received dupilumab upon TRAVERSE enrolment, AER decreased, and lung function and asthma control improved rapidly, as was observed upon initiation of dupilumab in QUEST. Dupilumab was efficacious regardless of exacerbation history., Conclusion: For patients with uncontrolled, moderate-to-severe asthma with elevation of at least one type 2 biomarker, dupilumab treatment provides sustained, long-term reduction of exacerbation rates and improvements in lung function and asthma control irrespective of exacerbation history., Competing Interests: Conflict of interest: J. Corren reports research grants from and is a consultant for AstraZeneca, Genentech, Novartis, Regeneron Pharmaceuticals Inc. and Sanofi; and speaker fees from AstraZeneca, Genentech and Novartis. C.H. Katelaris is a Principal Investigator of the dupilumab asthma phase 2b (NCT01854047) and phase 3 (NCT02414854) studies for Regeneron Pharmaceuticals Inc. and Sanofi. M. Castro reports research support from the American Lung Association, AstraZeneca, GlaxoSmithKline, NIH, Novartis, PCORI, Pulmatrix, Sanofi-Aventis and Shionogi; is a consultant for Genentech, Novartis, Sanofi-Aventis and Teva; reports speaker fees from AstraZeneca, Genentech, GlaxoSmithKline, Regeneron Pharmaceuticals Inc., Sanofi and Teva; and royalties from Elsevier. J.F. Maspero is a consultant for AstraZeneca and Sanofi; reports speaker fees from GlaxoSmithKline, Menarini, Novartis and Uriach; and research grants from Novartis. M. Humbert reports consultant and speaker fees from AstraZeneca, Chiesi, GlaxoSmithKlein, Novartis and Sanofi. D.M.G. Halpin reports advisory board membership, speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, GlaxoSmithKline, Novartis, Pfizer, Sandoz and Sanofi. A. Altincatal, N. Pandit-Abid, J.A. Jacob-Nara and P.J. Rowe are employees of Sanofi, and may hold stock and/or stock options in the company. X. Soler, A. Radwan and Y. Deniz are employees and shareholders of Regeneron Pharmaceuticals Inc., (Copyright ©The authors 2023.)
Published: 2023
Full Text: View/download PDF

32. Efficacy of mometasone/indacaterol/glycopyrronium in patients with inadequately controlled asthma with respect to baseline eosinophil count: Post hoc analysis of IRIDIUM study.

Author: Kostikas K, Maspero JF, Chapman KR, Mezzi K, Jaumont X, Lawrence D, and van Zyl-Smit R
Abstract: Background: Baseline characteristics could potentially guide asthma treatments. We evaluated whether baseline eosinophil levels affect the efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) in patients with inadequately controlled asthma., Method: In this post hoc analysis of IRIDIUM study, efficacy of high-dose MF/IND/GLY (160/150/50 μg, once-daily [o.d.]) versus high-dose MF/IND (320/150 μg o.d.) and high-dose fluticasone/salmeterol (FLU/SAL [500/50 μg, twice-daily [b.i.d.]); and efficacy of pooled MF/IND/GLY (160/150/50 μg and 80/150/50 μg) versus pooled MF/IND (320/150 μg and 160/150 μg) was evaluated in patient subgroups with baseline blood eosinophil count of <300 cells/μL or ≥300 cells/μL., Results: Overall, 3065 patients were included. At Week 26, high-dose MF/IND/GLY showed improved trough FEV 1 versus high-dose MF/IND (Δ78mL [<300 cells/μL]; Δ54mL [≥300 cells/μL]) and FLU/SAL (Δ112mL [<300 cells/μL]; Δ98mL [≥300 cells/μL]). Similarly, pooled MF/IND/GLY also showed improved trough FEV 1 versus pooled MF/IND (Δ75mL [<300 cells/μL]; Δ68mL [≥300 cells/μL]). Over 52 weeks, high-dose MF/IND/GLY reduced the annualized rate of moderate or severe asthma exacerbations by 23% and 10%, severe exacerbations by 31% and 15%, and all exacerbation by 33% and 10% versus high-dose MF/IND for subgroups with <300 cells/μL and ≥300 cells/μL, respectively; and by 33% and 41%, 45% and 42%, 42% and 39% versus FLU/SAL, respectively. Similarly, pooled MF/IND/GLY reduced exacerbations by 22% and 8%, 21% and 7%, 27% and 8%, versus pooled MF/IND, for the respective subgroups., Conclusion: MF/IND/GLY showed improvement in lung function and reduction in asthma exacerbations over MF/IND and FLU/SAL independent of baseline eosinophil levels, indicating that eosinophil levels did not affect the efficacy of MF/IND/GLY in patients with inadequately controlled asthma., Trial Registration: ClinicalTrials.gov, NCT02571777 (IRIDIUM)., Competing Interests: Declaration of competing interest Konstantinos Kostikas reports honoraria for presentations and consultancy fees from AstraZeneca, Boehringer Ingelheim, CSL Behring, Chiesi, ELPEN, GILEAD, GSK, Menarini, Novartis, Sanofi, Specialty Therapeutics, WebMD (paid to the University of Ioannina), is a member of the GOLD Assembly and was an employee of Novartis Pharma AG until October 31, 2018; his department received funding and grants from AstraZeneca, Boehringer Ingelheim, Chiesi, Innovis, ELPEN, GSK, Menarini, Novartis and NuvoAir (paid to the University of Ioannina). Jorge F. Maspero reports grants and personal fees from Novartis during the conduct of the study, grants and personal fees from Sanofi, and personal fees from AstraZeneca and ImmunoTek. Kenneth R. Chapman reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Grifols, Novartis, Regeneron, Sanofi, and Takeda, grants from Vertex, and personal fees from CSL Behring, Inhibrx, and Kamada, all outside of the submitted work. Richard van Zyl-Smit reports personal fees from Aspen–GSK, AstraZeneca, Cipla, Merck Sharp & Dohme, Novartis, Pfizer, and Roche, Glenmark and Boehringer Ingelheim outside of the submitted work. Karen Mezzi, Xavier Jaumont are employees of Novartis. David Lawrence is an employee as well as share owner of Novartis., (Copyright © 2023 Novartis Pharma AG. Published by Elsevier Ltd.. All rights reserved.)
Published: 2023
Full Text: View/download PDF

33. Assessment of dupilumab in children with moderate-to-severe type 2 asthma with or without evidence of allergic asthma.

Author: Papadopoulos NG, Szefler SJ, Bacharier LB, Maspero JF, Domingo C, Fiocchi A, Lee JK, Daizadeh N, Lederer DJ, Hardin M, Gall R, Djandji M, Siddiqui S, Jacob-Nara JA, Deniz Y, and Rowe PJ
Subjects: Humans, Male, Female, Child, Disease Progression, Placebos, Forced Expiratory Volume, Lung physiopathology, Antibodies, Monoclonal, Humanized therapeutic use, Asthma drug therapy, Asthma immunology, Asthma physiopathology
Abstract: Background: Cytokines, such as interleukins (IL)-4/5/13, play a key role in multiple type 2 inflammatory diseases, including allergic asthma. Dupilumab, a human monoclonal antibody, blocks the shared receptor component for IL-4/IL-13, inhibiting signaling. In this post hoc analysis of VOYAGE (NCT02948959), dupilumab efficacy was evaluated in patients aged 6-11 years with type 2 asthma with or without evidence of allergic asthma (baseline serum total IgE ≥30 IU/mL and ≥1 perennial aeroallergen-specific IgE ≥0.35kU/L)., Methods: Annualized severe exacerbation rates (AER) and changes in pre-bronchodilator (Pre-BD) forced expiratory volume in one second (FEV 1 ), percent-predicted pre-BD FEV 1 (ppFEV 1 ), and Asthma Control Score (ACQ)-7 were assessed during the treatment period., Results: 350 children (261 with and 89 without evidence of allergic asthma) were included. Dupilumab versus placebo significantly reduced AER in patients with (0.24 vs. 0.62, relative risk reduction [RRR]: 62% [95% CI, 39-76], P < .0001) and without (0.39 vs. 0.80, RRR: 51% [95% CI, 0-76], P < .05) evidence of allergic asthma. Significant improvements in ppFEV 1 , pre-bronchodilator FEV 1 , and ACQ-7 scores were observed in dupilumab versus placebo throughout the treatment period in patients with evidence of allergic asthma. In patients without evidence of allergic asthma, numerical improvements in pre-bronchodilator FEV 1 and asthma control were observed by Week 52., Conclusion: Dupilumab versus placebo reduced asthma exacerbations in children with type 2 asthma irrespective of evidence of allergic asthma; similar trends were observed in changes in lung function. Significant improvement in asthma control was observed in patients with evidence of allergic asthma, but not in those without., (© 2023 Sanofi and The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)
Published: 2023
Full Text: View/download PDF

34. Dupilumab efficacy and safety in Latin American patients with uncontrolled, moderate-to-severe asthma: phase 3 LIBERTY ASTHMA QUEST study.

Author: Maspero JF, Cardona G, Schonffeldt P, Tolcachier A, González-Diaz SN, Yañez A, Galvao CE, Msihid J, Gall R, Siddiqui S, Rowe PJ, Deniz Y, Jacob-Nara JA, and Djandji M
Subjects: Humans, Latin America, Bronchodilator Agents therapeutic use, Antibodies, Monoclonal, Double-Blind Method, Treatment Outcome, Asthma drug therapy, Anti-Asthmatic Agents adverse effects
Abstract: Objective: While advances in asthma care have been made in Latin America, there is still a large unmet need in patients with uncontrolled asthma. This post hoc analysis of the QUEST study assessed safety and efficacy of dupilumab in the subgroup of patients enrolled in Latin American countries with a type 2 inflammatory asthma phenotype (blood eosinophils ≥ 150cells/µL or FeNO ≥25ppb)., Methods: LIBERTY ASTHMA QUEST (NCT02414854) was a phase 3, multinational, randomized, double-blind, placebo-controlled study in patients with uncontrolled, moderate-to-severe asthma. Eligible patients ≥ 12 years of age were randomized in a 2:2:1:1 ratio to receive 52 weeks of add-on subcutaneous dupilumab 200 or 300 mg every 2 weeks or matched-volume placebos. Pre-specified co-primary efficacy endpoints were the annualized rate of severe exacerbations during the treatment period and the change from baseline in pre-bronchodilator FEV 1 at treatment week 12. Asthma control, changes in asthma biomarker levels, and dupilumab safety were also evaluated., Results: 530 (27.9% of the overall QUEST population; dupilumab: 353, placebo: 177) Latin-American patients were recruited; 420 (79.2%) had a type 2 inflammatory asthma phenotype. Dupilumab vs placebo reduced the annualized rate of severe exacerbations by 52.7% ( P < 0.001) and increased pre-bronchodilator FEV 1 at week 12 by 0.15 L ( P < 0.001), in the type 2 population. Safety was consistent with the known dupilumab safety profile., Conclusions: Consistent with the results in the overall population, dupilumab reduced the risk of severe asthma exacerbations and improved lung function in Latin American patients with uncontrolled, moderate-to-severe asthma and a type 2 phenotype.
Published: 2023
Full Text: View/download PDF

35. Efficacy of once-daily, single-inhaler, fixed-dose combination of mometasone/indacaterol/glycopyrronium in patients with asthma with or without persistent airflow limitation: Post hoc analysis from the IRIDIUM study.

Author: Van Zyl-Smit RN, Kerstjens HA, Maspero JF, Kostikas K, Hosoe M, Tanase AM, D'Andrea P, Mezzi K, Brittain D, Lawrence D, and Chapman KR
Subjects: Adult, Humans, Glycopyrrolate, Mometasone Furoate, Iridium therapeutic use, Drug Combinations, Forced Expiratory Volume, Lung, Indans, Nebulizers and Vaporizers, Administration, Inhalation, Bronchodilator Agents therapeutic use, Pulmonary Disease, Chronic Obstructive drug therapy, Asthma drug therapy
Abstract: Background: A novel, once-daily, fixed-dose combination of mometasone furoate/indacaterol acetate/glycopyrronium bromide (MF/IND/GLY) delivered via Breezhaler® is the first inhaled corticosteroid/long-acting ꞵ 2 -agonist/long-acting muscarinic antagonist (ICS/LABA/LAMA) therapy approved for the maintenance treatment of asthma in adults inadequately controlled on ICS/LABA combination. In patients with asthma and persistent airflow limitation (PAL), maximal treatment, especially with combination is suggested. This post hoc analysis of data from the IRIDIUM study assessed the efficacy of MF/IND/GLY in asthma patients with and without PAL., Methods: Patients with post-bronchodilator FEV 1 ≤80% of predicted and FEV 1 /FVC ratio of ≤0.7 were categorised as PAL subgroup and the remaining as the non-PAL subgroup. Lung function parameters (FEV 1 , PEF, and FEF 25%-75% ) and annualised asthma exacerbations rates were evaluated in both subgroups across the treatment arms: once-daily high-dose MF/IND/GLY (160/150/50 μg), high-dose MF/IND (320/150 μg) and twice-daily high-dose fluticasone/salmeterol (FLU/SAL; 500/50 μg)., Results: Of the 3092 randomised patients, 64% (n = 1981) met the criteria for PAL. Overall, there was no evidence of treatment difference between PAL and non-PAL subgroups (interaction P-value for FEV 1 , FEF 25%-75% , PEF, moderate or severe exacerbations, severe exacerbations and all exacerbations were 0.42, 0.08, 0.43 0.29, 0.35 and 0.12, respectively). In the PAL subgroup, high-dose MF/IND/GLY versus high-dose MF/IND and high-dose FLU/SAL improved trough FEV 1 (mean difference: 102 mL [P < 0.0001] and 137 mL [P < 0.0001]) and reduced moderate or severe (16% and 32%), severe (25% and 39%) and all exacerbations (19% and 38%), respectively., Conclusions: Once-daily fixed-dose MF/IND/GLY was efficacious in asthma patients with and without persistent airflow limitation., Competing Interests: Declaration of competing interest RVZS reports personal fees from Aspen/GSK, Pfizer, Roche, MSD, AstraZeneca, Novartis, Glenmark, Boehringer Ingelheim and Cipla, outside the submitted work. HAK reports grants and consultancy/advisory board participation from/for Novartis during the conduct of the study, grants and consultancy/advisory board participation from/for GlaxoSmithKline and Boehringer Ingelheim, and a grant from Chiesi, outside the submitted work. All were paid to his institution. JFM reports personal fees and grants from Novartis during the conduct of the study, personal fees from AstraZeneca, grants and personal fees from Sanofi and personal fees from ImmunoTek. KK reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, Chiesi, ELPEN, GSK, Novartis and Menarini; personal fees from Sanofi; and grants from NuvoAir, outside the submitted work, and was an employee of Novartis Pharma AG until October 31, 2018. KRC reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Grifols, Sanofi, Regeneron, Novartis and Takeda; personal fees from CSL Behring, Inhibrx and Kamada; and grants from Vertex, outside the submitted work. MH, AMT, KM, DB and DL are employees of Novartis Pharma AG. PD is an employee of Novartis Pharmaceutical Corporation., (Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Published: 2023
Full Text: View/download PDF

36. The use of systemic corticosteroids in asthma management in Latin American countries.

Author: Maspero JF, Cruz AA, Beltran CFP, Ali Munive A, Montero-Arias F, Hernandez Pliego R, and Farouk H
Abstract: The stepwise treatment approach recommended by the Global Initiative for Asthma (GINA) includes systemic corticosteroids (SCS) suggested as a final step if asthma is severe and/or difficult to treat. Yet, despite the effectiveness of SCS, they are also associated with potentially irreversible adverse outcomes such as type 2 diabetes, adrenal suppression, and cardiovascular disease. Based on recent data indicating that the risk of developing these conditions can increase after as few as 4 short-term (burst) courses of SCS, even patients with mild asthma who receive SCS occasionally for exacerbations are also at risk of these events. As a result, recent updates by GINA and the Latin American Thoracic Society recommend decreasing SCS use by optimizing administration of non-SCS therapies and/or increasing the use of alternatives, such as biologic agents. Recent and ongoing studies characterizing treatment patterns among patients with asthma have revealed alarming trends suggesting the widespread overuse of SCS around the world. In Latin America, asthma prevalence is approximately 17%, and data suggest that the majority of patients have uncontrolled disease. In this review, we summarize currently available data on asthma treatment patterns in Latin America, which indicate that SCS are prescribed to 20-40% of patients with asthma considered to be well controlled and over 50% of patients with uncontrolled disease. We also offer potential strategies to help reduce SCS use for asthma in everyday clinical practice., (© 2023 The Authors.)
Published: 2023
Full Text: View/download PDF

37. Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction.

Author: Hanania NA, Castro M, Bateman E, Pavord ID, Papi A, FitzGerald JM, Maspero JF, Katelaris CH, Singh D, Daizadeh N, Altincatal A, Pandit-Abid N, Soler X, Siddiqui S, Laws E, Jacob-Nara JA, Rowe PJ, Lederer DJ, Hardin M, and Deniz Y
Subjects: Aged, Humans, Bronchodilator Agents therapeutic use, Double-Blind Method, Lung, Quality of Life, Anti-Asthmatic Agents, Asthma, Pulmonary Disease, Chronic Obstructive drug therapy
Abstract: Background: The 52-week, phase 3 LIBERTY ASTHMA QUEST study (NCT02414854) in patients aged above or equal to 12 years with uncontrolled, moderate-to-severe asthma demonstrated the efficacy and safety of dupilumab 200 mg and 300 mg every 2 weeks vs matched placebo., Objective: To assess whether dupilumab improves clinical outcomes in QUEST patients with persistent airflow obstruction (PAO) defined as post-bronchodilator forced expiratory volume in 1 second/forced vital capacity ratio less than 0.7 at baseline., Methods: End points were annualized rate of severe exacerbations, pre and post-bronchodilator forced expiratory volume in 1 second over time, proportion achieving reversal of PAO, and quality of life. Efficacy was evaluated in patients with or without PAO at baseline in subpopulations with eosinophils ≥ 150 cells/µL or fractional exhaled nitric oxide (FeNO) ≥ 25 ppb or eosinophils ≥ 300 cells/µL and FeNO ≥ 25 ppb., Results: Of 1902 patients enrolled in QUEST, 1039 (55%) had PAO at baseline. Dupilumab vs placebo rapidly and significantly improved lung function in patients with PAO and elevated type 2 inflammatory biomarkers at baseline. Dupilumab improved probability of reversing airflow obstruction (hazard ratio vs placebo 1.616 [95% confidence interval, 1.272-2.052] and 1.813 [1.291-2.546]; both P < .001) and significantly reduced severe exacerbations by 69% (relative risk, 0.411; 95% confidence interval [0.327-0.516]; P < .0001) and by 75% (0.252 [0.178-0.356]; P < .0001) in patients with PAO with eosinophils ≥ 150 cells/µL or FeNO ≥ 25 ppb and eosinophils ≥ 300 cells/µL and FeNO ≥ 25 ppb, respectively. Similar results were observed in patient subgroups without PAO., Conclusion: In patients with uncontrolled moderate-to-severe asthma, treatment with dupilumab facilitates reversal of PAO status and improves clinical outcomes., Trial Registration: ClinicalTrials.gov identifier: NCT02414854., (Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.)
Published: 2023
Full Text: View/download PDF

38. Dupilumab Is Effective in Patients With Moderate-to-Severe Uncontrolled GINA-Defined Type 2 Asthma Irrespective of an Allergic Asthma Phenotype.

Author: Rabe KF, FitzGerald JM, Bateman ED, Castro M, Pavord ID, Maspero JF, Busse WW, Izuhara K, Daizadeh N, Ortiz B, Pandit-Abid N, Rowe PJ, and Deniz Y
Subjects: Humans, Eosinophils, Immunoglobulin E, Phenotype, Biomarkers, Asthma drug therapy, Hypersensitivity drug therapy, Anti-Asthmatic Agents therapeutic use
Abstract: Background: The Global Initiative for Asthma report recommends consideration of add-on biologics for patients with type 2 inflammation (blood eosinophils ≥150 cells/μL, fractional exhaled nitric oxide [Feno] ≥20 parts per billion or allergic asthma) whose asthma cannot be controlled by high-dose inhaled corticosteroids. In QUEST (NCT02414854), add-on dupilumab versus placebo was efficacious in patients with uncontrolled, moderate to severe asthma, including those with eosinophils greater than or equal to 150 cells/μL and/or Feno greater than or equal to 25 parts per billion., Objective: To assess dupilumab efficacy in patients with a type 2 phenotype in the presence or absence of allergic asthma phenotype., Methods: Patients aged 12 years or older received add-on dupilumab 200/300 mg versus matched placebo every 2 weeks for 52 weeks. Allergic asthma phenotype was defined as baseline serum total IgE greater than or equal to 30 IU/mL and 1 or more perennial aeroallergen-specific IgE level greater than or equal to 0.35 kU/L. Annualized rate of severe asthma exacerbations and changes from study baseline in prebronchodilator and postbronchodilator FEV 1 were evaluated in patients with allergic and nonallergic phenotype with baseline blood eosinophils greater than or equal to 150 cells/μL and/or Feno greater than or equal to 20 parts per billion., Results: Of 1902 patients in QUEST, 83.3% had eosinophils and/or Feno above Global Initiative for Asthma thresholds; 56.9% had evidence for allergic asthma. Dupilumab significantly reduced the rate of severe asthma exacerbations in patients with (48.8%) and without (64.0%) evidence of allergic asthma and improved prebronchodilator and postbronchodilator FEV 1 in patients with elevated type 2 biomarkers, irrespective of whether they showed evidence of an allergic asthma phenotype., Conclusions: In patients with type 2 biomarkers over Global Initiative for Asthma thresholds, dupilumab significantly reduced exacerbations and improved lung function. Efficacy was not impacted by allergic status., (Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.)
Published: 2022
Full Text: View/download PDF

39. Improvement in patient-reported "taste" and association with smell in dupilumab-treated patients with severe chronic rhinosinusitis with nasal polyps from the SINUS-24 and SINUS-52 trials.

Author: Peters AT, Soler ZM, Kern RC, Heffler E, Maspero JF, Crampette L, Fujieda S, Lane AP, Zhang H, Nash S, Khan AH, Siddiqui S, Jacob-Nara JA, Rowe P, and Deniz Y
Subjects: Antibodies, Monoclonal, Humanized, Chronic Disease, Humans, Patient Reported Outcome Measures, Quality of Life, Smell, Nasal Polyps complications, Nasal Polyps drug therapy, Rhinitis complications, Rhinitis drug therapy, Sinusitis complications, Sinusitis drug therapy
Published: 2022
Full Text: View/download PDF

40. Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma: An Analysis of the Phase 3, Open-Label Extension TRAVERSE Trial.

Author: Sher LD, Wechsler ME, Rabe KF, Maspero JF, Daizadeh N, Mao X, Ortiz B, Mannent LP, Laws E, Ruddy M, Pandit-Abid N, Jacob-Nara JA, Gall R, Rowe PJ, Deniz Y, Lederer DJ, and Hardin M
Subjects: Adrenal Cortex Hormones therapeutic use, Antibodies, Monoclonal, Humanized, Double-Blind Method, Humans, Injections, Subcutaneous, Treatment Outcome, Anti-Asthmatic Agents therapeutic use, Asthma
Abstract: Background: Many patients with severe asthma require chronic corticosteroid treatment to maintain asthma control., Research Question: Are the reduction in oral corticosteroid (OCS) use and the clinical efficacy observed with dupilumab treatment maintained long-term in patients with severe OCS-dependent asthma?, Study Design and Methods: The LIBERTY ASTHMA TRAVERSE study (ClinicalTrials.gov identifier: NCT02134028) was a multinational, multicenter, single-arm, open-label extension study in patients ≥ 12 years of age with asthma who participated in previous dupilumab studies. Treatment consisted of dupilumab 300 mg every 2 weeks for up to 96 weeks. In this analysis, we present the data from patients who initially enrolled in the LIBERTY ASTHMA VENTURE study (ClinicalTrials.gov identifier: NCT02528214), a 24-week placebo-controlled study of dupilumab in patients with OCS-dependent severe asthma, and continued in the TRAVERSE study. The subgroups analyzed were: those who received dupilumab in both (dupilumab/dupilumab group) and those who received placebo in the VENTURE study and dupilumab in the TRAVERSE study (placebo/dupilumab group). Outcomes included OCS use, exacerbation rates, and measures of lung function and asthma control., Results: Ninety patients treated with dupilumab/dupilumab and 97 patients treated with placebo/dupilumab in the VENTURE study were enrolled and treated in the TRAVERSE study, with a mean OCS dosage of 11.0 mg/d (dupilumab) and 11.6 mg/d (placebo) at VENTURE study baseline. At TRAVERSE week 0, the mean daily OCS dosage was 3.1 mg/d and 6.4 mg/d (percentage decrease from the VENTURE study baseline, 68.8% and 41.3%) for the dupilumab/dupilumab group and placebo/dupilumab group, respectively, and decreased to 2.2 mg/d and 4.9 mg/d (78.3% and 53.4%) at week 48 and to 1.2 mg/d and 3.0 mg/d (89.3% and 74.4%) at week 96, respectively. Exacerbation rates were low during the TRAVERSE study. Further improvements from the VENTURE to TRAVERSE studies also were seen in FEV 1 and 5-item Asthma Control Questionnaire scores. Safety findings were consistent with the known dupilumab safety profile., Interpretation: In the open-label TRAVERSE study, dupilumab demonstrated the ability to sustain the OCS dosage reduction from the parent OCS-sparing study, while maintaining a low exacerbation rate and improved lung function., Trial Registry: ClinicalTrials.gov; Nos.: NCT02134028 (TRAVERSE) and NCT02528214 (VENTURE); URL: www., Clinicaltrials: gov., (Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.)
Published: 2022
Full Text: View/download PDF

41. Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid Dose.

Author: Domingo C, Maspero JF, Castro M, Hanania NA, Ford LB, Halpin DMG, Jackson DJ, Daizadeh N, Djandji M, Mitchell CP, Crikelair N, Jacob-Nara JA, Deniz Y, Rowe PJ, and Ortiz B
Subjects: Adrenal Cortex Hormones therapeutic use, Antibodies, Monoclonal, Humanized, Bronchodilator Agents therapeutic use, Double-Blind Method, Humans, Injections, Subcutaneous, Steroids therapeutic use, Treatment Outcome, Anti-Asthmatic Agents, Asthma
Abstract: Background: Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4/-13, key and central drivers of type 2 inflammation in multiple diseases. In the phase 3 LIBERTY ASTHMA VENTURE (VENTURE) study (NCT02528214), dupilumab versus placebo reduced oral corticosteroid (OCS) dose and improved clinical outcomes in patients with OCS-dependent severe asthma. Dupilumab efficacy in patients with varying disease burden (defined by baseline OCS dose) has not been assessed., Objective: This post hoc analysis of VENTURE evaluated dupilumab efficacy across subgroups defined by baseline OCS dose., Methods: The OCS dose, proportion no longer needing OCS at week 24, annualized severe exacerbation rate, and least squares mean change from baseline in pre- and post-bronchodilator forced expiratory volume in 1 second at week 24 were evaluated in VENTURE patients with OCS-dependent severe asthma receiving dupilumab 300 mg every 2 weeks versus placebo, categorized by a baseline OCS dose of less than 10 mg/d or 10 or more mg/d., Results: Dupilumab reduced daily OCS dose from baseline at week 24 in both dose groups. In dupilumab-/placebo-treated patients with a baseline OCS dose of less than 10 mg/d and 10 or more mg/d, 72%/42% and 37%/23% stopped OCS by week 24 (P < .01/P < .05), respectively. Dupilumab significantly reduced the annualized severe exacerbation rate by 71% and 48% (P < .01/P < .05). At week 24, dupilumab improved pre- and post-bronchodilator forced expiratory volume in 1 second in patients in both dose groups., Conclusions: In patients with OCS-dependent severe asthma receiving lower or higher baseline OCS doses, dupilumab significantly reduced the OCS dose and improved the likelihood of no longer requiring OCS while also reducing exacerbations and improving lung function., (Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.)
Published: 2022
Full Text: View/download PDF

42. Phase 3b randomized controlled trial of fevipiprant in patients with nasal polyposis with asthma (THUNDER).

Author: Gevaert P, Bachert C, Maspero JF, Cuevas M, Steele D, Acharya S, and Altman P
Subjects: Chronic Disease, Double-Blind Method, Humans, Indoleacetic Acids, Mometasone Furoate therapeutic use, Pyridines, Treatment Outcome, Asthma complications, Asthma drug therapy, Nasal Polyps complications, Nasal Polyps drug therapy, Rhinitis drug therapy, Sinusitis drug therapy
Abstract: Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with asthma, particularly of late onset. Current treatment options for CRSwNP have limitations, and there is an unmet need for other safe and effective therapies., Objective: The aim of the THUNDER study was to determine the efficacy and safety of the prostaglandin D 2 receptor 2 (DP 2 ) antagonist fevipiprant in patients with CRSwNP and concomitant asthma, measured by improvement in nasal polyp score (primary end point), nasal congestion score, Sinonasal Outcome Test 22 score, and University of Pennsylvania Smell Identification Test score., Methods: THUNDER was a phase 3b, randomized, multicenter, double-blind, placebo-controlled, parallel-group, 16-week study of fevipiprant 150 mg or 450 mg once daily versus placebo. All patients received intranasal mometasone furoate 200 μg daily., Results: Ninety-eight patients were randomly assigned to fevipiprant 150 mg (n = 32), fevipiprant 450 mg (n = 34), or placebo (n = 32). Mean (SE) change from baseline in nasal polyp score at week 16 was 0.20 (0.224) for fevipiprant 150 mg, -0.10 (0.216) for fevipiprant 450 mg, and 0.14 (0.233) for placebo. Mean treatment difference was 0.05 (95% confidence interval, -0.59, 0.70; adjusted P = .979) for fevipiprant 150 mg versus placebo and -0.25 (95% confidence interval, -0.88, 0.39; adjusted P = .656) for fevipiprant 450 mg versus placebo. There was no meaningful difference in the secondary end points for fevipiprant versus placebo., Conclusions: THUNDER provided no evidence of a role for fevipiprant in the treatment of patients with CRSwNP and asthma; future studies may establish a role for other DP 2 antagonists, specifically in patients with aspirin-exacerbated respiratory disease., (Copyright © 2022. Published by Elsevier Inc.)
Published: 2022
Full Text: View/download PDF

43. Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count.

Author: Bachert C, Sousa AR, Han JK, Schlosser RJ, Sowerby LJ, Hopkins C, Maspero JF, Smith SG, Kante O, Karidi-Andrioti DE, Mayer B, Chan RH, Yancey SW, and Chaker AM
Subjects: Antibodies, Monoclonal, Humanized, Chronic Disease, Comorbidity, Eosinophils, Humans, Treatment Outcome, Asthma drug therapy, Asthma, Aspirin-Induced, Nasal Obstruction drug therapy, Nasal Polyps drug therapy, Sinusitis drug therapy
Abstract: Background: In the phase III SYNAPSE study, mepolizumab reduced nasal polyp (NP) size and nasal obstruction in chronic rhinosinusitis with NP., Objective: We sought to assess the efficacy of mepolizumab in patients from SYNAPSE grouped by comorbid asthma, aspirin-exacerbated respiratory disease (AERD), and baseline blood eosinophil count (BEC)., Methods: SYNAPSE, a randomized, double-blind, 52-week study (NCT03085797), included patients with severe bilateral chronic rhinosinusitis with NP eligible for surgery despite intranasal corticosteroid treatment. Patients received 4-weekly subcutaneous mepolizumab 100 mg or placebo plus standard of care for 52 weeks. Coprimary end points were change in total endoscopic NP score (week 52) and nasal obstruction visual analog scale score (weeks 49-52). Subgroup analyses by comorbid asthma and AERD status, and post hoc by BEC, were exploratory., Results: Analyses included 407 patients (289 with asthma; 108 with AERD; 371 and 278 with BEC counts ≥150 or ≥300 cells/μL, respectively). The proportion of patients with greater than or equal to 1-point improvement from baseline in NP score was higher with mepolizumab versus placebo across comorbid diseases (asthma: 52.9% vs 29.5%; AERD: 51.1% vs 20.6%) and baseline BEC subgroups (<150 cells/μL: 55.0% vs 31.3%; ≥150 cells/μL: 49.5% vs 28.1%; <300 cells/μL: 50.7% vs 29.0%; ≥300 cells/μL: 50.4% vs 28.1%). A similar trend was observed in patients without comorbid asthma or AERD. More patients had more than 3-point improvement in nasal obstruction VAS score with mepolizumab versus placebo across comorbid subgroups., Conclusions: Mepolizumab reduced polyp size and nasal obstruction in chronic rhinosinusitis with NP regardless of the presence of comorbid asthma or AERD., (Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.)
Published: 2022
Full Text: View/download PDF

44. Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials.

Author: Mullol J, Laidlaw TM, Bachert C, Mannent LP, Canonica GW, Han JK, Maspero JF, Picado C, Daizadeh N, Ortiz B, Li Y, Ruddy M, Laws E, and Amin N
Subjects: Adult, Anti-Inflammatory Agents, Non-Steroidal adverse effects, Asthma drug therapy, Chronic Disease, Clinical Trials, Phase III as Topic, Humans, Randomized Controlled Trials as Topic, Treatment Outcome, Antibodies, Monoclonal, Humanized adverse effects, Nasal Polyps complications, Respiration Disorders complications, Respiration Disorders diagnosis, Sinusitis drug therapy
Abstract: Background: About one-tenth of patients with difficult-to-treat chronic rhinosinusitis with nasal polyps (CRSwNP) have comorbid non-steroidal anti-inflammatory drug-exacerbated respiratory disease (NSAID-ERD). Dupilumab, a fully human monoclonal antibody that blocks the shared interleukin (IL)-4/IL-13 receptor component, is an approved add-on treatment in severe CRSwNP. This post hoc analysis evaluated dupilumab efficacy and safety in patients with CRSwNP with/without NSAID-ERD., Methods: Data were pooled from the phase 3 SINUS-24 and SINUS-52 studies in adults with uncontrolled severe CRSwNP who received dupilumab 300 mg or placebo every 2 weeks. CRSwNP, nasal airflow, lung function, and asthma control outcomes at Week 24 were evaluated, and treatment-subgroup interactions were assessed for patients with and without NSAID-ERD., Results: Of 724 patients, 204 (28.2%) had a diagnosis of NSAID-ERD. At Week 24, least squares mean treatment differences demonstrated significant improvements in nasal polyp score, nasal congestion (NC), Lund-Mackay computed tomography, 22-item Sinonasal Outcome Test (SNOT-22), Total Symptom Score (TSS), rhinosinusitis severity visual analog scale, peak nasal inspiratory flow (PNIF), six-item Asthma Control Questionnaire score, and improvement in smell with dupilumab versus placebo (all p < .0001) in patients with NSAID-ERD. Treatment comparisons demonstrated significantly greater improvements with dupilumab in patients with versus without NSAID-ERD for NC (p = .0044), SNOT-22 (p = .0313), TSS (p = .0425), and PNIF (p = .0123)., Conclusions: In patients with uncontrolled severe CRSwNP, dupilumab significantly improved objective measures and patient-reported symptoms to a greater extent in the presence of comorbid NSAID-ERD than without. Dupilumab was well tolerated in patients with/without NSAID-ERD., (© 2021 Sanofi Genzyme. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)
Published: 2022
Full Text: View/download PDF

45. Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study.

Author: Wechsler ME, Ford LB, Maspero JF, Pavord ID, Papi A, Bourdin A, Watz H, Castro M, Nenasheva NM, Tohda Y, Langton D, Cardona G, Domingo C, Park HS, Chapman KR, Mao X, Zhang Y, Khan AH, Deniz Y, Rowe PJ, Kapoor U, Khokhar FA, Mannent LP, Ruddy M, Laws E, Amin N, and Hardin M
Subjects: Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized adverse effects, Child, Double-Blind Method, Female, Humans, Male, Middle Aged, Quality of Life, Treatment Outcome, Young Adult, Anti-Asthmatic Agents adverse effects, Anti-Asthmatic Agents therapeutic use, Asthma drug therapy
Abstract: Background: Clinical trials have shown treatment benefits of dupilumab in patients with uncontrolled asthma for up to 1 year. This study aimed to evaluate the long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma, as data for extended treatment with dupilumab beyond 1 year are not available., Methods: TRAVERSE was an open-label extension study in 362 hospitals and clinical centres across 27 countries that assessed the safety and efficacy of dupilumab 300 mg every 2 weeks up to 96 weeks in adults and adolescents (aged 12-84 years) with moderate-to-severe or oral-corticosteroid-dependent severe asthma who had completed a previous dupilumab asthma study (phase 2A EXPEDITION, phase 2B DRI [P2b], phase 3 QUEST, or VENTURE). The primary endpoint was the number and percentage of patients with any treatment-emergent adverse events. Secondary endpoints included annualised exacerbation rate (AER) over the treatment period and change from parent study baseline in pre-bronchodilator FEV 1 , the five-item asthma control questionnaire (ACQ-5), the asthma quality of life questionnaire (AQLQ), type 2 biomarkers (blood eosinophils and serum total IgE), and anti-drug antibodies (ADAs). Statistical analyses were descriptive. We report safety in all enrolled patients, and efficacy in patients with non-oral-corticosteroid-dependent asthma and in subgroups, including patients with a type 2 inflammatory phenotype who received 148 weeks of treatment. This study is registered with ClinicalTrials.gov, NCT02134028., Findings: Between Aug 5, 2014, and Oct 11, 2019, of 2302 patients assessed for eligibility, 2282 adults and adolescents were enrolled (median age 50 years, 62·1% female and 37·9% male). Safety during TRAVERSE was consistent with the known dupilumab safety profile. The proportion of patients reporting treatment-emergent adverse events throughout the study duration was similar to that observed in the parent studies and ranged from 76·3% to 94·7%. The most frequently reported treatment-emergent adverse events were nasopharyngitis (17·5-25·9%), injection-site erythema (2·2-23·4%), and bronchitis (9·3-19·0%). Serious asthma exacerbations (0·5-3·6%) and pneumonia (0·7-2·7%) were the most frequently reported serious adverse events. There were four treatment-emergent adverse events leading to death. Efficacy during TRAVERSE was also consistent with the results of parent studies. In patients who were non-oral-corticosteroid-dependent, AER remained low (0·277-0·327) across parent study and treatment groups, pre-bronchodilator FEV 1 improvements were sustained to the end of treatment at week 96 (mean changes from parent study baseline ranged from 0·22 L [SD 0·44] to 0·33 L [0·44] across parent study and treatment groups), and improvements in ACQ-5 and AQLQ scores were sustained to the last timepoint assessed at week 48. Rapid improvements were observed in pre-bronchodilator FEV 1 and sustained improvements were seen in all outcome measures for patients given dupilumab who previously received placebo in parent studies; further improvements in AER, asthma control, and health-related quality of life were observed in patients who continued receiving dupilumab. Blood eosinophils and serum total IgE decreased progressively. ADA status had no effect on safety or efficacy. In the subgroup of patients with a type 2 inflammatory phenotype followed-up for 148 weeks, AER decreased progressively, and initial lung function improvements were sustained over 148 weeks., Interpretation: Data show that safety and efficacy of dupilumab in adult and adolescent patients with moderate-to-severe asthma are sustained when treatment is extended up to 148 weeks. These findings therefore support the long-term use of dupilumab in this patient population., Funding: Sanofi and Regeneron Pharmaceuticals., Competing Interests: Declaration of interests MEW reports personal fees from AstraZeneca, Boehringer Ingelheim, Equillium, Gala Therapeutics, Genentech, Genzyme, Mylan, Novartis, Pulmatrix, ResTORbio, Regeneron Pharmaceuticals, Sentien Biotechnologies, and Teva; and grants and personal fees from GSK and Sanofi. LBF reports grant support through the Asthma & Allergy Center, Bellevue, NE, USA, from 3M, Aimmune, AstraZeneca, DBV Technologies, Genentech, Glenmark, GSK, Hoffmann-La Roche, Novartis, Pearl, Sanofi, and Teva; and has served as a national consultant for Sanofi. JFM has served as a consultant for AstraZeneca and Sanofi; received speaker fees from Boehringer Ingelheim, GSK, Menarini, Novartis, and Uriach; and received research grants from Novartis. IDP reports speaker fees from Aerocrine AB, Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Novartis, Regeneron Pharmaceuticals, Sanofi, and Teva; payments for organisation of educational events from AstraZeneca, GSK, Regeneron Pharmaceuticals, Sanofi, and Teva; consultant fees from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Dey Pharma, Genentech, GSK, Knopp Biosciences, Merck, MSD, Napp Pharmaceuticals, Novartis, Regeneron Pharmaceuticals, RespiVert, Sanofi, Schering-Plough, and Teva; international scientific meeting sponsorship from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Napp Pharmaceuticals, Regeneron Pharmaceuticals, Sanofi, and Teva; and a research grant from Chiesi. AP reports grants, personal fees, and non-financial support from AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Mundipharma, and Teva; personal fees and non-financial support from Menarini, Novartis, and Zambon; and grants from Sanofi. AB reports non-financial support during the conduct of the study from GSK; serving as an investigator on clinical trials promoted by Acceleron Pharma, Actelion, Galapagos, MSD, Nuvaira, Pulmonx, United Therapeutic, and Vertex Pharmaceuticals; grants and personal fees from Boehringer Ingelheim; and personal fees from AstraZeneca, Chiesi, GSK, Regeneron Pharmaceuticals, and Sanofi. HW reports serving as a consultant and receiving travel and speaker fees from AstraZeneca, Bayer, Boehringer Ingelheim, Chiesi, GSK, Novartis, Sanofi, and Takeda. MC reports research support from the American Lung Association, AstraZeneca, Boehringer Ingelheim, Chiesi, Novartis, Patient-Centered Outcomes Research Institute, and Sanofi; serving as a consultant for 4D Pharma, Aviragen Therapeutics, Boston Scientific, Genentech, Nuvaira, Sanofi, Teva, Therabron Therapeutics, Theravance Biopharma, Vectura, and Vida Pharma; speaker fees from AstraZeneca, Boehringer Ingelheim, Boston Scientific, Genentech, Regeneron Pharmaceuticals, Sanofi, and Teva; and royalties from Elsevier. NMN reports speaker fees from ALK, AstraZeneca, Boehringer Ingelheim, Glenmark, MSD, Novartis, Sanofi, Stallergenes Greer, and Teva. YT has served as a consultant for AstraZeneca, Kyorin Pharmaceuticals, and Sanofi. DL has received research funding from Sanofi. CD reports travel and speaker fees from Allergy Therapeutics, ALK, Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Esteve, Ferrer, GSK, HAL Allergy, Inmunotek, Menarini, Novartis, Pfizer, Sanofi-Aventis, Stallergenes Greer, Takeda, and Teva. KRC reports grants and personal fees from AstraZeneca, Boehringer Ingelheim, CSL Behring, Genentech, Grifols, Kamada, Mereo BioPharma, Novartis, Roche, and Sanofi; grants from Amgen, Baxter, and GSK; and personal fees from the GSK-Canadian Institutes of Health Research chair in Respiratory Health Care Delivery at the University Health Network, and Merck. XM, AHK, PJR, UK, LPM, EL, and MH are Sanofi employees and hold stock or stock options in the company. YZ, YD, FAK, MR, and NA are employees and shareholders at Regeneron Pharmaceuticals. All other authors declare no competing interests., (Copyright © 2022 Elsevier Ltd. All rights reserved.)
Published: 2022
Full Text: View/download PDF

46. Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma.

Author: Bacharier LB, Maspero JF, Katelaris CH, Fiocchi AG, Gagnon R, de Mir I, Jain N, Sher LD, Mao X, Liu D, Zhang Y, Khan AH, Kapoor U, Khokhar FA, Rowe PJ, Deniz Y, Ruddy M, Laws E, Patel N, Weinreich DM, Yancopoulos GD, Amin N, Mannent LP, Lederer DJ, and Hardin M
Subjects: Anti-Asthmatic Agents administration & dosage, Anti-Asthmatic Agents adverse effects, Antibodies, Monoclonal, Humanized administration & dosage, Antibodies, Monoclonal, Humanized adverse effects, Asthma physiopathology, Biomarkers analysis, Breath Tests, Child, Double-Blind Method, Drug Therapy, Combination, Female, Forced Expiratory Volume, Humans, Injections, Subcutaneous, Lung physiopathology, Male, Nitric Oxide administration & dosage, Patient Acuity, Symptom Flare Up, Anti-Asthmatic Agents therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Asthma drug therapy
Abstract: Background: Children with moderate-to-severe asthma continue to have disease complications despite the receipt of standard-of-care therapy. The monoclonal antibody dupilumab has been approved for the treatment of adults and adolescents with asthma as well as with other type 2 inflammatory diseases., Methods: In this 52-week phase 3, randomized, double-blind, placebo-controlled trial, we assigned 408 children between the ages of 6 and 11 years who had uncontrolled moderate-to-severe asthma to receive a subcutaneous injection of dupilumab (at a dose of 100 mg for those weighing ≤30 kg and 200 mg for those weighing >30 kg) or matched placebo every 2 weeks. All the children continued to receive a stable dose of standard background therapy. The primary end point was the annualized rate of severe asthma exacerbations. Secondary end points included the change from baseline in the percentage of predicted prebronchodilator forced expiratory volume in 1 second (ppFEV 1 ) at week 12 and in the score on the Asthma Control Questionnaire 7 Interviewer-Administered (ACQ-7-IA) at week 24. End points were evaluated in the two primary efficacy populations who had either a type 2 inflammatory asthma phenotype (≥150 blood eosinophils per cubic millimeter or a fraction of exhaled nitric oxide of ≥20 ppb at baseline) or a blood eosinophil count of at least 300 cells per cubic millimeter at baseline., Results: In patients with the type 2 inflammatory phenotype, the annualized rate of severe asthma exacerbations was 0.31 (95% confidence interval [CI], 0.22 to 0.42) with dupilumab and 0.75 (95% CI, 0.54 to 1.03) with placebo (relative risk reduction in the dupilumab group, 59.3%; 95% CI, 39.5 to 72.6; P<0.001). The mean (±SE) change from baseline in the ppFEV 1 was 10.5±1.0 percentage points with dupilumab and 5.3±1.4 percentage points with placebo (mean difference, 5.2 percentage points; 95% CI, 2.1 to 8.3; P<0.001). Dupilumab also resulted in significantly better asthma control than placebo (P<0.001). Similar results were observed in the patients with an eosinophil count of at least 300 cells per cubic millimeter at baseline. The incidence of serious adverse events was similar in the two groups., Conclusions: Among children with uncontrolled moderate-to-severe asthma, those who received add-on dupilumab had fewer asthma exacerbations and better lung function and asthma control than those who received placebo. (Funded by Sanofi and Regeneron Pharmaceuticals; Liberty Asthma VOYAGE ClinicalTrials.gov number, NCT02948959.)., (Copyright © 2021 Massachusetts Medical Society.)
Published: 2021
Full Text: View/download PDF

47. Effect of exacerbation history on clinical response to dupilumab in moderate-to-severe uncontrolled asthma.

Author: Corren J, Katelaris CH, Castro M, Maspero JF, Ford LB, Halpin DMG, Rice MS, Radwan A, Deniz Y, Rowe PJ, Teper A, and Djandji M
Subjects: Antibodies, Monoclonal, Humanized therapeutic use, Double-Blind Method, Forced Expiratory Volume, Humans, Treatment Outcome, Anti-Asthmatic Agents therapeutic use, Asthma drug therapy
Abstract: Background: The phase 3 LIBERTY ASTHMA QUEST study (ClinicalTrials.gov: NCT02414854) in patients with uncontrolled, moderate-to-severe asthma has demonstrated the efficacy and safety of dupilumab 200 and 300 mg every 2 weeks versus placebo. This post hoc analysis assessed the effect of dupilumab on efficacy outcomes and asthma control across a range of historical exacerbation rates in patients with type 2-high asthma., Methods: Annualised severe exacerbation rates over the 52-week treatment period, pre-bronchodilator forced expiratory volume in 1 s (FEV 1 ) at weeks 12 and 52, and the five-item Asthma Control Questionnaire (ACQ-5) score at weeks 24 and 52 were assessed in patients with ≥1, ≥2 or ≥3 exacerbations in the previous year. Subgroups were stratified by baseline blood eosinophils ≥150 or ≥300 cells·μL -1 or baseline exhaled nitric oxide fraction ≥25 ppb and baseline inhaled corticosteroid (ICS) dose., Results: Across all type 2-high subgroups, dupilumab versus placebo significantly reduced severe exacerbations by 54-90%, with greater improvements in patients with more exacerbations prior to study initiation. Similarly, improvements in FEV 1 (least squares (LS) mean difference versus placebo: ≥1 exacerbations, 0.15-0.25 L; ≥2 exacerbations, 0.12-0.32 L; ≥3 exacerbations, 0.09-0.38 L; majority p<0.05) and ACQ-5 score (LS mean difference range: ≥1 exacerbations, -0.30 to -0.57; ≥2 exacerbations, -0.29 to -0.56; ≥3 exacerbations, -0.43 to -0.61; all p<0.05) were observed, irrespective of prior exacerbation history, across all subgroups., Conclusions: Dupilumab significantly reduced severe exacerbations and improved FEV 1 and asthma control in patients with elevated type 2 biomarkers irrespective of exacerbation history and baseline ICS dose., Competing Interests: Conflict of interest: J. Corren reports nonfinancial support for research from Sanofi, outside the submitted work. Conflict of interest: C.H. Katelaris reports nonfinancial support (advisory board member and principal study investigator) from Sanofi, outside the submitted work. Conflict of interest: M. Castro reports nonfinancial support for research from the American Lung Association, Gossamer, NIH, PCORI and Shionogi, personal fees for lectures and nonfinancial support for research from AstraZeneca, personal fees for lectures and consultancy, and nonfinancial support for research from Boehringer Ingelheim and Sanofi, personal fees for consultancy and nonfinancial support for research from Novartis, personal fees for consultancy from Boston Scientific and Vida Pharma, personal fees for lectures and consultancy from Teva, personal fees for lectures from Genentech and Regeneron Pharmaceuticals, Inc., personal fees (royalties) from Elsevier, outside the submitted work. Conflict of interest: J.F. Maspero reports being a speaker for AstraZeneca, GlaxoSmithKline, Menarini, Novartis, Sanofi, Teva and Uriach; and has received research grants from Novartis, outside the submitted work. Conflict of interest: L.B. Ford reports nonfinancial support for research from AstraZeneca, DBV, Genentech, Gossamer, Novartis and Teva, personal fees for consultancy from Sanofi, outside the submitted work. Conflict of interest: D.M.G. Halpin reports personal fees for lectures and advisory board work from AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, GlaxoSmithKline, Novartis, Pfizer, Sandoz and Sanofi, outside the submitted work. Conflict of interest: M.S. Rice is an employee of Sanofi and may hold stock and/or stock options in the company. Conflict of interest: A. Radwan is an employee and shareholder of Regeneron Pharmaceuticals, Inc. Conflict of interest: Y. Deniz is an employee and shareholder of Regeneron Pharmaceuticals, Inc. Conflict of interest: P.J. Rowe is an employee of Sanofi and may hold stock and/or stock options in the company. Conflict of interest: A. Teper is a former employee of Sanofi. Conflict of interest: M. Djandji is an employee of Sanofi and may hold stock and/or stock options in the company., (Copyright ©The authors 2021.)
Published: 2021
Full Text: View/download PDF

48. Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma.

Author: Wechsler ME, Ruddy MK, Pavord ID, Israel E, Rabe KF, Ford LB, Maspero JF, Abdulai RM, Hu CC, Martincova R, Jessel A, Nivens MC, Amin N, Weinreich DM, Yancopoulos GD, and Goulaouic H
Subjects: Adult, Aged, Anti-Asthmatic Agents adverse effects, Asthma drug therapy, Double-Blind Method, Drug Therapy, Combination, Female, Glucocorticoids therapeutic use, Humans, Injections, Subcutaneous, Male, Middle Aged, Quality of Life, Receptors, Interleukin-4 antagonists & inhibitors, Treatment Failure, Anti-Asthmatic Agents therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Interleukin-33 antagonists & inhibitors
Abstract: Background: Monoclonal antibodies targeting IgE, interleukin-4 and -13, and interleukin-5 are effective in treating severe type 2 asthma, but new targets are needed. Itepekimab is a new monoclonal antibody against the upstream alarmin interleukin-33. The efficacy and safety of itepekimab as monotherapy, as well as in combination with dupilumab, in patients with asthma are unclear., Methods: In a phase 2 trial, we randomly assigned, in a 1:1:1:1 ratio, adults with moderate-to-severe asthma receiving inhaled glucocorticoids plus long-acting beta-agonists (LABAs) to receive subcutaneous itepekimab (at a dose of 300 mg), itepekimab plus dupilumab (both at 300 mg; combination therapy), dupilumab (300 mg), or placebo every 2 weeks for 12 weeks. After randomization, LABA was discontinued at week 4, and inhaled glucocorticoids were tapered over weeks 6 through 9. The primary end point was an event indicating a loss of asthma control, assessed in the itepekimab group and the combination group, as compared with the placebo group. Secondary and other end points included lung function, asthma control, quality of life, type 2 biomarkers, and safety., Results: A total of 296 patients underwent randomization. By 12 weeks, an event indicating a loss of asthma control occurred in 22% of the patients in the itepekimab group, 27% of those in the combination group, and 19% of those in the dupilumab group, as compared with 41% of those in the placebo group; the corresponding odds ratios as compared with placebo were as follows: in the itepekimab group, 0.42 (95% confidence interval [CI], 0.20 to 0.88; P = 0.02); in the combination group, 0.52 (95% CI, 0.26 to 1.06; P = 0.07); and in the dupilumab group, 0.33 (95% CI, 0.15 to 0.70). As compared with placebo, the forced expiratory volume in 1 second before bronchodilator use increased with the itepekimab and dupilumab monotherapies but not with the combination therapy. Itepekimab treatment improved asthma control and quality of life, as compared with placebo, and led to a greater reduction in the mean blood eosinophil count. The incidence of adverse events was similar in all four trial groups., Conclusions: Interleukin-33 blockade with itepekimab led to a lower incidence of events indicating a loss of asthma control than placebo and improved lung function in patients with moderate-to-severe asthma. (Funded by Sanofi and Regeneron Pharmaceuticals; ClinicalTrials.gov number, NCT03387852.)., (Copyright © 2021 Massachusetts Medical Society.)
Published: 2021
Full Text: View/download PDF

49. Dupilumab efficacy in adolescents with uncontrolled, moderate-to-severe asthma: LIBERTY ASTHMA QUEST.

Author: Maspero JF, FitzGerald JM, Pavord ID, Rice MS, Maroni J, Rowe PJ, Pirozzi G, Amin N, Ruddy M, Graham NMH, Teper A, and Hardin M
Subjects: Adolescent, Antibodies, Monoclonal, Humanized therapeutic use, Humans, Anti-Asthmatic Agents therapeutic use, Asthma drug therapy
Published: 2021
Full Text: View/download PDF

50. Differentiation of COVID-19 signs and symptoms from allergic rhinitis and common cold: An ARIA-EAACI-GA 2 LEN consensus.

Author: Hagemann J, Onorato GL, Jutel M, Akdis CA, Agache I, Zuberbier T, Czarlewski W, Mullol J, Bedbrook A, Bachert C, Bennoor KS, Bergmann KC, Braido F, Camargos P, Caraballo L, Cardona V, Casale T, Cecchi L, Chivato T, Chu DK, Cingi C, Correia-de-Sousa J, Del Giacco S, Dokic D, Dykewicz M, Ebisawa M, El-Gamal Y, Emuzyte R, Fauquert JL, Fiocchi A, Fokkens WJ, Fonseca JA, Gemicioglu B, Gomez RM, Gotua M, Haahtela T, Hamelmann E, Iinuma T, Ivancevich JC, Jassem E, Kalayci O, Kardas P, Khaitov M, Kuna P, Kvedariene V, Larenas-Linnemann DE, Lipworth B, Makris M, Maspero JF, Miculinic N, Mihaltan F, Mohammad Y, Montefort S, Morais-Almeida M, Mösges R, Naclerio R, Neffen H, Niedoszytko M, O'Hehir RE, Ohta K, Okamoto Y, Okubo K, Panzner P, Papadopoulos NG, Passalacqua G, Patella V, Pereira A, Pfaar O, Plavec D, Popov TA, Prokopakis EP, Puggioni F, Raciborski F, Reijula J, Regateiro FS, Reitsma S, Romano A, Rosario N, Rottem M, Ryan D, Samolinski B, Sastre J, Solé D, Sova M, Stellato C, Suppli-Ulrik C, Tsiligianni I, Valero A, Valiulis A, Valovirta E, Vasankari T, Ventura MT, Wallace D, Wang Y, Williams S, Yorgancioglu A, Yusuf OM, Zernotti M, Bousquet J, and Klimek L
Subjects: Consensus, Humans, SARS-CoV-2, Asthma, COVID-19, Common Cold, Rhinitis, Allergic diagnosis
Abstract: Background: Although there are many asymptomatic patients, one of the problems of COVID-19 is early recognition of the disease. COVID-19 symptoms are polymorphic and may include upper respiratory symptoms. However, COVID-19 symptoms may be mistaken with the common cold or allergic rhinitis. An ARIA-EAACI study group attempted to differentiate upper respiratory symptoms between the three diseases., Methods: A modified Delphi process was used. The ARIA members who were seeing COVID-19 patients were asked to fill in a questionnaire on the upper airway symptoms of COVID-19, common cold and allergic rhinitis., Results: Among the 192 ARIA members who were invited to respond to the questionnaire, 89 responded and 87 questionnaires were analysed. The consensus was then reported. A two-way ANOVA revealed significant differences in the symptom intensity between the three diseases (p < .001)., Conclusions: This modified Delphi approach enabled the differentiation of upper respiratory symptoms between COVID-19, the common cold and allergic rhinitis. An electronic algorithm will be devised using the questionnaire., (© 2021 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)
Published: 2021
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

80 results on '"Maspero, Jf"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources